

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request cder\_mpl1r\_wp277

**Request ID:** cder\_mpl1r\_wp277

**Request Description:** In this report, we estimated background rates of interstitial lung disease (ILD) among patients with inflammatory bowel disease (IBD) and IBD subtypes in the Sentinel Distributed Database (SDD). Patients were further stratified based on prior receipt of natalizumab/vedolizumab and of other advanced therapies for IBD. In addition, ILD rates are described within cohorts of patients with IBD initiating advanced therapy for IBD.

**Sentinel Routine Querying Module:** Cohort Identification and Descriptive Analysis (CIDA) module, version 13.0.1

**Data Source:** We distributed this query to six Sentinel Data Partners (DP) on February 16, 2024. The study period included data from January 1, 2006, through April 30, 2023. Please see Appendix A for a list of dates of available data for each Data

**Study Design:** We assessed background rates of ILD separately among adults aged 18 years and older with prevalent and incident diagnoses of IBD, as well as within subgroups of IBD patients with the two subtypes of IBD: ulcerative colitis (UC) and Crohn's disease (CD). We also assessed ILD background rates in subgroups of IBD, UC, and CD patients with no prior exposure to vedolizumab or natalizumab, with no prior exposure to vedolizumab or natalizumab who had used another advanced therapy for IBD, and among those initiating an advanced therapy for IBD. This is a Type 2 analysis in the Query Request Package (QRP) documentation.

**Assessment Episode of Interest:** For the cohorts that indexed on IBD diagnosis, we defined the start of the assessment episode (index date) as the date as the first diagnosis code for IBD, UC, and CD in the data for the prevalent IBD, UC, and CD cohorts, respectively. Individuals in the UC and CD cohorts could not have had evidence of the other subtype or indeterminate colitis codes prior to their index date. Only the first qualifying IBD diagnosis code in any care setting for each member was included; cohort re-entry was not allowed. Incident cohorts could not have had a prior IBD diagnosis code (any type) in all prior enrollment history.

For the cohorts that indexed on advanced therapy initiation, individuals had to initiate infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib (where initiation is defined as the first claim in 183 days). Only the first qualifying advanced therapy initiation for each member was included; cohort re-entry was not allowed. Individuals were additionally required to have a diagnosis code for IBD, UC, or CD in prior enrollment history.

We defined the index date using diagnosis codes, drug dispensings, and procedure codes, as appropriate. Please see Appendix B for a list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes used to define IBD, UC, and CD in this request. Please see Appendix C for a list of non-proprietary and proprietary names of medical products and Appendix D for a list of Healthcare Common Procedure Coding System (HCPCS) codes used to define advanced IBD therapies in this request.

**Outcome of Interest:** We defined the outcome of interest, ILD, using a single ICD-9-CM or ICD-10-CM diagnosis code. Please see Appendix E for a list of the ICD-10-CM and ICD-9-CM codes used to define ILD in this report.

**Cohort Eligibility Criteria:** Patients with a history of ILD at any time prior to the index date were excluded. We restricted all cohorts to males and females aged 18 years and older on the index date. Patients were required to be enrolled in health plans with medical and drug coverage for at least 183 days prior to their index date, during which gaps in coverage of up to 45 days were allowed. Within each subtype cohort, individuals could not have had any codes for the other subtype, nor any indeterminate colitis codes, in all available enrollment history through the index date, such that subtype cohorts were mutually exclusive.

In the subgroups in which patients could not have prior history of vedolizumab or natalizumab, we excluded those patients with any evidence of either drug in their available enrollment history through the index date, based on HCPCS codes and National Drug Codes (NDCs). For the subgroup in which patients were additionally required to have used a prior advanced therapy for IBD, patients were only included if they had evidence of infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib in their available enrollment history through the index date.

## Overview for Request cder\_mpl1r\_wp277

In the cohorts that indexed on advanced therapy initiation, patients were required to have a diagnosis code for IBD, CD, or UC, respectively, in all available enrollment history through the index date. Similar to the vedolizumab and natalizumab initiation-indexed cohorts in query cder\_mpl1r\_wp258, patients were required to have:

1. no prior vedolizumab use (including antibody assessment) or natalizumab use in the 183 days prior to and including the index date,
2. no prior use of other IBD treatments (methotrexate, bleomycin, azathioprine, cyclophosphamide, sulfasalazine) or cancer immunotherapy associated with increased ILD risk (including checkpoint inhibitors [ipilimumab, tremelimumab, nivolumab, pembrolizumab, cemiplimab, dostarlimab, retifanlimab, atezolizumab, durvalumab, avelumab] and tyrosine kinase inhibitors [selpercatinib, pirtobrutinib, dasatinib, deucravacitinib, imatinib, bosutinib, axitinib, dacomitinib, lorlatinib, sunitinib, crizotinib, nilotinib, ceritinib, pazopanib, lapatinib, midostaurin, capmatinib, asciminib, erlotinib, gefitinib, acalabrutinib, osimertinib, vandetanib, gilteritinib, afatinib, nintedanib, tepotinib, tivozanib, entrectinib, alectinib, pralsetinib, larotrectinib, pemigatinib, tucatinib, ibrutinib, fedratinib, erdafitinib, lenvatinib, mobocertinib, brigatinib, futibatinib, pexidartinib, quizartinib, neratinib, fostamatinib, avapritinib, pacritinib, zanubrutinib, infigratinib, ripretinib]) during a period equivalent to five times the drug's half-life prior to and including the index date, and
3. no use of amiodarone on the index date, after implementing a forced 710 days' supply (five times its half-life) for all amiodarone dispensings.

Please see the following appendices to identify various inclusion and exclusion criteria:

- Vedolizumab and natalizumab exclusion: Please see Appendix F for a list of non-proprietary and proprietary names of medical products and Appendix G for a list of Current Procedural Terminology, Fourth Edition (CPT-4) and HCPCS codes used to define vedolizumab and natalizumab as exclusion criteria in this request.
- Advanced IBD therapy inclusion: Please see Appendix H for a list of non-proprietary and proprietary names of medical products and Appendix I for a list of HCPCS codes used to define advanced IBD therapies as inclusion criteria in this request.
- Other IBD treatment/cancer immunotherapy exclusion: Please see Appendix J for a list of non-proprietary and proprietary names of medical products and Appendix K for a list International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) and HCPCS codes used to define other IBD and cancer immunotherapy-related exclusion criteria for this request. Please see Appendix K.1 for information on half-lives used to exclude patients with other IBD treatments and cancer immunotherapy exposure prior to the index date.

**Follow-up Time:** We followed patients for ILD events from the day after the index date until the earliest occurrence of any of the following: 1) disenrollment; 2) death; 3) the end of the data provided by each Data Partner; 4) the end of the query period; or 5) occurrence of the outcome. In the cohorts that excluded individuals previously exposed to vedolizumab or natalizumab, we additionally ended follow-up at initiation of either of these drugs (based on drug or procedure codes). In the advanced therapy-indexed cohorts, we also ended follow-up at initiation of other IBD or cancer immunotherapies (using drug or procedure codes). Please see Appendix L for a list of non-proprietary and proprietary names of medical products and Appendix M for a list of CPT-4, HCPCS, and ICD-10-PCS codes used to define vedolizumab, natalizumab, other IBD therapies, and cancer immunotherapies as censoring criteria in this request.

## Overview for Request cder\_mpl1r\_wp277

**Baseline Characteristics:** We assessed age, sex, race, and ethnicity on the index date and the following characteristics in the 183 days prior to and including the index date: tobacco use (based on diagnosis or procedure codes or smoking cessation product dispensings), systemic sclerosis, rheumatoid arthritis, dermatomyositis/polymyositis, anti-synthetase syndrome, and use of other IBD therapies (methotrexate, amiodarone, bleomycin, azathioprine, cyclophosphamide, sulfasalazine) and cancer immunotherapies (checkpoint inhibitors, tyrosine kinase inhibitors). Healthcare services/drug utilization metrics were assessed in the 183 days prior to the index date. We assessed the Combined Comorbidity Score<sup>1</sup> in all prior enrollment history including the index date. Chronic conditions were also assessed in all prior history, and were defined using Centers for Medicare and Medicaid Services (CMS) Chronic Conditions Data Warehouse<sup>2</sup> code lists and included: acute myocardial infarction, Alzheimer's disease, Alzheimer's disease and related disorders or senile dementia, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, hip/pelvic fracture, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack, breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease and bronchiectasis, glaucoma, cataract, and osteoporosis. Lastly, amongst the advanced therapy-indexed cohorts, we described length of IBD history in the database as <1 year, 1-<2 years, or ≥2 years. Please see Appendix N for a list of non-proprietary and proprietary names of medical products and Appendix O for a list of ICD-10-PCS, CPT-4, HCPCS, ICD-9-CM, and ICD-10-CM codes used to define baseline characteristics in this request.

**Please see Appendix P for the specifications used to define parameters for this request. Please see Appendix Q for a list of baseline characteristics used in this request. Please see Appendix R for the design diagram used in this request for cohorts 1-18 and Appendix S for the design diagram used in this request for cohorts 19-21.**

**Limitations:** Algorithms to define start of follow-up, outcomes, inclusion and exclusion criteria, and baseline characteristics are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

**Notes:** Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

<sup>1</sup>The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the index date (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051).

<sup>2</sup>Chronic Conditions Data Warehouse. Condition Categories - Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

## Table of Contents

<b><u>Glossary (CIDA)</u></b>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<b><u>Table 1a</u></b>	Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1b</u></b>	Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1c</u></b>	Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1d</u></b>	Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1e</u></b>	Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1f</u></b>	Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1g</u></b>	Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1h</u></b>	Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1i</u></b>	Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1j</u></b>	Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1k</u></b>	Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1l</u></b>	Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1m</u></b>	Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1n</u></b>	Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1o</u></b>	Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1p</u></b>	Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1q</u></b>	Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1r</u></b>	Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1s</u></b>	Aggregated Characteristics of Advanced Therapy Initiators with Inflammatory Bowel Disease (IBD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 1t</u></b>	Aggregated Characteristics of Advanced Therapy Initiators with Crohn's Disease (CD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023

## Table of Contents

<b><u>Table 1u</u></b>	Aggregated Characteristics of Advanced Therapy Initiators with Ulcerative Colitis (UC) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 2</u></b>	Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Table 3</u></b>	Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Sex
<b><u>Table 4</u></b>	Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group
<b><u>Table 5</u></b>	Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year
<b><u>Table 6</u></b>	Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race
<b><u>Table 7</u></b>	Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin
<b><u>Table 8</u></b>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023
<b><u>Appendix A</u></b>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (February 16, 2024)
<b><u>Appendix B</u></b>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inflammatory Bowel Disease (IBD) Index Dates in this Request
<b><u>Appendix C</u></b>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapy Exposures in this Request
<b><u>Appendix D</u></b>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapy Exposures in this Request
<b><u>Appendix E</u></b>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request
<b><u>Appendix F</u></b>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Vedolizumab and Natalizumab as Exclusion Criteria in this Request
<b><u>Appendix G</u></b>	List of Current Procedural Terminology, Fourth Edition (CPT-4) and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Vedolizumab and Natalizumab as Exclusion Criteria in this Request
<b><u>Appendix H</u></b>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapies as Inclusion Criteria in this Request
<b><u>Appendix I</u></b>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapies as Inclusion Criteria in this Request
<b><u>Appendix J</u></b>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Other Inflammatory Bowel Disease (IBD) and Cancer Immunotherapy-Related Exclusion Criteria for this Request
<b><u>Appendix K</u></b>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Other Inflammatory Bowel Disease (IBD) and Cancer Immunotherapy-Related Exclusion Criteria for this Request
<b><u>Appendix K.1</u></b>	Half-Life Information for Other Inflammatory Bowel Disease (IBD) Therapies and Cancer Immunotherapies Used as Exclusion Criteria
<b><u>Appendix L</u></b>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Vedolizumab, Natalizumab, Other Inflammatory Bowel Disease (IBD) Therapies, and Cancer Immunotherapies as Censoring Criteria in this Request

## Table of Contents

<b><u>Appendix M</u></b>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Vedolizumab, Natalizumab, Other Inflammatory Bowel Disease (IBD) Therapies, and Cancer Immunotherapies as Censoring Criteria in this Request
<b><u>Appendix N</u></b>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request
<b><u>Appendix O</u></b>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request
<b><u>Appendix P</u></b>	Specifications Defining Parameters for this Request
<b><u>Appendix Q</u></b>	Baseline Characteristics Used In This Request
<b><u>Appendix R</u></b>	Design Diagram of Cohort Entry Requirements, Index Event, and Outcome Assessment for this Request, Cohorts 1-18
<b><u>Appendix S</u></b>	Design Diagram of Cohort Entry Requirements, Index Event, and Outcome Assessment for this Request, Cohorts 19-21



**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

**Ambulatory Visit (AV)** - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

**Emergency Department (ED)** - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

**Inpatient Hospital Stay (IP)** - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

**Non-Acute Institutional Stay (IS)** - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

**Other Ambulatory Visit (OA)** - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

**Charlson/Elixhauser Combined Comorbidity Score** - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

**Code Days** - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

**Cohort Definition (drug/exposure)** - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

**Computed Start Marketing Date** - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

**Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Event Deduplication** - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Lookback Period** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Maximum Episode Duration** - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.



**Member-Years** - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

**Switch Gap Inclusion Indicator** - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

**Switch Pattern Cohort Inclusion Date** - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

**Switch Pattern Cohort Inclusion Strategy** - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

**Treatment Episode Truncation Indicator** - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

**Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

\*all terms may not be used in this report

**Table 1a. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	2,439,541	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	57.4	14.6
Age	<b>Number</b>	<b>Percent</b>
18-24 years	137,476	5.6%
25-34 years	260,092	10.7%
35-44 years	283,600	11.6%
45-54 years	340,736	14.0%
55-64 years	354,165	14.5%
≥ 65 years	1,063,472	43.6%
Sex		
Female	1,438,795	59.0%
Male	1,000,746	41.0%
Race <sup>1</sup>		
American Indian or Alaska Native	7,569	0.3%
Asian	28,421	1.2%
Black or African American	141,072	5.8%
Multi-racial	5,882	0.2%
Native Hawaiian or Other Pacific Islander	2,090	0.1%
Unknown	1,029,879	42.2%
White	1,224,628	50.2%
Hispanic origin		
Yes	60,629	2.5%
No	1,324,958	54.3%
Unknown	1,053,954	43.2%
Year		
2006	28,743	1.2%
2007	37,095	1.5%
2008	85,683	3.5%
2009	78,754	3.2%
2010	170,395	7.0%
2011	161,485	6.6%
2012	144,460	5.9%
2013	161,873	6.6%
2014	169,957	7.0%
2015	183,208	7.5%
2016	199,849	8.2%

**Table 1a. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	194,272	8.0%
2018	179,946	7.4%
2019	181,699	7.4%
2020	174,265	7.1%
2021	140,460	5.8%
2022	136,467	5.6%
2023	10,930	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.9	3.6
Combined comorbidity score categories	Number	Percent
≤0	828,235	34.0%
1-2	685,605	28.1%
3-4	317,636	13.0%
≥5	608,065	24.9%
Systemic sclerosis	4,901	0.2%
Rheumatoid arthritis	82,953	3.4%
Dermatomyositis/polymyositis	2,236	0.1%
Anti-synthetase syndrome	210	0.0%
Acquired hypothyroidism	548,156	22.5%
Acute myocardial infarction	79,468	3.3%
Alzheimer's disease	54,517	2.2%
Alzheimer's disease and related disorders	169,172	6.9%
Anemia	917,680	37.6%
Asthma	364,921	15.0%
Atrial fibrillation	262,765	10.8%
Benign prostatic hyperplasia	250,409	10.3%
Breast cancer	91,779	3.8%
Colorectal cancer	78,481	3.2%
Endometrial cancer	18,409	0.8%
Lung cancer	30,087	1.2%
Prostate cancer	72,714	3.0%
Cataract	671,025	27.5%
Chronic kidney disease	593,114	24.3%
Chronic obstructive pulmonary disease and bronchiectasis	526,557	21.6%
Depression	686,714	28.1%
Diabetes	460,259	18.9%
Glaucoma	255,549	10.5%

**Table 1a. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	230,899	9.5%
Hip/pelvic fracture	52,158	2.1%
Hyperlipidemia	1,285,715	52.7%
Hypertension	1,340,958	55.0%
Ischemic heart disease	559,163	22.9%
Osteoporosis	351,360	14.4%
Rheumatoid arthritis/osteoarthritis	947,260	38.8%
Stroke/transient ischemic attack	226,279	9.3%
Tobacco use	261,337	10.7%
<b>Medical Product Use</b>		
Methotrexate	36,515	1.5%
Amiodarone	23,764	1.0%
Bleomycin	214	0.0%
Azathioprine	72,268	3.0%
Cyclophosphamide	2,818	0.1%
Sulfasalazine	84,785	3.5%
Checkpoint inhibitors	4,884	0.2%
Tyrosine kinase inhibitors	3,322	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.5	13.6
Mean number of emergency room encounters	0.5	1.6
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	5.1	13.0
Mean number of filled prescriptions	18.6	19.0
Mean number of generics dispensed	7.3	5.6
Mean number of unique drug classes dispensed	6.9	5.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1b. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	976,715	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	54.3	14.9
<b>Age</b>	<b>Number</b>	<b>Percent</b>
18-24 years	70,897	7.3%
25-34 years	126,230	12.9%
35-44 years	131,010	13.4%
45-54 years	147,269	15.1%
55-64 years	141,473	14.5%
≥ 65 years	359,836	36.8%
<b>Sex</b>		
Female	577,126	59.1%
Male	399,589	40.9%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	3,141	0.3%
Asian	9,677	1.0%
Black or African American	59,730	6.1%
Multi-racial	2,464	0.3%
Native Hawaiian or Other Pacific Islander	804	0.1%
Unknown	428,333	43.9%
White	472,566	48.4%
<b>Hispanic origin</b>		
Yes	20,910	2.1%
No	514,264	52.7%
Unknown	441,541	45.2%
<b>Year</b>		
2006	13,265	1.4%
2007	15,321	1.6%
2008	37,128	3.8%
2009	31,746	3.3%
2010	74,257	7.6%
2011	63,911	6.5%
2012	57,357	5.9%
2013	65,227	6.7%
2014	70,778	7.2%
2015	76,003	7.8%
2016	85,045	8.7%

**Table 1b. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	78,535	8.0%
2018	69,614	7.1%
2019	69,261	7.1%
2020	67,455	6.9%
2021	49,453	5.1%
2022	48,117	4.9%
2023	4,242	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.5	3.2
Combined comorbidity score categories	Number	Percent
≤0	350,736	35.9%
1-2	296,107	30.3%
3-4	128,361	13.1%
≥5	201,511	20.6%
Systemic sclerosis	1,911	0.2%
Rheumatoid arthritis	31,990	3.3%
Dermatomyositis/polymyositis	948	0.1%
Anti-synthetase syndrome	84	0.0%
Acquired hypothyroidism	191,435	19.6%
Acute myocardial infarction	24,135	2.5%
Alzheimer's disease	15,124	1.5%
Alzheimer's disease and related disorders	48,298	4.9%
Anemia	339,933	34.8%
Asthma	140,792	14.4%
Atrial fibrillation	85,051	8.7%
Benign prostatic hyperplasia	84,223	8.6%
Breast cancer	30,615	3.1%
Colorectal cancer	27,650	2.8%
Endometrial cancer	6,467	0.7%
Lung cancer	9,917	1.0%
Prostate cancer	21,699	2.2%
Cataract	221,133	22.6%
Chronic kidney disease	204,565	20.9%
Chronic obstructive pulmonary disease and bronchiectasis	190,904	19.5%
Depression	264,445	27.1%
Diabetes	157,396	16.1%
Glaucoma	83,896	8.6%

**Table 1b. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	72,298	7.4%
Hip/pelvic fracture	15,229	1.6%
Hyperlipidemia	448,176	45.9%
Hypertension	487,010	49.9%
Ischemic heart disease	187,339	19.2%
Osteoporosis	118,793	12.2%
Rheumatoid arthritis/osteoarthritis	337,258	34.5%
Stroke/transient ischemic attack	71,419	7.3%
Tobacco use	122,815	12.6%
<b>Medical Product Use</b>		
Methotrexate	18,179	1.9%
Amiodarone	7,543	0.8%
Bleomycin	77	0.0%
Azathioprine	40,099	4.1%
Cyclophosphamide	862	0.1%
Sulfasalazine	25,083	2.6%
Checkpoint inhibitors	909	0.1%
Tyrosine kinase inhibitors	1,022	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.1	13.0
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.3	11.7
Mean number of filled prescriptions	18.0	18.8
Mean number of generics dispensed	7.1	5.6
Mean number of unique drug classes dispensed	6.6	5.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.



**Table 1c. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

Patient Characteristics	Number	Percent
Unique patients	1,320,770	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	60.0	14.1
Age		
18-24 years	52,813	4.0%
25-34 years	116,443	8.8%
35-44 years	135,273	10.2%
45-54 years	174,057	13.2%
55-64 years	193,117	14.6%
≥ 65 years	649,067	49.1%
Sex		
Female	778,469	58.9%
Male	542,301	41.1%
Race <sup>1</sup>		
American Indian or Alaska Native	3,995	0.3%
Asian	17,221	1.3%
Black or African American	73,486	5.6%
Multi-racial	3,039	0.2%
Native Hawaiian or Other Pacific Islander	1,148	0.1%
Unknown	538,513	40.8%
White	683,368	51.7%
Hispanic origin		
Yes	35,534	2.7%
No	736,978	55.8%
Unknown	548,258	41.5%
Year		
2006	13,396	1.0%
2007	19,967	1.5%
2008	43,210	3.3%
2009	43,207	3.3%
2010	86,349	6.5%
2011	91,394	6.9%
2012	82,007	6.2%
2013	90,061	6.8%
2014	92,721	7.0%
2015	100,530	7.6%
2016	105,500	8.0%

**Table 1c. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	100,602	7.6%
2018	95,630	7.2%
2019	97,642	7.4%
2020	93,200	7.1%
2021	80,872	6.1%
2022	78,614	6.0%
2023	5,868	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.2	3.8
Combined comorbidity score categories	Number	Percent
≤0	435,244	33.0%
1-2	345,814	26.2%
3-4	167,692	12.7%
≥5	372,020	28.2%
Systemic sclerosis	2,738	0.2%
Rheumatoid arthritis	46,080	3.5%
Dermatomyositis/polymyositis	1,172	0.1%
Anti-synthetase syndrome	109	0.0%
Acquired hypothyroidism	326,956	24.8%
Acute myocardial infarction	51,131	3.9%
Alzheimer's disease	37,185	2.8%
Alzheimer's disease and related disorders	113,110	8.6%
Anemia	519,231	39.3%
Asthma	201,993	15.3%
Atrial fibrillation	164,800	12.5%
Benign prostatic hyperplasia	153,476	11.6%
Breast cancer	56,120	4.2%
Colorectal cancer	46,664	3.5%
Endometrial cancer	11,052	0.8%
Lung cancer	18,574	1.4%
Prostate cancer	47,799	3.6%
Cataract	414,515	31.4%
Chronic kidney disease	354,988	26.9%
Chronic obstructive pulmonary disease and bronchiectasis	307,536	23.3%
Depression	380,445	28.8%
Diabetes	276,269	20.9%
Glaucoma	157,864	12.0%

**Table 1c. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	146,461	11.1%
Hip/pelvic fracture	34,382	2.6%
Hyperlipidemia	768,993	58.2%
Hypertension	781,980	59.2%
Ischemic heart disease	343,686	26.0%
Osteoporosis	213,165	16.1%
Rheumatoid arthritis/osteoarthritis	557,298	42.2%
Stroke/transient ischemic attack	143,802	10.9%
Tobacco use	122,731	9.3%
<b>Medical Product Use</b>		
Methotrexate	15,390	1.2%
Amiodarone	15,122	1.1%
Bleomycin	116	0.0%
Azathioprine	25,000	1.9%
Cyclophosphamide	1,809	0.1%
Sulfasalazine	54,160	4.1%
Checkpoint inhibitors	3,585	0.3%
Tyrosine kinase inhibitors	2,115	0.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.8	14.0
Mean number of emergency room encounters	0.5	1.5
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	5.7	13.9
Mean number of filled prescriptions	19.0	19.2
Mean number of generics dispensed	7.5	5.6
Mean number of unique drug classes dispensed	7.0	5.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1d. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	1,718,382	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	59.7	14.3
Age	<b>Number</b>	<b>Percent</b>
18-24 years	72,917	4.2%
25-34 years	153,789	8.9%
35-44 years	180,816	10.5%
45-54 years	233,538	13.6%
55-64 years	253,246	14.7%
≥ 65 years	824,076	48.0%
Sex		
Female	1,036,756	60.3%
Male	681,626	39.7%
Race <sup>1</sup>		
American Indian or Alaska Native	5,804	0.3%
Asian	23,478	1.4%
Black or African American	104,261	6.1%
Multi-racial	3,873	0.2%
Native Hawaiian or Other Pacific Islander	1,522	0.1%
Unknown	682,147	39.7%
White	897,297	52.2%
Hispanic origin		
Yes	46,681	2.7%
No	982,986	57.2%
Unknown	688,715	40.1%
Year		
2006	13,067	0.8%
2007	24,274	1.4%
2008	47,565	2.8%
2009	55,760	3.2%
2010	97,145	5.7%
2011	121,777	7.1%
2012	111,899	6.5%
2013	116,079	6.8%
2014	122,198	7.1%
2015	132,517	7.7%
2016	135,467	7.9%

**Table 1d. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	139,671	8.1%
2018	133,256	7.8%
2019	133,369	7.8%
2020	124,588	7.3%
2021	103,734	6.0%
2022	98,701	5.7%
2023	7,315	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.5	3.8
Combined comorbidity score categories	Number	Percent
≤0	504,436	29.4%
1-2	448,558	26.1%
3-4	235,606	13.7%
≥5	529,782	30.8%
Systemic sclerosis	3,856	0.2%
Rheumatoid arthritis	61,261	3.6%
Dermatomyositis/polymyositis	1,784	0.1%
Anti-synthetase syndrome	168	0.0%
Acquired hypothyroidism	452,891	26.4%
Acute myocardial infarction	72,789	4.2%
Alzheimer's disease	49,416	2.9%
Alzheimer's disease and related disorders	153,034	8.9%
Anemia	718,293	41.8%
Asthma	292,226	17.0%
Atrial fibrillation	226,167	13.2%
Benign prostatic hyperplasia	206,360	12.0%
Breast cancer	76,294	4.4%
Colorectal cancer	67,324	3.9%
Endometrial cancer	16,373	1.0%
Lung cancer	26,084	1.5%
Prostate cancer	60,337	3.5%
Cataract	569,873	33.2%
Chronic kidney disease	500,427	29.1%
Chronic obstructive pulmonary disease and bronchiectasis	445,727	25.9%
Depression	539,557	31.4%
Diabetes	385,236	22.4%
Glaucoma	214,809	12.5%

**Table 1d. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	206,951	12.0%
Hip/pelvic fracture	47,334	2.8%
Hyperlipidemia	1,028,486	59.9%
Hypertension	1,057,401	61.5%
Ischemic heart disease	478,328	27.8%
Osteoporosis	291,648	17.0%
Rheumatoid arthritis/osteoarthritis	776,689	45.2%
Stroke/transient ischemic attack	202,761	11.8%
Tobacco use	199,474	11.6%
<b>Medical Product Use</b>		
Methotrexate	19,472	1.1%
Amiodarone	20,362	1.2%
Bleomycin	145	0.0%
Azathioprine	12,563	0.7%
Cyclophosphamide	2,370	0.1%
Sulfasalazine	39,903	2.3%
Checkpoint inhibitors	4,572	0.3%
Tyrosine kinase inhibitors	2,858	0.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.1	14.4
Mean number of emergency room encounters	0.6	1.6
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	5.9	14.0
Mean number of filled prescriptions	19.2	19.6
Mean number of generics dispensed	7.6	5.7
Mean number of unique drug classes dispensed	7.1	5.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1e. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	630,457	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	56.9	14.7
Age	<b>Number</b>	<b>Percent</b>
18-24 years	35,262	5.6%
25-34 years	69,361	11.0%
35-44 years	77,629	12.3%
45-54 years	93,429	14.8%
55-64 years	92,803	14.7%
≥ 65 years	261,973	41.6%
Sex		
Female	377,718	59.9%
Male	252,739	40.1%
Race <sup>1</sup>		
American Indian or Alaska Native	2,263	0.4%
Asian	8,050	1.3%
Black or African American	39,337	6.2%
Multi-racial	1,514	0.2%
Native Hawaiian or Other Pacific Islander	573	0.1%
Unknown	264,873	42.0%
White	313,847	49.8%
Hispanic origin		
Yes	15,434	2.4%
No	346,196	54.9%
Unknown	268,827	42.6%
Year		
2006	5,258	0.8%
2007	9,395	1.5%
2008	18,647	3.0%
2009	21,613	3.4%
2010	37,518	6.0%
2011	45,987	7.3%
2012	42,428	6.7%
2013	44,263	7.0%
2014	47,944	7.6%
2015	51,012	8.1%
2016	52,564	8.3%



**Table 1e. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	51,940	8.2%
2018	47,223	7.5%
2019	45,882	7.3%
2020	43,080	6.8%
2021	32,414	5.1%
2022	30,728	4.9%
2023	2,561	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.1	3.5
Combined comorbidity score categories	Number	Percent
≤0	197,416	31.3%
1-2	178,341	28.3%
3-4	88,159	14.0%
≥5	166,541	26.4%
Systemic sclerosis	1,427	0.2%
Rheumatoid arthritis	21,007	3.3%
Dermatomyositis/polymyositis	751	0.1%
Anti-synthetase syndrome	65	0.0%
Acquired hypothyroidism	150,269	23.8%
Acute myocardial infarction	21,464	3.4%
Alzheimer's disease	13,263	2.1%
Alzheimer's disease and related disorders	42,137	6.7%
Anemia	243,745	38.7%
Asthma	106,038	16.8%
Atrial fibrillation	70,237	11.1%
Benign prostatic hyperplasia	67,711	10.7%
Breast cancer	24,245	3.8%
Colorectal cancer	23,255	3.7%
Endometrial cancer	5,557	0.9%
Lung cancer	8,079	1.3%
Prostate cancer	17,498	2.8%
Cataract	180,319	28.6%
Chronic kidney disease	161,131	25.6%
Chronic obstructive pulmonary disease and bronchiectasis	151,255	24.0%
Depression	189,621	30.1%
Diabetes	125,618	19.9%
Glaucoma	67,691	10.7%

**Table 1e. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	62,059	9.8%
Hip/pelvic fracture	13,156	2.1%
Hyperlipidemia	343,270	54.4%
Hypertension	360,027	57.1%
Ischemic heart disease	153,932	24.4%
Osteoporosis	91,339	14.5%
Rheumatoid arthritis/osteoarthritis	259,815	41.2%
Stroke/transient ischemic attack	61,466	9.7%
Tobacco use	82,858	13.1%
<b>Medical Product Use</b>		
Methotrexate	7,605	1.2%
Amiodarone	6,136	1.0%
Bleomycin	46	0.0%
Azathioprine	6,186	1.0%
Cyclophosphamide	662	0.1%
Sulfasalazine	10,773	1.7%
Checkpoint inhibitors	804	0.1%
Tyrosine kinase inhibitors	810	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.5	13.8
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	4.8	12.4
Mean number of filled prescriptions	18.3	19.1
Mean number of generics dispensed	7.3	5.7
Mean number of unique drug classes dispensed	6.8	5.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1f. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	1,024,124	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	61.5	14.0
<b>Age</b>	<b>Number</b>	<b>Percent</b>
18-24 years	34,285	3.3%
25-34 years	78,772	7.7%
35-44 years	96,911	9.5%
45-54 years	132,218	12.9%
55-64 years	151,120	14.8%
≥ 65 years	530,818	51.8%
<b>Sex</b>		
Female	618,773	60.4%
Male	405,351	39.6%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	3,329	0.3%
Asian	14,476	1.4%
Black or African American	61,397	6.0%
Multi-racial	2,180	0.2%
Native Hawaiian or Other Pacific Islander	878	0.1%
Unknown	393,564	38.4%
White	548,300	53.5%
<b>Hispanic origin</b>		
Yes	28,994	2.8%
No	599,106	58.5%
Unknown	396,024	38.7%
<b>Year</b>		
2006	7,586	0.7%
2007	14,566	1.4%
2008	28,199	2.8%
2009	33,190	3.2%
2010	58,403	5.7%
2011	74,404	7.3%
2012	68,238	6.7%
2013	70,557	6.9%
2014	72,949	7.1%
2015	80,175	7.8%
2016	79,908	7.8%

**Table 1f. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	78,203	7.6%
2018	76,253	7.4%
2019	77,758	7.6%
2020	73,006	7.1%
2021	64,716	6.3%
2022	61,745	6.0%
2023	4,268	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.7	3.9
Combined comorbidity score categories	Number	Percent
≤0	293,531	28.7%
1-2	253,299	24.7%
3-4	137,041	13.4%
≥5	340,253	33.2%
Systemic sclerosis	2,318	0.2%
Rheumatoid arthritis	38,124	3.7%
Dermatomyositis/polymyositis	980	0.1%
Anti-synthetase syndrome	94	0.0%
Acquired hypothyroidism	283,763	27.7%
Acute myocardial infarction	48,085	4.7%
Alzheimer's disease	34,522	3.4%
Alzheimer's disease and related disorders	105,140	10.3%
Anemia	445,273	43.5%
Asthma	173,470	16.9%
Atrial fibrillation	147,430	14.4%
Benign prostatic hyperplasia	130,755	12.8%
Breast cancer	48,668	4.8%
Colorectal cancer	41,627	4.1%
Endometrial cancer	10,162	1.0%
Lung cancer	16,895	1.6%
Prostate cancer	40,912	4.0%
Cataract	364,593	35.6%
Chronic kidney disease	317,516	31.0%
Chronic obstructive pulmonary disease and bronchiectasis	276,122	27.0%
Depression	326,506	31.9%
Diabetes	241,526	23.6%
Glaucoma	137,625	13.4%

**Table 1f. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	135,876	13.3%
Hip/pelvic fracture	32,285	3.2%
Hyperlipidemia	644,158	62.9%
Hypertension	656,329	64.1%
Ischemic heart disease	305,979	29.9%
Osteoporosis	187,942	18.4%
Rheumatoid arthritis/osteoarthritis	483,733	47.2%
Stroke/transient ischemic attack	133,295	13.0%
Tobacco use	108,192	10.6%
<b>Medical Product Use</b>		
Methotrexate	11,163	1.1%
Amiodarone	13,536	1.3%
Bleomycin	92	0.0%
Azathioprine	6,149	0.6%
Cyclophosphamide	1,613	0.2%
Sulfasalazine	28,325	2.8%
Checkpoint inhibitors	3,410	0.3%
Tyrosine kinase inhibitors	1,912	0.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.4	14.8
Mean number of emergency room encounters	0.6	1.6
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	6.5	14.8
Mean number of filled prescriptions	19.8	19.9
Mean number of generics dispensed	7.8	5.7
Mean number of unique drug classes dispensed	7.3	5.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1g. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

Patient Characteristics	Number	Percent
Unique patients	296,808	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	45.1	14.4
Age		
18-24 years	42,102	14.2%
25-34 years	62,186	21.0%
35-44 years	52,449	17.7%
45-54 years	45,873	15.5%
55-64 years	36,727	12.4%
≥ 65 years	57,471	19.4%
Sex		
Female	161,757	54.5%
Male	135,051	45.5%
Race <sup>1</sup>		
American Indian or Alaska Native	738	0.2%
Asian	1,864	0.6%
Black or African American	15,508	5.2%
Multi-racial	1,232	0.4%
Native Hawaiian or Other Pacific Islander	167	0.1%
Unknown	168,633	56.8%
White	108,666	36.6%
Hispanic origin		
Yes	6,650	2.2%
No	115,236	38.8%
Unknown	174,922	58.9%
Year		
2006	2,589	0.9%
2007	2,464	0.8%
2008	8,980	3.0%
2009	6,863	2.3%
2010	15,400	5.2%
2011	10,592	3.6%
2012	11,170	3.8%
2013	15,562	5.2%
2014	18,765	6.3%
2015	21,311	7.2%

**Table 1g. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2016	27,442	9.2%
2017	27,223	9.2%
2018	26,203	8.8%
2019	28,481	9.6%
2020	28,991	9.8%
2021	20,966	7.1%
2022	21,656	7.3%
2023	2,150	0.7%
Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	1.9	2.5
Combined comorbidity score categories	Number	Percent
≤0	112,302	37.8%
1-2	102,520	34.5%
3-4	42,993	14.5%
≥5	38,993	13.1%
Systemic sclerosis	385	0.1%
Rheumatoid arthritis	23,849	8.0%
Dermatomyositis/polymyositis	208	0.1%
Anti-synthetase syndrome	24	0.0%
Acquired hypothyroidism	35,858	12.1%
Acute myocardial infarction	3,229	1.1%
Alzheimer's disease	868	0.3%
Alzheimer's disease and related disorders	4,156	1.4%
Anemia	110,001	37.1%
Asthma	36,928	12.4%
Atrial fibrillation	11,605	3.9%
Benign prostatic hyperplasia	14,884	5.0%
Breast cancer	4,561	1.5%
Colorectal cancer	3,256	1.1%
Endometrial cancer	636	0.2%
Lung cancer	1,211	0.4%
Prostate cancer	3,089	1.0%
Cataract	39,307	13.2%
Chronic kidney disease	40,663	13.7%
Chronic obstructive pulmonary disease and bronchiectasis	34,906	11.8%
Depression	71,413	24.1%



**Table 1g. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Diabetes	29,289	9.9%
Glaucoma	16,190	5.5%
Heart failure	9,134	3.1%
Hip/pelvic fracture	2,065	0.7%
Hyperlipidemia	86,175	29.0%
Hypertension	95,679	32.2%
Ischemic heart disease	26,898	9.1%
Osteoporosis	26,770	9.0%
Rheumatoid arthritis/osteoarthritis	83,233	28.0%
Stroke/transient ischemic attack	9,314	3.1%
Tobacco use	27,534	9.3%
<b>Medical Product Use</b>		
Methotrexate	20,226	6.8%
Amiodarone	820	0.3%
Bleomycin	26	0.0%
Azathioprine	36,361	12.3%
Cyclophosphamide	70	0.0%
Sulfasalazine	12,037	4.1%
Checkpoint inhibitors	609	0.2%
Tyrosine kinase inhibitors	105	0.0%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.4	10.2
Mean number of emergency room encounters	0.5	1.4
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.8	9.4
Mean number of filled prescriptions	18.6	17.1
Mean number of generics dispensed	7.5	5.5
Mean number of unique drug classes dispensed	7.1	5.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. *J Clin Epidemiol.* 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051.

**Table 1h. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	167,458	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	43.5	14.3
	<b>Number</b>	<b>Percent</b>
Age		
18-24 years	25,963	15.5%
25-34 years	37,753	22.5%
35-44 years	30,855	18.4%
45-54 years	26,109	15.6%
55-64 years	19,810	11.8%
≥ 65 years	26,968	16.1%
Sex		
Female	92,680	55.3%
Male	74,778	44.7%
Race <sup>1</sup>		
American Indian or Alaska Native	360	0.2%
Asian	861	0.5%
Black or African American	9,920	5.9%
Multi-racial	693	0.4%
Native Hawaiian or Other Pacific Islander	84	0.1%
Unknown	94,440	56.4%
White	61,100	36.5%
Hispanic origin		
Yes	3,142	1.9%
No	65,444	39.1%
Unknown	98,872	59.0%
Year		
2006	1,919	1.1%
2007	1,621	1.0%
2008	5,916	3.5%
2009	4,112	2.5%
2010	9,916	5.9%
2011	6,092	3.6%
2012	6,279	3.7%
2013	8,742	5.2%
2014	10,628	6.3%
2015	12,141	7.3%
2016	15,800	9.4%

**Table 1h. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	15,146	9.0%
2018	14,128	8.4%
2019	15,432	9.2%
2020	16,089	9.6%
2021	11,013	6.6%
2022	11,326	6.8%
2023	1,158	0.7%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	1.6	2.2
Combined comorbidity score categories	Number	Percent
≤0	70,291	42.0%
1-2	58,760	35.1%
3-4	21,767	13.0%
≥5	16,640	9.9%
Systemic sclerosis	216	0.1%
Rheumatoid arthritis	11,032	6.6%
Dermatomyositis/polymyositis	101	0.1%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	16,597	9.9%
Acute myocardial infarction	1,162	0.7%
Alzheimer's disease	321	0.2%
Alzheimer's disease and related disorders	1,567	0.9%
Anemia	53,449	31.9%
Asthma	18,808	11.2%
Atrial fibrillation	4,861	2.9%
Benign prostatic hyperplasia	6,292	3.8%
Breast cancer	2,047	1.2%
Colorectal cancer	1,404	0.8%
Endometrial cancer	303	0.2%
Lung cancer	455	0.3%
Prostate cancer	1,273	0.8%
Cataract	17,156	10.2%
Chronic kidney disease	19,193	11.5%
Chronic obstructive pulmonary disease and bronchiectasis	16,782	10.0%
Depression	38,385	22.9%
Diabetes	13,123	7.8%
Glaucoma	7,212	4.3%

**Table 1h. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	3,669	2.2%
Hip/pelvic fracture	806	0.5%
Hyperlipidemia	39,776	23.8%
Hypertension	47,841	28.6%
Ischemic heart disease	11,612	6.9%
Osteoporosis	12,871	7.7%
Rheumatoid arthritis/osteoarthritis	40,235	24.0%
Stroke/transient ischemic attack	3,869	2.3%
Tobacco use	18,289	10.9%
<b>Medical Product Use</b>		
Methotrexate	11,327	6.8%
Amiodarone	333	0.2%
Bleomycin	14	0.0%
Azathioprine	20,257	12.1%
Cyclophosphamide	40	0.0%
Sulfasalazine	4,675	2.8%
Checkpoint inhibitors	69	0.0%
Tyrosine kinase inhibitors	57	0.0%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	10.8	10.1
Mean number of emergency room encounters	0.5	1.4
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.4	9.1
Mean number of filled prescriptions	17.9	17.2
Mean number of generics dispensed	7.1	5.4
Mean number of unique drug classes dispensed	6.7	4.9

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1i. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

Patient Characteristics	Number	Percent
Unique patients	72,886	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	48.5	13.8
Age	Number	Percent
18-24 years	7,470	10.2%
25-34 years	13,742	18.9%
35-44 years	11,971	16.4%
45-54 years	11,024	15.1%
55-64 years	9,794	13.4%
≥ 65 years	18,885	25.9%
Sex		
Female	38,602	53.0%
Male	34,284	47.0%
Race <sup>1</sup>		
American Indian or Alaska Native	229	0.3%
Asian	657	0.9%
Black or African American	2,737	3.8%
Multi-racial	341	0.5%
Native Hawaiian or Other Pacific Islander	55	0.1%
Unknown	41,617	57.1%
White	27,250	37.4%
Hispanic origin		
Yes	2,124	2.9%
No	27,936	38.3%
Unknown	42,826	58.8%
Year		
2006	224	0.3%
2007	344	0.5%
2008	1,363	1.9%
2009	1,185	1.6%
2010	2,560	3.5%
2011	2,117	2.9%
2012	2,282	3.1%
2013	3,502	4.8%
2014	4,405	6.0%
2015	5,139	7.1%

**Table 1i. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2016	7,060	9.7%
2017	7,148	9.8%
2018	6,900	9.5%
2019	7,576	10.4%
2020	7,626	10.5%
2021	6,174	8.5%
2022	6,625	9.1%
2023	656	0.9%
Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.1	2.8
Combined comorbidity score categories	Number	Percent
≤0	27,485	37.7%
1-2	24,001	32.9%
3-4	10,306	14.1%
≥5	11,094	15.2%
Systemic sclerosis	114	0.2%
Rheumatoid arthritis	9,641	13.2%
Dermatomyositis/polymyositis	66	0.1%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	10,829	14.9%
Acute myocardial infarction	1,211	1.7%
Alzheimer's disease	332	0.5%
Alzheimer's disease and related disorders	1,519	2.1%
Anemia	27,478	37.7%
Asthma	9,398	12.9%
Atrial fibrillation	3,814	5.2%
Benign prostatic hyperplasia	4,697	6.4%
Breast cancer	1,479	2.0%
Colorectal cancer	833	1.1%
Endometrial cancer	180	0.2%
Lung cancer	476	0.7%
Prostate cancer	1,055	1.4%
Cataract	13,102	18.0%
Chronic kidney disease	11,131	15.3%
Chronic obstructive pulmonary disease and bronchiectasis	9,767	13.4%
Depression	16,879	23.2%

**Table 1i. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Diabetes	9,509	13.0%
Glaucoma	5,221	7.2%
Heart failure	3,119	4.3%
Hip/pelvic fracture	740	1.0%
Hyperlipidemia	26,692	36.6%
Hypertension	27,108	37.2%
Ischemic heart disease	8,699	11.9%
Osteoporosis	7,878	10.8%
Rheumatoid arthritis/osteoarthritis	25,325	34.7%
Stroke/transient ischemic attack	3,105	4.3%
Tobacco use	3,777	5.2%
<b>Medical Product Use</b>		
Methotrexate	5,764	7.9%
Amiodarone	282	0.4%
Bleomycin	*****	*****
Azathioprine	8,251	11.3%
Cyclophosphamide	17	0.0%
Sulfasalazine	4,567	6.3%
Checkpoint inhibitors	468	0.6%
Tyrosine kinase inhibitors	27	0.0%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.6	10.0
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.9	9.0
Mean number of filled prescriptions	19.3	16.7
Mean number of generics dispensed	7.8	5.4
Mean number of unique drug classes dispensed	7.3	4.9

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. *J Clin Epidemiol.* 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.



**Table 1j. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

Patient Characteristics	Number	Percent
Unique patients	26,272	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	53.1	13.9
Age		
18-24 years	1,685	6.4%
25-34 years	3,678	14.0%
35-44 years	3,769	14.3%
45-54 years	4,327	16.5%
55-64 years	4,208	16.0%
≥ 65 years	8,605	32.8%
Sex		
Female	16,386	62.4%
Male	9,886	37.6%
Race <sup>1</sup>		
American Indian or Alaska Native	109	0.4%
Asian	216	0.8%
Black or African American	1,239	4.7%
Multi-racial	106	0.4%
Native Hawaiian or Other Pacific Islander	19	0.1%
Unknown	12,217	46.5%
White	12,366	47.1%
Hispanic origin		
Yes	693	2.6%
No	12,953	49.3%
Unknown	12,626	48.1%
Year		
2006	58	0.2%
2007	122	0.5%
2008	374	1.4%
2009	447	1.7%
2010	884	3.4%
2011	1,019	3.9%
2012	1,068	4.1%
2013	1,348	5.1%
2014	1,586	6.0%
2015	1,836	7.0%

**Table 1j. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2016	2,271	8.6%
2017	2,369	9.0%
2018	2,413	9.2%
2019	2,574	9.8%
2020	2,792	10.6%
2021	2,393	9.1%
2022	2,501	9.5%
2023	217	0.8%
Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.0	3.5
Combined comorbidity score categories	Number	Percent
≤0	9,514	36.2%
1-2	6,611	25.2%
3-4	3,389	12.9%
≥5	6,758	25.7%
Systemic sclerosis	92	0.4%
Rheumatoid arthritis	9,952	37.9%
Dermatomyositis/polymyositis	68	0.3%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	6,191	23.6%
Acute myocardial infarction	851	3.2%
Alzheimer's disease	288	1.1%
Alzheimer's disease and related disorders	1,251	4.8%
Anemia	9,916	37.7%
Asthma	4,872	18.5%
Atrial fibrillation	2,257	8.6%
Benign prostatic hyperplasia	1,844	7.0%
Breast cancer	870	3.3%
Colorectal cancer	493	1.9%
Endometrial cancer	144	0.5%
Lung cancer	327	1.2%
Prostate cancer	408	1.6%
Cataract	7,531	28.7%
Chronic kidney disease	6,385	24.3%
Chronic obstructive pulmonary disease and bronchiectasis	6,003	22.8%
Depression	8,532	32.5%

**Table 1j. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Diabetes	5,086	19.4%
Glaucoma	2,914	11.1%
Heart failure	2,304	8.8%
Hip/pelvic fracture	646	2.5%
Hyperlipidemia	12,447	47.4%
Hypertension	13,417	51.1%
Ischemic heart disease	5,315	20.2%
Osteoporosis	5,904	22.5%
Rheumatoid arthritis/osteoarthritis	15,865	60.4%
Stroke/transient ischemic attack	2,213	8.4%
Tobacco use	2,473	9.4%
<b>Medical Product Use</b>		
Methotrexate	5,134	19.5%
Amiodarone	152	0.6%
Bleomycin	*****	*****
Azathioprine	905	3.4%
Cyclophosphamide	16	0.1%
Sulfasalazine	1,324	5.0%
Checkpoint inhibitors	329	1.3%
Tyrosine kinase inhibitors	23	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.8	12.9
Mean number of emergency room encounters	0.4	1.2
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	4.5	10.9
Mean number of filled prescriptions	24.2	21.7
Mean number of generics dispensed	9.1	6.6
Mean number of unique drug classes dispensed	8.5	5.8

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1k. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

Patient Characteristics	Number	Percent
Unique patients	14,011	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	49.0	14.1
Age		
18-24 years	1,229	8.8%
25-34 years	2,563	18.3%
35-44 years	2,390	17.1%
45-54 years	2,396	17.1%
55-64 years	2,005	14.3%
≥ 65 years	3,428	24.5%
Sex		
Female	8,232	58.8%
Male	5,779	41.2%
Race <sup>1</sup>		
American Indian or Alaska Native	*****	*****
Asian	98	0.7%
Black or African American	687	4.9%
Multi-racial	59	0.4%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	7,193	51.3%
White	5,921	42.3%
Hispanic origin		
Yes	343	2.4%
No	6,171	44.0%
Unknown	7,497	53.5%
Year		
2006	41	0.3%
2007	66	0.5%
2008	246	1.8%
2009	292	2.1%
2010	523	3.7%
2011	573	4.1%
2012	567	4.0%
2013	757	5.4%
2014	928	6.6%
2015	1,025	7.3%
2016	1,263	9.0%

**Table 1k. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	1,266	9.0%
2018	1,243	8.9%
2019	1,333	9.5%
2020	1,477	10.5%
2021	1,098	7.8%
2022	1,181	8.4%
2023	132	0.9%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.2	2.9
Combined comorbidity score categories	Number	Percent
≤0	6,170	44.0%
1-2	3,720	26.6%
3-4	1,636	11.7%
≥5	2,485	17.7%
Systemic sclerosis	39	0.3%
Rheumatoid arthritis	4,086	29.2%
Dermatomyositis/polymyositis	35	0.2%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	2,542	18.1%
Acute myocardial infarction	269	1.9%
Alzheimer's disease	96	0.7%
Alzheimer's disease and related disorders	416	3.0%
Anemia	4,257	30.4%
Asthma	2,206	15.7%
Atrial fibrillation	841	6.0%
Benign prostatic hyperplasia	772	5.5%
Breast cancer	352	2.5%
Colorectal cancer	151	1.1%
Endometrial cancer	53	0.4%
Lung cancer	89	0.6%
Prostate cancer	170	1.2%
Cataract	2,981	21.3%
Chronic kidney disease	2,504	17.9%
Chronic obstructive pulmonary disease and bronchiectasis	2,430	17.3%
Depression	3,782	27.0%
Diabetes	2,107	15.0%
Glaucoma	1,160	8.3%

**Table 1k. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	803	5.7%
Hip/pelvic fracture	199	1.4%
Hyperlipidemia	5,294	37.8%
Hypertension	5,841	41.7%
Ischemic heart disease	2,064	14.7%
Osteoporosis	2,279	16.3%
Rheumatoid arthritis/osteoarthritis	6,961	49.7%
Stroke/transient ischemic attack	780	5.6%
Tobacco use	1,254	9.0%
<b>Medical Product Use</b>		
Methotrexate	2,368	16.9%
Amiodarone	46	0.3%
Bleomycin	*****	*****
Azathioprine	569	4.1%
Cyclophosphamide	*****	*****
Sulfasalazine	555	4.0%
Checkpoint inhibitors	41	0.3%
Tyrosine kinase inhibitors	*****	*****
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	10.8	12.3
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.2	9.2
Mean number of filled prescriptions	21.6	20.5
Mean number of generics dispensed	8.0	6.3
Mean number of unique drug classes dispensed	7.5	5.6

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 11. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	11,518	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	57.8	13.1
<b>Age</b>	<b>Number</b>	<b>Percent</b>
18-24 years	416	3.6%
25-34 years	1,042	9.0%
35-44 years	1,302	11.3%
45-54 years	1,816	15.8%
55-64 years	2,079	18.1%
≥ 65 years	4,863	42.2%
<b>Sex</b>		
Female	7,641	66.3%
Male	3,877	33.7%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	58	0.5%
Asian	110	1.0%
Black or African American	523	4.5%
Multi-racial	44	0.4%
Native Hawaiian or Other Pacific Islander	13	0.1%
Unknown	4,703	40.8%
White	6,067	52.7%
<b>Hispanic origin</b>		
Yes	324	2.8%
No	6,383	55.4%
Unknown	4,811	41.8%
<b>Year</b>		
2006	16	0.1%
2007	53	0.5%
2008	127	1.1%
2009	147	1.3%
2010	352	3.1%
2011	434	3.8%
2012	490	4.3%
2013	580	5.0%
2014	640	5.6%
2015	794	6.9%
2016	971	8.4%

**Table 1I. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	1,011	8.8%
2018	1,061	9.2%
2019	1,144	9.9%
2020	1,202	10.4%
2021	1,197	10.4%
2022	1,218	10.6%
2023	81	0.7%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.9	3.9
Combined comorbidity score categories	Number	Percent
≤0	3,198	27.8%
1-2	2,727	23.7%
3-4	1,614	14.0%
≥5	3,979	34.5%
Systemic sclerosis	52	0.5%
Rheumatoid arthritis	5,514	47.9%
Dermatomyositis/polymyositis	32	0.3%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	3,420	29.7%
Acute myocardial infarction	540	4.7%
Alzheimer's disease	176	1.5%
Alzheimer's disease and related disorders	774	6.7%
Anemia	5,280	45.8%
Asthma	2,494	21.7%
Atrial fibrillation	1,319	11.5%
Benign prostatic hyperplasia	995	8.6%
Breast cancer	482	4.2%
Colorectal cancer	324	2.8%
Endometrial cancer	85	0.7%
Lung cancer	222	1.9%
Prostate cancer	224	1.9%
Cataract	4,250	36.9%
Chronic kidney disease	3,602	31.3%
Chronic obstructive pulmonary disease and bronchiectasis	3,333	28.9%
Depression	4,424	38.4%
Diabetes	2,758	23.9%
Glaucoma	1,618	14.0%



**Table 1I. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	1,415	12.3%
Hip/pelvic fracture	409	3.6%
Hyperlipidemia	6,698	58.2%
Hypertension	7,109	61.7%
Ischemic heart disease	3,057	26.5%
Osteoporosis	3,400	29.5%
Rheumatoid arthritis/osteoarthritis	8,337	72.4%
Stroke/transient ischemic attack	1,346	11.7%
Tobacco use	1,116	9.7%
<b>Medical Product Use</b>		
Methotrexate	2,595	22.5%
Amiodarone	103	0.9%
Bleomycin	0	0.0%
Azathioprine	320	2.8%
Cyclophosphamide	*****	*****
Sulfasalazine	734	6.4%
Checkpoint inhibitors	277	2.4%
Tyrosine kinase inhibitors	15	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	15.0	13.4
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	6.0	12.5
Mean number of filled prescriptions	27.2	22.8
Mean number of generics dispensed	10.4	6.7
Mean number of unique drug classes dispensed	9.7	6.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1m. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	2,460,987	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	57.3	14.6
Age	<b>Number</b>	<b>Percent</b>
18-24 years	139,819	5.7%
25-34 years	264,796	10.8%
35-44 years	287,287	11.7%
45-54 years	343,648	14.0%
55-64 years	356,685	14.5%
≥ 65 years	1,068,752	43.4%
Sex		
Female	1,450,411	58.9%
Male	1,010,576	41.1%
Race <sup>1</sup>		
American Indian or Alaska Native	7,599	0.3%
Asian	28,593	1.2%
Black or African American	141,938	5.8%
Multi-racial	6,027	0.2%
Native Hawaiian or Other Pacific Islander	2,109	0.1%
Unknown	1,041,098	42.3%
White	1,233,623	50.1%
Hispanic origin		
Yes	61,063	2.5%
No	1,333,565	54.2%
Unknown	1,066,359	43.3%
Year		
2006	28,743	1.2%
2007	37,101	1.5%
2008	85,708	3.5%
2009	78,774	3.2%
2010	170,481	6.9%
2011	161,549	6.6%
2012	144,537	5.9%
2013	161,966	6.6%
2014	170,097	6.9%
2015	183,816	7.5%
2016	201,516	8.2%

**Table 1m. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	196,408	8.0%
2018	182,077	7.4%
2019	184,793	7.5%
2020	178,128	7.2%
2021	143,791	5.8%
2022	140,264	5.7%
2023	11,238	0.5%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.9	3.6
Combined comorbidity score categories	Number	Percent
≤0	837,221	34.0%
1-2	693,070	28.2%
3-4	320,303	13.0%
≥5	610,393	24.8%
Systemic sclerosis	4,907	0.2%
Rheumatoid arthritis	83,384	3.4%
Dermatomyositis/polymyositis	2,240	0.1%
Anti-synthetase syndrome	213	0.0%
Acquired hypothyroidism	550,167	22.4%
Acute myocardial infarction	79,624	3.2%
Alzheimer's disease	54,552	2.2%
Alzheimer's disease and related disorders	169,412	6.9%
Anemia	924,063	37.5%
Asthma	366,923	14.9%
Atrial fibrillation	263,446	10.7%
Benign prostatic hyperplasia	251,348	10.2%
Breast cancer	92,100	3.7%
Colorectal cancer	78,649	3.2%
Endometrial cancer	18,448	0.7%
Lung cancer	30,197	1.2%
Prostate cancer	72,956	3.0%
Cataract	672,910	27.3%
Chronic kidney disease	595,591	24.2%
Chronic obstructive pulmonary disease and bronchiectasis	528,120	21.5%
Depression	691,250	28.1%
Diabetes	462,479	18.8%
Glaucoma	256,460	10.4%

**Table 1m. Aggregated Characteristics of Prevalent Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	231,484	9.4%
Hip/pelvic fracture	52,231	2.1%
Hyperlipidemia	1,290,811	52.5%
Hypertension	1,346,927	54.7%
Ischemic heart disease	560,578	22.8%
Osteoporosis	352,720	14.3%
Rheumatoid arthritis/osteoarthritis	951,065	38.6%
Stroke/transient ischemic attack	226,693	9.2%
Tobacco use	262,923	10.7%
<b>Medical Product Use</b>		
Methotrexate	37,531	1.5%
Amiodarone	23,813	1.0%
Bleomycin	216	0.0%
Azathioprine	73,858	3.0%
Cyclophosphamide	2,828	0.1%
Sulfasalazine	85,339	3.5%
Checkpoint inhibitors	4,929	0.2%
Tyrosine kinase inhibitors	3,341	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.5	13.5
Mean number of emergency room encounters	0.5	1.6
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	5.1	13.0
Mean number of filled prescriptions	18.5	19.0
Mean number of generics dispensed	7.3	5.6
Mean number of unique drug classes dispensed	6.8	5.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1n. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	986,629	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	54.2	14.9
Age	<b>Number</b>	<b>Percent</b>
18-24 years	71,823	7.3%
25-34 years	128,424	13.0%
35-44 years	132,778	13.5%
45-54 years	148,739	15.1%
55-64 years	142,695	14.5%
≥ 65 years	362,170	36.7%
Sex		
Female	582,932	59.1%
Male	403,697	40.9%
Race <sup>1</sup>		
American Indian or Alaska Native	3,150	0.3%
Asian	9,727	1.0%
Black or African American	60,207	6.1%
Multi-racial	2,515	0.3%
Native Hawaiian or Other Pacific Islander	813	0.1%
Unknown	433,094	43.9%
White	477,123	48.4%
Hispanic origin		
Yes	21,073	2.1%
No	518,696	52.6%
Unknown	446,860	45.3%
Year		
2006	13,265	1.3%
2007	15,326	1.6%
2008	37,145	3.8%
2009	31,759	3.2%
2010	74,316	7.5%
2011	63,947	6.5%
2012	57,410	5.8%
2013	65,278	6.6%
2014	70,855	7.2%
2015	76,338	7.7%
2016	85,986	8.7%

**Table 1n. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	79,650	8.1%
2018	70,614	7.2%
2019	70,651	7.2%
2020	69,182	7.0%
2021	50,878	5.2%
2022	49,667	5.0%
2023	4,362	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.5	3.2

  

Combined comorbidity score categories	Number	Percent
≤0	354,738	36.0%
1-2	299,694	30.4%
3-4	129,644	13.1%
≥5	202,553	20.5%
Systemic sclerosis	1,913	0.2%
Rheumatoid arthritis	32,223	3.3%
Dermatomyositis/polymyositis	949	0.1%
Anti-synthetase syndrome	86	0.0%
Acquired hypothyroidism	192,357	19.5%
Acute myocardial infarction	24,201	2.5%
Alzheimer's disease	15,137	1.5%
Alzheimer's disease and related disorders	48,400	4.9%
Anemia	342,934	34.8%
Asthma	141,705	14.4%
Atrial fibrillation	85,367	8.7%
Benign prostatic hyperplasia	84,595	8.6%
Breast cancer	30,754	3.1%
Colorectal cancer	27,738	2.8%
Endometrial cancer	6,483	0.7%
Lung cancer	9,956	1.0%
Prostate cancer	21,791	2.2%
Cataract	221,976	22.5%
Chronic kidney disease	205,734	20.9%
Chronic obstructive pulmonary disease and bronchiectasis	191,644	19.4%
Depression	266,742	27.0%
Diabetes	158,351	16.0%
Glaucoma	84,296	8.5%

**Table 1n. Aggregated Characteristics of Prevalent Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	72,564	7.4%
Hip/pelvic fracture	15,265	1.5%
Hyperlipidemia	450,351	45.6%
Hypertension	489,869	49.7%
Ischemic heart disease	187,973	19.1%
Osteoporosis	119,512	12.1%
Rheumatoid arthritis/osteoarthritis	339,126	34.4%
Stroke/transient ischemic attack	71,604	7.3%
Tobacco use	123,874	12.6%
<b>Medical Product Use</b>		
Methotrexate	18,757	1.9%
Amiodarone	7,561	0.8%
Bleomycin	77	0.0%
Azathioprine	40,848	4.1%
Cyclophosphamide	868	0.1%
Sulfasalazine	25,286	2.6%
Checkpoint inhibitors	918	0.1%
Tyrosine kinase inhibitors	1,033	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.1	13.0
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.3	11.7
Mean number of filled prescriptions	18.0	18.8
Mean number of generics dispensed	7.1	5.6
Mean number of unique drug classes dispensed	6.6	5.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1o. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	1,329,505	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	59.9	14.1
Age	<b>Number</b>	<b>Percent</b>
18-24 years	53,685	4.0%
25-34 years	118,353	8.9%
35-44 years	136,750	10.3%
45-54 years	175,186	13.2%
55-64 years	194,130	14.6%
≥ 65 years	651,401	49.0%
Sex		
Female	782,841	58.9%
Male	546,664	41.1%
Race <sup>1</sup>		
American Indian or Alaska Native	4,011	0.3%
Asian	17,308	1.3%
Black or African American	73,753	5.5%
Multi-racial	3,121	0.2%
Native Hawaiian or Other Pacific Islander	1,157	0.1%
Unknown	543,422	40.9%
White	686,733	51.7%
Hispanic origin		
Yes	35,740	2.7%
No	740,105	55.7%
Unknown	553,660	41.6%
Year		
2006	13,396	1.0%
2007	19,968	1.5%
2008	43,214	3.3%
2009	43,214	3.3%
2010	86,368	6.5%
2011	91,416	6.9%
2012	82,027	6.2%
2013	90,099	6.8%
2014	92,769	7.0%
2015	100,686	7.6%
2016	105,988	8.0%



**Table 1o. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	101,304	7.6%
2018	96,452	7.3%
2019	98,928	7.4%
2020	94,809	7.1%
2021	82,392	6.2%
2022	80,456	6.1%
2023	6,019	0.5%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.2	3.8

  

Combined comorbidity score categories	Number	Percent
≤0	439,362	33.0%
1-2	348,705	26.2%
3-4	168,611	12.7%
≥5	372,827	28.0%
Systemic sclerosis	2,742	0.2%
Rheumatoid arthritis	46,209	3.5%
Dermatomyositis/polymyositis	1,175	0.1%
Anti-synthetase syndrome	110	0.0%
Acquired hypothyroidism	327,785	24.7%
Acute myocardial infarction	51,193	3.9%
Alzheimer's disease	37,205	2.8%
Alzheimer's disease and related disorders	113,220	8.5%
Anemia	521,444	39.2%
Asthma	202,748	15.2%
Atrial fibrillation	165,081	12.4%
Benign prostatic hyperplasia	153,890	11.6%
Breast cancer	56,257	4.2%
Colorectal cancer	46,715	3.5%
Endometrial cancer	11,067	0.8%
Lung cancer	18,634	1.4%
Prostate cancer	47,919	3.6%
Cataract	415,336	31.2%
Chronic kidney disease	355,869	26.8%
Chronic obstructive pulmonary disease and bronchiectasis	308,139	23.2%
Depression	382,004	28.7%
Diabetes	277,232	20.9%
Glaucoma	158,252	11.9%

**Table 1o. Aggregated Characteristics of Prevalent Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	146,694	11.0%
Hip/pelvic fracture	34,411	2.6%
Hyperlipidemia	771,290	58.0%
Hypertension	784,339	59.0%
Ischemic heart disease	344,266	25.9%
Osteoporosis	213,617	16.1%
Rheumatoid arthritis/osteoarthritis	558,735	42.0%
Stroke/transient ischemic attack	143,984	10.8%
Tobacco use	123,055	9.3%
<b>Medical Product Use</b>		
Methotrexate	15,633	1.2%
Amiodarone	15,143	1.1%
Bleomycin	118	0.0%
Azathioprine	25,605	1.9%
Cyclophosphamide	1,812	0.1%
Sulfasalazine	54,417	4.1%
Checkpoint inhibitors	3,618	0.3%
Tyrosine kinase inhibitors	2,120	0.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.8	14.0
Mean number of emergency room encounters	0.5	1.5
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	5.7	13.9
Mean number of filled prescriptions	18.9	19.1
Mean number of generics dispensed	7.5	5.6
Mean number of unique drug classes dispensed	7.0	5.0

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1q. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	630,987	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	56.9	14.7
Age	<b>Number</b>	<b>Percent</b>
18-24 years	35,290	5.6%
25-34 years	69,441	11.0%
35-44 years	77,728	12.3%
45-54 years	93,546	14.8%
55-64 years	92,910	14.7%
≥ 65 years	262,072	41.5%
Sex		
Female	378,089	59.9%
Male	252,898	40.1%
Race <sup>1</sup>		
American Indian or Alaska Native	2,266	0.4%
Asian	8,054	1.3%
Black or African American	39,373	6.2%
Multi-racial	1,515	0.2%
Native Hawaiian or Other Pacific Islander	574	0.1%
Unknown	265,077	42.0%
White	314,128	49.8%
Hispanic origin		
Yes	15,449	2.4%
No	346,507	54.9%
Unknown	269,031	42.6%
Year		
2006	5,258	0.8%
2007	9,398	1.5%
2008	18,652	3.0%
2009	21,616	3.4%
2010	37,527	5.9%
2011	46,008	7.3%
2012	42,458	6.7%
2013	44,281	7.0%
2014	47,972	7.6%
2015	51,054	8.1%
2016	52,613	8.3%

**Table 1q. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	51,985	8.2%
2018	47,274	7.5%
2019	45,952	7.3%
2020	43,140	6.8%
2021	32,464	5.1%
2022	30,770	4.9%
2023	2,565	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.1	3.5

  

Combined comorbidity score categories	Number	Percent
≤0	197,584	31.3%
1-2	178,482	28.3%
3-4	88,236	14.0%
≥5	166,685	26.4%
Systemic sclerosis	1,428	0.2%
Rheumatoid arthritis	21,019	3.3%
Dermatomyositis/polymyositis	751	0.1%
Anti-synthetase syndrome	65	0.0%
Acquired hypothyroidism	150,396	23.8%
Acute myocardial infarction	21,477	3.4%
Alzheimer's disease	13,270	2.1%
Alzheimer's disease and related disorders	42,176	6.7%
Anemia	243,947	38.7%
Asthma	106,142	16.8%
Atrial fibrillation	70,278	11.1%
Benign prostatic hyperplasia	67,753	10.7%
Breast cancer	24,261	3.8%
Colorectal cancer	23,269	3.7%
Endometrial cancer	5,560	0.9%
Lung cancer	8,084	1.3%
Prostate cancer	17,503	2.8%
Cataract	180,440	28.6%
Chronic kidney disease	161,238	25.6%
Chronic obstructive pulmonary disease and bronchiectasis	151,371	24.0%
Depression	189,860	30.1%
Diabetes	125,705	19.9%
Glaucoma	67,754	10.7%

**Table 1q. Aggregated Characteristics of Incident Crohn's Disease (CD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	62,091	9.8%
Hip/pelvic fracture	13,172	2.1%
Hyperlipidemia	343,510	54.4%
Hypertension	360,271	57.1%
Ischemic heart disease	154,027	24.4%
Osteoporosis	91,425	14.5%
Rheumatoid arthritis/osteoarthritis	260,029	41.2%
Stroke/transient ischemic attack	61,514	9.7%
Tobacco use	82,926	13.1%
<b>Medical Product Use</b>		
Methotrexate	7,616	1.2%
Amiodarone	6,138	1.0%
Bleomycin	46	0.0%
Azathioprine	6,190	1.0%
Cyclophosphamide	663	0.1%
Sulfasalazine	10,776	1.7%
Checkpoint inhibitors	808	0.1%
Tyrosine kinase inhibitors	810	0.1%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.5	13.8
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	4.8	12.4
Mean number of filled prescriptions	18.3	19.1
Mean number of generics dispensed	7.3	5.7
Mean number of unique drug classes dispensed	6.8	5.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1p. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	1,719,777	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	59.7	14.3
Age	<b>Number</b>	<b>Percent</b>
18-24 years	72,979	4.2%
25-34 years	153,993	9.0%
35-44 years	181,060	10.5%
45-54 years	233,806	13.6%
55-64 years	253,518	14.7%
≥ 65 years	824,421	47.9%
Sex		
Female	1,037,689	60.3%
Male	682,088	39.7%
Race <sup>1</sup>		
American Indian or Alaska Native	5,809	0.3%
Asian	23,487	1.4%
Black or African American	104,356	6.1%
Multi-racial	3,879	0.2%
Native Hawaiian or Other Pacific Islander	1,524	0.1%
Unknown	682,692	39.7%
White	898,030	52.2%
Hispanic origin		
Yes	46,719	2.7%
No	983,783	57.2%
Unknown	689,275	40.1%
Year		
2006	13,067	0.8%
2007	24,277	1.4%
2008	47,574	2.8%
2009	55,769	3.2%
2010	97,169	5.7%
2011	121,816	7.1%
2012	111,945	6.5%
2013	116,128	6.8%
2014	122,253	7.1%
2015	132,585	7.7%
2016	135,563	7.9%

**Table 1p. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	139,789	8.1%
2018	133,371	7.8%
2019	133,558	7.8%
2020	124,793	7.3%
2021	103,910	6.0%
2022	98,876	5.7%
2023	7,334	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.5	3.8

  

Combined comorbidity score categories	Number	Percent
≤0	504,847	29.4%
1-2	448,917	26.1%
3-4	235,802	13.7%
≥5	530,211	30.8%
Systemic sclerosis	3,857	0.2%
Rheumatoid arthritis	61,296	3.6%
Dermatomyositis/polymyositis	1,785	0.1%
Anti-synthetase syndrome	168	0.0%
Acquired hypothyroidism	453,230	26.4%
Acute myocardial infarction	72,823	4.2%
Alzheimer's disease	49,432	2.9%
Alzheimer's disease and related disorders	153,150	8.9%
Anemia	718,838	41.8%
Asthma	292,485	17.0%
Atrial fibrillation	226,260	13.2%
Benign prostatic hyperplasia	206,487	12.0%
Breast cancer	76,349	4.4%
Colorectal cancer	67,351	3.9%
Endometrial cancer	16,381	1.0%
Lung cancer	26,113	1.5%
Prostate cancer	60,360	3.5%
Cataract	570,211	33.2%
Chronic kidney disease	500,768	29.1%
Chronic obstructive pulmonary disease and bronchiectasis	446,025	25.9%
Depression	540,171	31.4%
Diabetes	385,478	22.4%
Glaucoma	214,954	12.5%

**Table 1p. Aggregated Characteristics of Incident Inflammatory Bowel Disease (IBD) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	207,049	12.0%
Hip/pelvic fracture	47,366	2.8%
Hyperlipidemia	1,029,147	59.8%
Hypertension	1,058,070	61.5%
Ischemic heart disease	478,567	27.8%
Osteoporosis	291,864	17.0%
Rheumatoid arthritis/osteoarthritis	777,262	45.2%
Stroke/transient ischemic attack	202,902	11.8%
Tobacco use	199,641	11.6%
<b>Medical Product Use</b>		
Methotrexate	19,494	1.1%
Amiodarone	20,368	1.2%
Bleomycin	145	0.0%
Azathioprine	12,586	0.7%
Cyclophosphamide	2,372	0.1%
Sulfasalazine	39,916	2.3%
Checkpoint inhibitors	4,605	0.3%
Tyrosine kinase inhibitors	2,859	0.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.1	14.4
Mean number of emergency room encounters	0.6	1.6
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	5.9	14.0
Mean number of filled prescriptions	19.2	19.6
Mean number of generics dispensed	7.6	5.7
Mean number of unique drug classes dispensed	7.1	5.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.



**Table 1r. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	1,024,941	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	61.5	14.0
Age	<b>Number</b>	<b>Percent</b>
18-24 years	34,318	3.3%
25-34 years	78,888	7.7%
35-44 years	97,051	9.5%
45-54 years	132,362	12.9%
55-64 years	151,276	14.8%
≥ 65 years	531,046	51.8%
Sex		
Female	619,296	60.4%
Male	405,645	39.6%
Race <sup>1</sup>		
American Indian or Alaska Native	3,331	0.3%
Asian	14,481	1.4%
Black or African American	61,450	6.0%
Multi-racial	2,185	0.2%
Native Hawaiian or Other Pacific Islander	879	0.1%
Unknown	393,890	38.4%
White	548,725	53.5%
Hispanic origin		
Yes	29,014	2.8%
No	599,561	58.5%
Unknown	396,366	38.7%
Year		
2006	7,586	0.7%
2007	14,566	1.4%
2008	28,203	2.8%
2009	33,196	3.2%
2010	58,418	5.7%
2011	74,422	7.3%
2012	68,254	6.7%
2013	70,587	6.9%
2014	72,975	7.1%
2015	80,200	7.8%
2016	79,954	7.8%

**Table 1r. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	78,271	7.6%
2018	76,312	7.4%
2019	77,867	7.6%
2020	73,140	7.1%
2021	64,834	6.3%
2022	61,873	6.0%
2023	4,283	0.4%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	3.7	3.9

  

Combined comorbidity score categories	Number	Percent
≤0	293,766	28.7%
1-2	253,505	24.7%
3-4	137,154	13.4%
≥5	340,516	33.2%
Systemic sclerosis	2,318	0.2%
Rheumatoid arthritis	38,146	3.7%
Dermatomyositis/polymyositis	981	0.1%
Anti-synthetase syndrome	94	0.0%
Acquired hypothyroidism	283,958	27.7%
Acute myocardial infarction	48,104	4.7%
Alzheimer's disease	34,531	3.4%
Alzheimer's disease and related disorders	105,210	10.3%
Anemia	445,586	43.5%
Asthma	173,614	16.9%
Atrial fibrillation	147,480	14.4%
Benign prostatic hyperplasia	130,835	12.8%
Breast cancer	48,701	4.8%
Colorectal cancer	41,639	4.1%
Endometrial cancer	10,166	1.0%
Lung cancer	16,919	1.7%
Prostate cancer	40,929	4.0%
Cataract	364,792	35.6%
Chronic kidney disease	317,735	31.0%
Chronic obstructive pulmonary disease and bronchiectasis	276,292	27.0%
Depression	326,862	31.9%
Diabetes	241,672	23.6%
Glaucoma	137,701	13.4%

**Table 1r. Aggregated Characteristics of Incident Ulcerative Colitis (UC) Cohort in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	135,937	13.3%
Hip/pelvic fracture	32,301	3.2%
Hyperlipidemia	644,552	62.9%
Hypertension	656,724	64.1%
Ischemic heart disease	306,109	29.9%
Osteoporosis	188,060	18.3%
Rheumatoid arthritis/osteoarthritis	484,073	47.2%
Stroke/transient ischemic attack	133,380	13.0%
Tobacco use	108,286	10.6%
<b>Medical Product Use</b>		
Methotrexate	11,173	1.1%
Amiodarone	13,539	1.3%
Bleomycin	92	0.0%
Azathioprine	6,167	0.6%
Cyclophosphamide	1,614	0.2%
Sulfasalazine	28,335	2.8%
Checkpoint inhibitors	3,436	0.3%
Tyrosine kinase inhibitors	1,913	0.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.4	14.8
Mean number of emergency room encounters	0.6	1.6
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	6.5	14.8
Mean number of filled prescriptions	19.8	19.9
Mean number of generics dispensed	7.8	5.7
Mean number of unique drug classes dispensed	7.3	5.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

**Table 1s. Aggregated Characteristics of Advanced Therapy Initiators with Inflammatory Bowel Disease (IBD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	134,061	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	45.9	14.4
<b>Age</b>	<b>Number</b>	<b>Percent</b>
18-24 years	17,092	12.7%
25-34 years	27,630	20.6%
35-44 years	24,518	18.3%
45-54 years	21,764	16.2%
55-64 years	17,008	12.7%
≥ 65 years	26,049	19.4%
<b>Sex</b>		
Female	74,939	55.9%
Male	59,122	44.1%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	387	0.3%
Asian	866	0.6%
Black or African American	7,635	5.7%
Multi-racial	526	0.4%
Native Hawaiian or Other Pacific Islander	78	0.1%
Unknown	74,222	55.4%
White	50,347	37.6%
<b>Hispanic origin</b>		
Yes	3,208	2.4%
No	55,003	41.0%
Unknown	75,850	56.6%
<b>Year</b>		
2006	352	0.3%
2007	1,112	0.8%
2008	2,315	1.7%
2009	3,652	2.7%
2010	4,484	3.3%
2011	5,254	3.9%
2012	5,642	4.2%
2013	6,411	4.8%
2014	8,417	6.3%
2015	9,565	7.1%
2016	11,467	8.6%

**Table 1s. Aggregated Characteristics of Advanced Therapy Initiators with Inflammatory Bowel Disease (IBD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	13,301	9.9%
2018	13,739	10.2%
2019	14,213	10.6%
2020	14,013	10.5%
2021	9,485	7.1%
2022	9,574	7.1%
2023	1,065	0.8%

  

Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.6	2.7
Combined comorbidity score categories	Number	Percent
≤0	35,186	26.2%
1-2	47,344	35.3%
3-4	25,334	18.9%
≥5	26,197	19.5%
Systemic sclerosis	159	0.1%
Rheumatoid arthritis	9,026	6.7%
Dermatomyositis/polymyositis	88	0.1%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	20,954	15.6%
Acute myocardial infarction	2,044	1.5%
Alzheimer's disease	505	0.4%
Alzheimer's disease and related disorders	2,558	1.9%
Anemia	64,519	48.1%
Asthma	21,980	16.4%
Atrial fibrillation	6,217	4.6%
Benign prostatic hyperplasia	9,036	6.7%
Breast cancer	2,630	2.0%
Colorectal cancer	2,113	1.6%
Endometrial cancer	418	0.3%
Lung cancer	633	0.5%
Prostate cancer	1,793	1.3%
Cataract	23,579	17.6%
Chronic kidney disease	25,228	18.8%
Chronic obstructive pulmonary disease and bronchiectasis	22,121	16.5%
Depression	41,282	30.8%
Diabetes	16,595	12.4%
Glaucoma	9,492	7.1%

**Table 1s. Aggregated Characteristics of Advanced Therapy Initiators with Inflammatory Bowel Disease (IBD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	5,513	4.1%
Hip/pelvic fracture	1,241	0.9%
Hyperlipidemia	47,967	35.8%
Hypertension	50,934	38.0%
Ischemic heart disease	15,922	11.9%
Osteoporosis	15,007	11.2%
Rheumatoid arthritis/osteoarthritis	45,816	34.2%
Stroke/transient ischemic attack	6,063	4.5%
Tobacco use	15,523	11.6%
Length of inflammatory bowel disease (IBD) history		
<1 years	56,377	42.1%
1-<2 years	24,749	18.5%
≥2 years	52,935	39.5%
<b>Medical Product Use</b>		
Methotrexate	3,275	2.4%
Amiodarone	0	0.0%
Bleomycin	*****	*****
Azathioprine	6,765	5.0%
Cyclophosphamide	29	0.0%
Sulfasalazine	3,654	2.7%
Checkpoint inhibitors	62	0.0%
Tyrosine kinase inhibitors	*****	*****
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.5	10.5
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.8	10.8
Mean number of filled prescriptions	18.0	16.7
Mean number of generics dispensed	7.8	5.5
Mean number of unique drug classes dispensed	7.3	4.9

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1t. Aggregated Characteristics of Advanced Therapy Initiators with Crohn's Disease (CD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	64,551	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	43.9	14.3
<b>Age</b>	<b>Number</b>	<b>Percent</b>
18-24 years	9,308	14.4%
25-34 years	14,459	22.4%
35-44 years	12,324	19.1%
45-54 years	10,611	16.4%
55-64 years	7,740	12.0%
≥ 65 years	10,109	15.7%
<b>Sex</b>		
Female	36,822	57.0%
Male	27,729	43.0%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	166	0.3%
Asian	336	0.5%
Black or African American	4,283	6.6%
Multi-racial	256	0.4%
Native Hawaiian or Other Pacific Islander	38	0.1%
Unknown	34,921	54.1%
White	24,551	38.0%
<b>Hispanic origin</b>		
Yes	1,304	2.0%
No	27,363	42.4%
Unknown	35,884	55.6%
<b>Year</b>		
2006	195	0.3%
2007	683	1.1%
2008	1,325	2.1%
2009	1,999	3.1%
2010	2,358	3.7%
2011	2,728	4.2%
2012	2,816	4.4%
2013	3,080	4.8%
2014	4,041	6.3%
2015	4,625	7.2%
2016	5,597	8.7%

**Table 1t. Aggregated Characteristics of Advanced Therapy Initiators with Crohn's Disease (CD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	6,582	10.2%
2018	6,607	10.2%
2019	6,628	10.3%
2020	6,652	10.3%
2021	4,093	6.3%
2022	4,063	6.3%
2023	479	0.7%
Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.3	2.5
Combined comorbidity score categories	Number	Percent
≤0	18,873	29.2%
1-2	23,649	36.6%
3-4	11,561	17.9%
≥5	10,468	16.2%
Systemic sclerosis	81	0.1%
Rheumatoid arthritis	3,859	6.0%
Dermatomyositis/polymyositis	35	0.1%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	8,626	13.4%
Acute myocardial infarction	725	1.1%
Alzheimer's disease	172	0.3%
Alzheimer's disease and related disorders	923	1.4%
Anemia	27,800	43.1%
Asthma	10,120	15.7%
Atrial fibrillation	2,355	3.6%
Benign prostatic hyperplasia	3,426	5.3%
Breast cancer	1,020	1.6%
Colorectal cancer	847	1.3%
Endometrial cancer	185	0.3%
Lung cancer	249	0.4%
Prostate cancer	638	1.0%
Cataract	9,262	14.3%
Chronic kidney disease	10,744	16.6%
Chronic obstructive pulmonary disease and bronchiectasis	9,822	15.2%
Depression	19,875	30.8%
Diabetes	6,549	10.1%
Glaucoma	3,757	5.8%



**Table 1t. Aggregated Characteristics of Advanced Therapy Initiators with Crohn's Disease (CD) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	2,082	3.2%
Hip/pelvic fracture	450	0.7%
Hyperlipidemia	19,418	30.1%
Hypertension	22,210	34.4%
Ischemic heart disease	6,257	9.7%
Osteoporosis	6,355	9.8%
Rheumatoid arthritis/osteoarthritis	19,784	30.6%
Stroke/transient ischemic attack	2,405	3.7%
Tobacco use	9,360	14.5%
Length of inflammatory bowel disease (IBD) history		
<1 years	29,493	45.7%
1-<2 years	11,918	18.5%
≥2 years	23,140	35.8%
<b>Medical Product Use</b>		
Methotrexate	1,599	2.5%
Amiodarone	0	0.0%
Bleomycin	*****	*****
Azathioprine	3,303	5.1%
Cyclophosphamide	16	0.0%
Sulfasalazine	1,231	1.9%
Checkpoint inhibitors	*****	*****
Tyrosine kinase inhibitors	*****	*****
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.0	10.6
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.5	10.7
Mean number of filled prescriptions	16.8	16.8
Mean number of generics dispensed	7.4	5.5
Mean number of unique drug classes dispensed	6.9	4.9

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1u. Aggregated Characteristics of Advanced Therapy Initiators with Ulcerative Colitis (UC) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

<b>Patient Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	33,993	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	48.3	13.9
Age	<b>Number</b>	<b>Percent</b>
18-24 years	3,540	10.4%
25-34 years	6,491	19.1%
35-44 years	5,781	17.0%
45-54 years	5,309	15.6%
55-64 years	4,566	13.4%
≥ 65 years	8,306	24.4%
Sex		
Female	18,293	53.8%
Male	15,700	46.2%
Race <sup>1</sup>		
American Indian or Alaska Native	132	0.4%
Asian	311	0.9%
Black or African American	1,320	3.9%
Multi-racial	155	0.5%
Native Hawaiian or Other Pacific Islander	29	0.1%
Unknown	19,712	58.0%
White	12,334	36.3%
Hispanic origin		
Yes	1,071	3.2%
No	12,898	37.9%
Unknown	20,024	58.9%
Year		
2006	56	0.2%
2007	162	0.5%
2008	397	1.2%
2009	629	1.9%
2010	883	2.6%
2011	993	2.9%
2012	1,084	3.2%
2013	1,365	4.0%
2014	2,038	6.0%
2015	2,436	7.2%
2016	3,179	9.4%

**Table 1u. Aggregated Characteristics of Advanced Therapy Initiators with Ulcerative Colitis (UC) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
2017	3,509	10.3%
2018	3,498	10.3%
2019	3,824	11.2%
2020	3,824	11.2%
2021	2,828	8.3%
2022	2,963	8.7%
2023	325	1.0%
Health Characteristics	Mean	Standard Deviation
Combined comorbidity score <sup>2</sup>	2.4	2.7
Combined comorbidity score categories	Number	Percent
≤0	9,766	28.7%
1-2	11,907	35.0%
3-4	6,072	17.9%
≥5	6,248	18.4%
Systemic sclerosis	41	0.1%
Rheumatoid arthritis	3,308	9.7%
Dermatomyositis/polymyositis	23	0.1%
Anti-synthetase syndrome	*****	*****
Acquired hypothyroidism	5,888	17.3%
Acute myocardial infarction	625	1.8%
Alzheimer's disease	161	0.5%
Alzheimer's disease and related disorders	742	2.2%
Anemia	15,710	46.2%
Asthma	5,361	15.8%
Atrial fibrillation	1,767	5.2%
Benign prostatic hyperplasia	2,602	7.7%
Breast cancer	787	2.3%
Colorectal cancer	449	1.3%
Endometrial cancer	100	0.3%
Lung cancer	196	0.6%
Prostate cancer	581	1.7%
Cataract	7,145	21.0%
Chronic kidney disease	6,047	17.8%
Chronic obstructive pulmonary disease and bronchiectasis	5,521	16.2%
Depression	9,169	27.0%
Diabetes	4,990	14.7%
Glaucoma	2,821	8.3%

**Table 1u. Aggregated Characteristics of Advanced Therapy Initiators with Ulcerative Colitis (UC) in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number	Percent
Heart failure	1,525	4.5%
Hip/pelvic fracture	365	1.1%
Hyperlipidemia	13,935	41.0%
Hypertension	13,678	40.2%
Ischemic heart disease	4,558	13.4%
Osteoporosis	3,881	11.4%
Rheumatoid arthritis/osteoarthritis	12,695	37.3%
Stroke/transient ischemic attack	1,725	5.1%
Tobacco use	2,017	5.9%
Length of inflammatory bowel disease (IBD) history		
<1 years	15,463	45.5%
1-<2 years	6,414	18.9%
≥2 years	12,116	35.6%
<b>Medical Product Use</b>		
Methotrexate	971	2.9%
Amiodarone	0	0.0%
Bleomycin	*****	*****
Azathioprine	1,563	4.6%
Cyclophosphamide	*****	*****
Sulfasalazine	1,361	4.0%
Checkpoint inhibitors	45	0.1%
Tyrosine kinase inhibitors	*****	*****
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	12.1	9.9
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.3	9.5
Mean number of filled prescriptions	18.6	16.0
Mean number of generics dispensed	8.0	5.3
Mean number of unique drug classes dispensed	7.5	4.8

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 2. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent cohorts excluding prior vedolizumab/natalizumab use</b>						
Prevalent inflammatory bowel disease (IBD) cohort excluding prior vedolizumab/natalizumab use	2,439,541	2,439,541	29,489,959	29,489,959	122,636	484,990
Prevalent Crohn's disease (CD) cohort excluding prior vedolizumab/natalizumab use	976,715	976,715	14,884,092	14,884,092	46,739	182,375
Prevalent ulcerative colitis (UC) cohort excluding prior vedolizumab/natalizumab use	1,320,770	1,320,770	10,612,760	10,612,760	69,985	279,435
<b>Incident cohorts excluding prior vedolizumab/natalizumab use</b>						
Incident IBD cohort excluding prior vedolizumab/natalizumab use	1,718,382	1,718,382	12,028,200	12,028,200	93,178	361,658
Incident CD cohort excluding prior vedolizumab/natalizumab use	630,457	630,457	4,807,321	4,807,321	32,663	126,238
Incident UC cohort excluding prior vedolizumab/natalizumab use	1,024,124	1,024,124	5,893,085	5,893,085	57,909	226,449
<b>Prevalent cohorts excluding prior vedolizumab/natalizumab use and requiring other advanced therapy</b>						
Prevalent IBD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	296,808	296,808	9,686,858	9,686,858	8,673	37,151
Prevalent CD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	167,458	167,458	5,796,871	5,796,871	4,584	19,391
Prevalent UC cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	72,886	72,886	1,572,878	1,572,878	2,398	11,021

**Table 2. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident cohorts excluding prior vedolizumab/natalizumab use and requiring other advanced therapy</b>						
Incident IBD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	26,272	26,272	265,002	265,002	1,501	7,665
Incident CD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	14,011	14,011	166,249	166,249	638	3,578
Incident UC cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	11,518	11,518	76,941	76,941	833	3,891
<b>Prevalent cohorts</b>						
Prevalent IBD cohort	2,460,987	2,460,987	32,198,108	32,198,108	124,385	494,658
Prevalent CD cohort	986,629	986,629	16,279,377	16,279,377	47,598	186,873
Prevalent UC cohort	1,329,505	1,329,505	11,432,848	11,432,848	70,675	283,341
<b>Incident cohorts</b>						
Incident IBD cohort	1,719,777	1,719,777	12,685,143	12,685,143	93,722	364,725
Incident CD cohort	630,987	630,987	5,049,767	5,049,767	32,885	127,162
Incident UC cohort	1,024,941	1,024,941	6,192,569	6,192,569	58,210	228,488
<b>Advanced therapy initiators cohorts</b>						
Advanced therapy initiators with IBD	134,061	134,061	1,924,385	1,927,120	2,819	9,497
Advanced therapy initiators with CD	64,551	64,551	945,856	947,131	1,264	3,946
Advanced therapy initiators with UC	33,993	33,993	453,131	453,938	743	2,798

**Table 2. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent cohorts excluding prior vedolizumab/natalizumab use</b>						
Prevalent inflammatory bowel disease (IBD) cohort excluding prior vedolizumab/natalizumab use	2,815,502,861	7,708,426.7	229,160,541	259,454,063,623	710,346,512.3	159.09 (158.21, 159.99)
Prevalent Crohn's disease (CD) cohort excluding prior vedolizumab/natalizumab use	1,129,686,892	3,092,914.1	228,661,234	259,241,732,741	709,765,182.0	151.12 (149.75, 152.49)
Prevalent ulcerative colitis (UC) cohort excluding prior vedolizumab/natalizumab use	1,538,896,472	4,213,268.9	228,643,831	259,297,897,760	709,918,953.5	166.11 (164.88, 167.34)
<b>Incident cohorts excluding prior vedolizumab/natalizumab use</b>						
Incident IBD cohort excluding prior vedolizumab/natalizumab use	1,969,435,912	5,392,021.7	228,210,697	259,101,821,278	709,382,125.3	172.81 (171.70, 173.92)
Incident CD cohort excluding prior vedolizumab/natalizumab use	733,311,272	2,007,696.8	228,209,407	259,100,733,230	709,379,146.4	162.69 (160.93, 164.46)
Incident UC cohort excluding prior vedolizumab/natalizumab use	1,180,832,723	3,232,943.8	228,209,669	259,101,126,952	709,380,224.4	179.12 (177.67, 180.59)
<b>Prevalent cohorts excluding prior vedolizumab/natalizumab use and requiring other advanced therapy</b>						
Prevalent IBD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	280,022,907	766,660.9	1,175,080	1,012,695,023	2,772,607.9	113.13 (110.77, 115.53)
Prevalent CD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	161,031,594	440,880.5	1,048,550	1,002,047,551	2,743,456.7	103.97 (101.01, 107.03)
Prevalent UC cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	64,261,649	175,938.8	952,657	998,300,169	2,733,196.9	136.30 (130.95, 141.86)

**Table 2. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident cohorts excluding prior vedolizumab/natalizumab use and requiring other advanced therapy</b>						
Incident IBD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	25,349,185	69,402.3	882,642	990,280,748	2,711,240.9	216.28 (205.61, 227.50)
Incident CD cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	13,517,482	37,008.8	882,001	990,268,487	2,711,207.4	172.39 (159.52, 186.30)
Incident UC cohort excluding prior vedolizumab/natalizumab use and requiring other advanced therapy	11,210,302	30,692.1	881,581	990,265,994	2,711,200.5	271.41 (253.59, 290.48)
<b>Prevalent cohorts</b>						
Prevalent IBD cohort	2,868,757,749	7,854,230.7	229,204,515	259,526,991,590	710,546,178.2	158.37 (157.49, 159.25)
Prevalent CD cohort	1,154,961,237	3,162,111.5	228,695,417	259,314,206,929	709,963,605.6	150.53 (149.18, 151.88)
Prevalent UC cohort	1,560,982,090	4,273,736.0	228,676,416	259,370,410,239	710,117,481.8	165.37 (164.16, 166.59)
<b>Incident cohorts</b>						
Incident IBD cohort	1,984,757,707	5,433,970.5	228,235,902	259,173,967,719	709,579,651.5	172.47 (171.37, 173.58)
Incident CD cohort	739,101,887	2,023,550.7	228,234,610	259,172,878,806	709,576,670.2	162.51 (160.76, 164.28)
Incident UC cohort	1,189,798,408	3,257,490.5	228,234,874	259,173,272,815	709,577,749.0	178.70 (177.25, 180.15)
<b>Advanced therapy initiators cohorts</b>						
Advanced therapy initiators with IBD	101,339,731	277,453.1	2,562,309	2,840,882,609	7,777,912.7	101.60 (97.92, 105.42)
Advanced therapy initiators with CD	49,919,471	136,672.1	1,006,621	1,002,538,723	2,744,801.4	92.48 (87.52, 97.73)
Advanced therapy initiators with UC	23,802,699	65,168.2	1,427,711	1,515,238,460	4,148,496.8	114.01 (106.10, 122.51)

<sup>1</sup>Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



**Table 3. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Sex**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	1,438,795	1,438,795	17,106,440	17,106,440	75,451	298,028
Male	1,000,746	1,000,746	12,383,519	12,383,519	47,185	186,962
<b>Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	577,126	577,126	8,869,336	8,869,336	29,132	116,688
Male	399,589	399,589	6,014,756	6,014,756	17,607	65,687
<b>Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	778,469	778,469	5,937,551	5,937,551	42,717	167,174
Male	542,301	542,301	4,675,209	4,675,209	27,268	112,261
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	1,036,756	1,036,756	7,034,415	7,034,415	58,230	226,087
Male	681,626	681,626	4,993,785	4,993,785	34,948	135,571
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	377,718	377,718	2,842,116	2,842,116	20,373	81,197
Male	252,739	252,739	1,965,205	1,965,205	12,290	45,041
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	618,773	618,773	3,399,159	3,399,159	36,213	139,327
Male	405,351	405,351	2,493,926	2,493,926	21,696	87,122
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	161,757	161,757	5,516,962	5,516,962	5,285	23,558
Male	135,051	135,051	4,169,896	4,169,896	3,388	13,593
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	92,680	92,680	3,387,648	3,387,648	2,917	13,040
Male	74,778	74,778	2,409,223	2,409,223	1,667	6,351
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	38,602	38,602	819,201	819,201	1,413	6,834
Male	34,284	34,284	753,677	753,677	985	4,187

**Table 3. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Sex**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	16,386	16,386	160,140	160,140	1,100	5,658
Male	9,886	9,886	104,862	104,862	401	2,007
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	8,232	8,232	97,679	97,679	461	2,710
Male	5,779	5,779	68,570	68,570	177	868
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	7,641	7,641	48,667	48,667	616	2,889
Male	3,877	3,877	28,274	28,274	217	1,002
<b>Prevalent IBD Cohort</b>						
Female	1,450,411	1,450,411	18,635,879	18,635,879	76,375	303,114
Male	1,010,576	1,010,576	13,562,229	13,562,229	48,010	191,544
<b>Prevalent CD Cohort</b>						
Female	582,932	582,932	9,707,628	9,707,628	29,647	119,282
Male	403,697	403,697	6,571,749	6,571,749	17,951	67,591
<b>Prevalent UC Cohort</b>						
Female	782,841	782,841	6,352,370	6,352,370	43,017	168,989
Male	546,664	546,664	5,080,478	5,080,478	27,658	114,352
<b>Incident IBD Cohort</b>						
Female	1,037,689	1,037,689	7,395,727	7,395,727	58,524	227,694
Male	682,088	682,088	5,289,416	5,289,416	35,198	137,031
<b>Incident CD Cohort</b>						
Female	378,089	378,089	2,985,536	2,985,536	20,507	81,697
Male	252,898	252,898	2,064,231	2,064,231	12,378	45,465
<b>Incident UC Cohort</b>						
Female	619,296	619,296	3,552,018	3,552,018	36,359	140,398
Male	405,645	405,645	2,640,551	2,640,551	21,851	88,090

**Table 3. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Sex**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Advanced Therapy Initiators with IBD</b>						
Female	74,939	74,939	1,040,640	1,042,103	1,682	5,676
Male	59,122	59,122	883,745	885,017	1,137	3,821
<b>Advanced Therapy Initiators with CD</b>						
Female	36,822	36,822	516,251	516,973	789	2,466
Male	27,729	27,729	429,605	430,158	475	1,480
<b>Advanced Therapy Initiators with UC</b>						
Female	18,293	18,293	236,378	236,765	410	1,524
Male	15,700	15,700	216,753	217,173	333	1,274

**Table 3. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Sex**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	1,700,980,985	4,657,032.1	122,416,412	141,703,035,544	387,961,767.4	162.02 (160.86, 163.18)
Male	1,114,521,876	3,051,394.6	106,744,129	117,751,028,079	322,384,744.9	154.63 (153.25, 156.04)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	685,245,806	1,876,100.8	122,141,866	141,576,094,235	387,614,221.0	155.28 (153.51, 157.07)
Male	444,441,086	1,216,813.4	106,519,368	117,665,638,506	322,150,961.0	144.70 (142.58, 146.85)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	928,578,735	2,542,310.0	122,121,150	141,610,052,082	387,707,192.6	168.02 (166.44, 169.63)
Male	610,317,737	1,670,958.9	106,522,681	117,687,845,678	322,211,760.9	163.19 (161.26, 165.14)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	1,217,939,426	3,334,536.4	121,882,711	141,492,633,468	387,385,717.9	174.63 (173.21, 176.05)
Male	751,496,486	2,057,485.2	106,327,986	117,609,187,810	321,996,407.4	169.86 (168.09, 171.65)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	450,714,944	1,233,990.3	121,881,991	141,491,974,353	387,383,913.4	165.10 (162.85, 167.38)
Male	282,596,328	773,706.6	106,327,416	117,608,758,877	321,995,233.1	158.85 (156.06, 161.68)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Female	731,946,041	2,003,959.0	121,882,110	141,492,215,445	387,384,573.4	180.71 (178.86, 182.58)
Male	448,886,682	1,228,984.8	106,327,559	117,608,911,507	321,995,650.9	176.54 (174.20, 178.90)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	156,775,047	429,226.7	739,932	682,837,154	1,869,506.2	123.13 (119.85, 126.49)
Male	123,247,860	337,434.3	435,148	329,857,869	903,101.6	100.40 (97.08, 103.84)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	91,838,361	251,439.7	673,511	676,283,946	1,851,564.5	116.01 (111.88, 120.30)
Male	69,193,233	189,440.7	375,039	325,763,605	891,892.1	88.00 (83.87, 92.32)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	35,016,623	95,870.3	618,216	674,596,158	1,846,943.6	147.39 (139.90, 155.28)
Male	29,245,026	80,068.5	334,441	323,704,011	886,253.3	123.02 (115.57, 130.95)

**Table 3. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Sex**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	16,654,098	45,596.4	582,092	669,506,848	1,833,009.9	241.25 (227.40, 255.93)
Male	8,695,087	23,805.9	300,550	320,773,900	878,231.1	168.45 (152.74, 185.77)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	8,404,250	23,009.6	581,798	669,498,694	1,832,987.5	200.35 (182.87, 219.50)
Male	5,113,232	13,999.3	300,203	320,769,793	878,219.8	126.44 (109.12, 146.50)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Female	7,800,076	21,355.4	581,562	669,498,103	1,832,985.9	288.45 (266.55, 312.15)
Male	3,410,226	9,336.7	300,019	320,767,891	878,214.6	232.42 (203.46, 265.49)
<b>Prevalent IBD Cohort</b>						
Female	1,730,439,562	4,737,685.3	122,444,986	141,756,617,170	388,108,465.9	161.21 (160.07, 162.35)
Male	1,138,318,187	3,116,545.3	106,759,529	117,770,374,420	322,437,712.3	154.05 (152.68, 155.43)
<b>Prevalent CD Cohort</b>						
Female	700,342,455	1,917,433.1	122,165,623	141,629,434,250	387,760,258.0	154.62 (152.87, 156.39)
Male	454,618,782	1,244,678.4	106,529,794	117,684,772,679	322,203,347.5	144.22 (142.13, 146.35)
<b>Prevalent UC Cohort</b>						
Female	939,825,812	2,573,102.8	122,143,332	141,663,387,916	387,853,218.1	167.18 (165.61, 168.77)
Male	621,156,278	1,700,633.2	106,533,084	117,707,022,323	322,264,263.7	162.63 (160.73, 164.56)
<b>Incident IBD Cohort</b>						
Female	1,226,409,188	3,357,725.4	121,901,287	141,545,773,848	387,531,208.3	174.30 (172.89, 175.71)
Male	758,348,519	2,076,245.1	106,334,615	117,628,193,871	322,048,443.2	169.53 (167.77, 171.31)
<b>Incident CD Cohort</b>						
Female	454,188,272	1,243,499.7	121,900,566	141,545,114,171	387,529,402.2	164.91 (162.67, 167.19)
Male	284,913,615	780,051.0	106,334,044	117,627,764,635	322,047,268.0	158.68 (155.91, 161.50)
<b>Incident UC Cohort</b>						
Female	736,648,260	2,016,833.0	121,900,686	141,545,355,415	387,530,062.7	180.28 (178.43, 182.14)
Male	453,150,148	1,240,657.5	106,334,188	117,627,917,400	322,047,686.2	176.12 (173.80, 178.48)

**Table 3. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Sex**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Advanced Therapy Initiators with IBD</b>						
Female	56,911,979	155,816.5	1,519,025	1,739,427,285	4,762,292.4	107.95 (102.91, 113.23)
Male	44,427,752	121,636.6	1,043,284	1,101,455,324	3,015,620.3	93.48 (88.20, 99.07)
<b>Advanced Therapy Initiators with CD</b>						
Female	28,494,652	78,014.1	599,006	615,884,412	1,686,199.6	101.14 (94.32, 108.44)
Male	21,424,819	58,658.0	407,615	386,654,311	1,058,601.8	80.98 (74.01, 88.60)
<b>Advanced Therapy Initiators with UC</b>						
Female	12,890,205	35,291.5	844,249	927,620,132	2,539,685.5	116.18 (105.46, 127.98)
Male	10,912,494	29,876.8	583,462	587,618,328	1,608,811.3	111.46 (100.11, 124.10)

<sup>1</sup>Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	137,476	137,476	2,078,684	2,078,684	519	1,698
25-34 years	260,092	260,092	3,652,889	3,652,889	1,931	6,728
35-44 years	283,600	283,600	3,872,982	3,872,982	4,362	16,487
45-54 years	340,736	340,736	4,253,796	4,253,796	9,950	35,864
55-64 years	354,165	354,165	3,750,173	3,750,173	15,901	55,654
≥ 65 years	1,063,472	1,063,472	11,881,435	11,881,435	89,973	368,559
<b>Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	70,897	70,897	1,163,647	1,163,647	288	811
25-34 years	126,230	126,230	2,100,902	2,100,902	1,020	3,390
35-44 years	131,010	131,010	2,224,156	2,224,156	2,243	8,428
45-54 years	147,269	147,269	2,356,954	2,356,954	4,732	16,691
55-64 years	141,473	141,473	1,953,558	1,953,558	6,769	22,567
≥ 65 years	359,836	359,836	5,084,875	5,084,875	31,687	130,488
<b>Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	52,813	52,813	534,774	534,774	178	730
25-34 years	116,443	116,443	1,017,720	1,017,720	777	2,952
35-44 years	135,273	135,273	1,110,733	1,110,733	1,880	7,273
45-54 years	174,057	174,057	1,315,339	1,315,339	4,652	17,301
55-64 years	193,117	193,117	1,306,385	1,306,385	8,309	29,970
≥ 65 years	649,067	649,067	5,327,809	5,327,809	54,189	221,209

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	72,917	72,917	696,117	696,117	285	880
25-34 years	153,789	153,789	1,254,324	1,254,324	1,203	4,463
35-44 years	180,816	180,816	1,372,436	1,372,436	2,924	11,838
45-54 years	233,538	233,538	1,613,562	1,613,562	6,957	24,996
55-64 years	253,246	253,246	1,533,965	1,533,965	11,876	40,582
≥ 65 years	824,076	824,076	5,557,796	5,557,796	69,933	278,899
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	35,262	35,262	343,371	343,371	147	342
25-34 years	69,361	69,361	601,031	601,031	569	1,963
35-44 years	77,629	77,629	634,304	634,304	1,331	5,784
45-54 years	93,429	93,429	709,511	709,511	2,959	10,872
55-64 years	92,803	92,803	618,352	618,352	4,541	15,255
≥ 65 years	261,973	261,973	1,900,752	1,900,752	23,116	92,022
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	34,285	34,285	258,746	258,746	128	514
25-34 years	78,772	78,772	510,325	510,325	597	2,392
35-44 years	96,911	96,911	581,011	581,011	1,525	5,876
45-54 years	132,218	132,218	722,229	722,229	3,803	13,595
55-64 years	151,120	151,120	745,147	745,147	6,953	24,099
≥ 65 years	530,818	530,818	3,075,627	3,075,627	44,903	179,973



**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	42,102	42,102	1,097,096	1,097,096	137	455
25-34 years	62,186	62,186	1,773,977	1,773,977	378	1,252
35-44 years	52,449	52,449	1,679,751	1,679,751	708	2,298
45-54 years	45,873	45,873	1,552,477	1,552,477	1,123	4,110
55-64 years	36,727	36,727	1,138,554	1,138,554	1,447	4,971
≥ 65 years	57,471	57,471	2,445,003	2,445,003	4,880	24,065
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	25,963	25,963	676,854	676,854	93	240
25-34 years	37,753	37,753	1,114,180	1,114,180	233	784
35-44 years	30,855	30,855	1,062,419	1,062,419	473	1,339
45-54 years	26,109	26,109	961,022	961,022	702	2,375
55-64 years	19,810	19,810	679,956	679,956	802	2,832
≥ 65 years	26,968	26,968	1,302,440	1,302,440	2,281	11,821
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	7,470	7,470	148,948	148,948	12	159
25-34 years	13,742	13,742	262,619	262,619	56	165
35-44 years	11,971	11,971	234,317	234,317	109	570
45-54 years	11,024	11,024	222,024	222,024	206	870
55-64 years	9,794	9,794	182,633	182,633	360	1,218
≥ 65 years	18,885	18,885	522,337	522,337	1,655	8,039

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	1,685	1,685	20,392	20,392	*****	*****
25-34 years	3,678	3,678	43,474	43,474	*****	*****
35-44 years	3,769	3,769	44,123	44,123	64	447
45-54 years	4,327	4,327	44,373	44,373	139	475
55-64 years	4,208	4,208	37,395	37,395	247	1,098
≥ 65 years	8,605	8,605	75,245	75,245	1,019	5,542
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	1,229	1,229	14,682	14,682	*****	*****
25-34 years	2,563	2,563	32,275	32,275	*****	*****
35-44 years	2,390	2,390	31,310	31,310	38	211
45-54 years	2,396	2,396	28,607	28,607	70	284
55-64 years	2,005	2,005	21,437	21,437	103	565
≥ 65 years	3,428	3,428	37,938	37,938	403	2,433
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	416	416	3,875	3,875	*****	*****
25-34 years	1,042	1,042	8,713	8,713	*****	*****
35-44 years	1,302	1,302	9,329	9,329	*****	234
45-54 years	1,816	1,816	11,751	11,751	66	185
55-64 years	2,079	2,079	12,852	12,852	143	528
≥ 65 years	4,863	4,863	30,421	30,421	592	2,928

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent IBD Cohort</b>						
18-24 years	139,819	139,819	2,326,702	2,326,702	541	1,771
25-34 years	264,796	264,796	4,117,502	4,117,502	2,011	7,300
35-44 years	287,287	287,287	4,283,096	4,283,096	4,490	16,861
45-54 years	343,648	343,648	4,613,120	4,613,120	10,142	36,779
55-64 years	356,685	356,685	4,018,223	4,018,223	16,142	56,605
≥ 65 years	1,068,752	1,068,752	12,839,465	12,839,465	91,059	375,342
<b>Prevalent CD Cohort</b>						
18-24 years	71,823	71,823	1,275,547	1,275,547	298	864
25-34 years	128,424	128,424	2,360,451	2,360,451	1,067	3,860
35-44 years	132,778	132,778	2,450,335	2,450,335	2,317	8,603
45-54 years	148,739	148,739	2,559,465	2,559,465	4,839	17,086
55-64 years	142,695	142,695	2,102,310	2,102,310	6,896	23,025
≥ 65 years	362,170	362,170	5,531,269	5,531,269	32,181	133,435
<b>Prevalent UC Cohort</b>						
18-24 years	53,685	53,685	606,765	606,765	187	743
25-34 years	118,353	118,353	1,140,732	1,140,732	800	2,996
35-44 years	136,750	136,750	1,223,981	1,223,981	1,919	7,423
45-54 years	175,186	175,186	1,407,822	1,407,822	4,715	17,687
55-64 years	194,130	194,130	1,379,552	1,379,552	8,391	30,318
≥ 65 years	651,401	651,401	5,673,996	5,673,996	54,663	224,174

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident IBD Cohort</b>						
18-24 years	72,979	72,979	748,328	748,328	291	929
25-34 years	153,993	153,993	1,338,578	1,338,578	1,219	4,490
35-44 years	181,060	181,060	1,454,816	1,454,816	2,958	11,927
45-54 years	233,806	233,806	1,691,953	1,691,953	7,011	25,254
55-64 years	253,518	253,518	1,592,857	1,592,857	11,933	40,861
≥ 65 years	824,421	824,421	5,858,611	5,858,611	70,310	281,264
<b>Incident CD Cohort</b>						
18-24 years	35,290	35,290	360,152	360,152	149	384
25-34 years	69,441	69,441	633,224	633,224	575	1,972
35-44 years	77,728	77,728	664,358	664,358	1,346	5,815
45-54 years	93,546	93,546	740,733	740,733	2,987	10,930
55-64 years	92,910	92,910	640,825	640,825	4,563	15,326
≥ 65 years	262,072	262,072	2,010,475	2,010,475	23,265	92,735
<b>Incident UC Cohort</b>						
18-24 years	34,318	34,318	284,815	284,815	132	521
25-34 years	78,888	78,888	548,847	548,847	606	2,409
35-44 years	97,051	97,051	619,868	619,868	1,542	5,926
45-54 years	132,362	132,362	756,021	756,021	3,827	13,793
55-64 years	151,276	151,276	769,220	769,220	6,985	24,303
≥ 65 years	531,046	531,046	3,213,798	3,213,798	45,118	181,536

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Advanced Therapy Initiators with IBD</b>						
18-24 years	17,092	17,092	222,976	223,417	35	47
25-34 years	27,630	27,630	371,135	371,779	142	483
35-44 years	24,518	24,518	367,561	368,140	261	602
45-54 years	21,764	21,764	338,338	338,893	382	1,214
55-64 years	17,008	17,008	241,812	242,158	481	1,097
≥ 65 years	26,049	26,049	382,563	382,733	1,518	6,054
<b>Advanced Therapy Initiators with CD</b>						
18-24 years	9,308	9,308	125,234	125,467	24	31
25-34 years	14,459	14,459	195,461	195,774	68	193
35-44 years	12,324	12,324	185,055	185,302	153	396
45-54 years	10,611	10,611	168,502	168,773	198	520
55-64 years	7,740	7,740	113,082	113,234	231	528
≥ 65 years	10,109	10,109	158,522	158,581	590	2,278
<b>Advanced Therapy Initiators with UC</b>						
18-24 years	3,540	3,540	43,091	43,211	*****	*****
25-34 years	6,491	6,491	83,000	83,189	*****	*****
35-44 years	5,781	5,781	82,199	82,398	46	67
45-54 years	5,309	5,309	74,874	75,024	70	279
55-64 years	4,566	4,566	59,569	59,663	113	266
≥ 65 years	8,306	8,306	110,398	110,453	490	2,130

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	103,976,130	284,671.1	41,283,664	24,537,372,258	67,179,664.0	18.23 (16.73, 19.87)
25-34 years	215,803,479	590,837.7	55,031,773	34,708,595,121	95,026,954.5	32.68 (31.26, 34.17)
35-44 years	287,534,786	787,227.3	46,124,665	34,762,922,060	95,175,693.5	55.41 (53.79, 57.08)
45-54 years	385,529,827	1,055,523.1	44,132,640	37,202,636,337	101,855,267.2	94.27 (92.43, 96.14)
55-64 years	367,091,912	1,005,042.9	39,056,444	35,541,947,311	97,308,548.4	158.21 (155.77, 160.69)
≥ 65 years	1,455,566,727	3,985,124.5	58,094,149	92,700,590,536	253,800,384.8	225.77 (224.30, 227.25)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	54,077,940	148,057.3	41,241,738	24,527,737,129	67,153,284.4	19.45 (17.33, 21.83)
25-34 years	106,692,065	292,107.0	54,960,639	34,691,630,698	94,980,508.4	34.92 (32.84, 37.13)
35-44 years	134,778,856	369,004.4	46,051,333	34,741,204,445	95,116,233.9	60.79 (58.32, 63.35)
45-54 years	169,614,553	464,379.3	44,050,447	37,174,590,261	101,778,481.2	101.90 (99.04, 104.84)
55-64 years	151,795,416	415,593.2	38,973,678	35,509,859,687	97,220,697.3	162.88 (159.04, 166.80)
≥ 65 years	512,728,062	1,403,772.9	57,898,877	92,596,710,521	253,515,976.8	225.73 (223.26, 228.23)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	39,385,092	107,830.5	41,220,445	24,524,249,216	67,143,735.0	16.51 (14.25, 19.12)
25-34 years	95,169,501	260,559.9	54,941,122	34,690,963,055	94,978,680.5	29.82 (27.80, 31.99)
35-44 years	136,227,718	372,971.2	46,038,676	34,743,023,716	95,121,214.8	50.41 (48.18, 52.74)
45-54 years	195,798,003	536,065.7	44,044,799	37,179,794,803	101,792,730.5	86.78 (84.32, 89.31)
55-64 years	196,724,979	538,603.6	38,976,455	35,519,013,331	97,245,758.6	154.27 (150.99, 157.62)
≥ 65 years	875,591,179	2,397,238.0	57,944,390	92,640,853,639	253,636,834.1	226.05 (224.15, 227.96)

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	54,606,859	149,505.4	41,189,739	24,516,329,542	67,122,052.1	19.06 (16.97, 21.41)
25-34 years	128,006,692	350,463.2	54,881,184	34,675,806,073	94,937,183.0	34.33 (32.44, 36.32)
35-44 years	183,159,567	501,463.6	45,975,454	34,723,229,500	95,067,021.2	58.31 (56.23, 60.46)
45-54 years	264,078,585	723,007.8	43,972,831	37,153,941,043	101,721,946.7	96.22 (93.99, 98.51)
55-64 years	260,515,821	713,253.4	38,902,886	35,489,183,564	97,164,089.2	166.50 (163.54, 169.53)
≥ 65 years	1,079,068,388	2,954,328.2	57,767,840	92,543,331,556	253,369,833.1	236.71 (234.97, 238.47)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	26,770,347	73,293.2	41,189,671	24,516,291,886	67,121,949.0	20.06 (17.06, 23.58)
25-34 years	58,659,209	160,600.2	54,881,007	34,675,721,641	94,936,951.8	35.43 (32.63, 38.46)
35-44 years	79,453,225	217,531.1	45,975,263	34,723,126,303	95,066,738.7	61.19 (57.99, 64.56)
45-54 years	107,598,412	294,588.4	43,972,579	37,153,800,917	101,721,563.1	100.45 (96.89, 104.13)
55-64 years	99,185,679	271,555.6	38,902,640	35,489,023,104	97,163,649.8	167.22 (162.43, 172.16)
≥ 65 years	361,644,400	990,128.4	57,767,341	92,542,769,379	253,368,294.0	233.46 (230.47, 236.49)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
18-24 years	25,590,099	70,061.9	41,189,653	24,516,290,909	67,121,946.4	18.27 (15.36, 21.73)
25-34 years	65,374,228	178,984.9	54,880,992	34,675,731,049	94,936,977.5	33.35 (30.78, 36.14)
35-44 years	98,598,292	269,947.4	45,975,283	34,723,145,588	95,066,791.5	56.49 (53.73, 59.40)
45-54 years	149,616,706	409,628.2	43,972,631	37,153,839,717	101,721,669.3	92.84 (89.94, 95.84)
55-64 years	153,993,815	421,612.1	38,902,716	35,489,081,424	97,163,809.5	164.91 (161.08, 168.84)
≥ 65 years	687,659,583	1,882,709.3	57,767,514	92,543,038,265	253,369,030.2	238.50 (236.31, 240.72)

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	30,205,699	82,698.7	81,321	22,089,844	60,478.7	16.57 (14.01, 19.59)
25-34 years	47,604,759	130,334.7	165,206	61,011,553	167,040.5	29.00 (26.22, 32.08)
35-44 years	47,848,021	131,000.7	211,356	114,739,696	314,140.2	54.05 (50.21, 58.18)
45-54 years	46,130,325	126,297.9	267,538	175,516,743	480,538.7	88.92 (83.87, 94.27)
55-64 years	34,247,903	93,765.6	280,096	213,000,779	583,164.4	154.32 (146.57, 162.48)
≥ 65 years	73,986,200	202,563.2	358,589	426,336,408	1,167,245.5	240.91 (234.25, 247.77)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	18,960,014	51,909.7	64,405	21,234,160	58,136.0	17.92 (14.62, 21.95)
25-34 years	29,767,967	81,500.3	139,791	59,604,991	163,189.6	28.59 (25.14, 32.51)
35-44 years	29,375,677	80,426.2	189,308	113,234,110	310,018.1	58.81 (53.74, 64.36)
45-54 years	27,158,886	74,357.0	247,811	173,869,669	476,029.2	94.41 (87.68, 101.66)
55-64 years	19,196,909	52,558.3	263,518	211,283,401	578,462.4	152.59 (142.39, 163.53)
≥ 65 years	36,572,141	100,129.1	330,527	422,821,220	1,157,621.4	227.81 (218.65, 237.35)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	4,833,658	13,233.8	44,963	20,136,033	55,129.5	9.07 (5.15, 15.97)
25-34 years	9,179,446	25,132.0	115,132	58,212,783	159,377.9	22.28 (17.15, 28.95)
35-44 years	9,443,529	25,855.0	170,319	112,255,215	307,338.0	42.16 (34.94, 50.86)
45-54 years	9,961,418	27,272.9	232,539	173,119,908	473,976.5	75.53 (65.89, 86.59)
55-64 years	8,356,722	22,879.5	253,320	210,992,379	577,665.7	157.35 (141.90, 174.47)
≥ 65 years	22,486,876	61,565.7	321,903	423,583,851	1,159,709.4	268.82 (256.17, 282.09)



**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	*****	*****	37,088	19,684,140	53,892.2	31.01 (16.13, 59.60)
25-34 years	*****	*****	100,664	57,261,437	156,773.3	33.57 (22.31, 50.52)
35-44 years	3,320,999	9,092.4	157,991	111,189,412	304,420.0	70.39 (55.09, 89.93)
45-54 years	4,296,706	11,763.7	221,588	171,908,444	470,659.7	118.16 (100.06, 139.53)
55-64 years	4,011,836	10,983.8	243,878	209,650,913	573,992.9	224.88 (198.51, 254.74)
≥ 65 years	10,157,395	27,809.4	305,348	420,586,402	1,151,502.8	366.42 (344.60, 389.63)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	*****	*****	37,022	19,683,684	53,891.0	37.32 (18.66, 74.63)
25-34 years	*****	*****	100,566	57,260,322	156,770.2	33.61 (20.59, 54.86)
35-44 years	2,110,381	5,777.9	157,917	111,188,033	304,416.2	65.77 (47.85, 90.39)
45-54 years	2,419,207	6,623.4	221,499	171,906,513	470,654.4	105.69 (83.61, 133.58)
55-64 years	1,935,279	5,298.5	243,803	209,648,710	573,986.9	194.39 (160.25, 235.81)
≥ 65 years	4,530,863	12,404.8	305,107	420,581,225	1,151,488.6	324.87 (294.65, 358.19)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
18-24 years	*****	*****	36,899	19,682,871	53,888.8	14.36 (2.02, 101.91)
25-34 years	*****	*****	100,440	57,258,801	156,766.1	31.08 (13.96, 69.17)
35-44 years	*****	*****	157,828	111,186,945	304,413.3	80.76 (54.57, 119.51)
45-54 years	1,781,597	4,877.7	221,419	171,905,933	470,652.8	135.31 (106.30, 172.23)
55-64 years	1,985,092	5,434.9	243,751	209,648,784	573,987.1	263.12 (223.34, 309.98)
≥ 65 years	5,353,232	14,656.4	305,157	420,582,660	1,151,492.6	403.92 (372.66, 437.80)

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort</b>						
18-24 years	108,560,645	297,222.8	41,286,780	24,538,561,145	67,182,918.9	18.20 (16.73, 19.80)
25-34 years	224,520,390	614,703.3	55,042,018	34,716,888,840	95,049,661.4	32.71 (31.32, 34.18)
35-44 years	295,655,693	809,461.2	46,139,310	34,780,527,256	95,223,893.9	55.47 (53.87, 57.12)
45-54 years	392,607,710	1,074,901.3	44,148,146	37,223,171,299	101,911,488.8	94.35 (92.53, 96.21)
55-64 years	372,418,595	1,019,626.5	39,068,405	35,557,608,429	97,351,426.2	158.31 (155.89, 160.77)
≥ 65 years	1,474,994,716	4,038,315.4	58,103,991	92,710,234,621	253,826,788.8	225.49 (224.03, 226.96)
<b>Prevalent CD Cohort</b>						
18-24 years	56,006,453	153,337.3	41,243,500	24,528,873,907	67,156,396.7	19.43 (17.35, 21.77)
25-34 years	111,076,515	304,110.9	54,968,601	34,699,837,413	95,002,977.2	35.09 (33.04, 37.26)
35-44 years	138,850,654	380,152.4	46,064,296	34,758,740,603	95,164,245.3	60.95 (58.52, 63.48)
45-54 years	173,289,481	474,440.7	44,064,689	37,195,056,749	101,834,515.4	101.99 (99.16, 104.91)
55-64 years	154,475,323	422,930.4	38,984,537	35,525,445,126	97,263,367.9	163.05 (159.25, 166.95)
≥ 65 years	521,262,811	1,427,139.8	57,906,059	92,606,253,131	253,542,103.0	225.49 (223.04, 227.97)
<b>Prevalent UC Cohort</b>						
18-24 years	41,146,598	112,653.2	41,222,146	24,525,384,624	67,146,843.6	16.60 (14.38, 19.16)
25-34 years	98,503,515	269,687.9	54,948,768	34,699,162,811	95,001,130.2	29.66 (27.68, 31.79)
35-44 years	139,443,634	381,775.9	46,051,272	34,760,547,387	95,169,192.0	50.27 (48.07, 52.57)
45-54 years	198,522,973	543,526.3	44,058,686	37,200,257,976	101,848,755.6	86.75 (84.31, 89.26)
55-64 years	198,811,822	544,317.1	38,987,048	35,534,630,163	97,288,515.2	154.16 (150.89, 157.49)
≥ 65 years	884,553,548	2,421,775.6	57,951,453	92,650,427,278	253,663,045.3	225.71 (223.83, 227.61)

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident IBD Cohort</b>						
18-24 years	55,747,201	152,627.5	41,190,623	24,517,433,467	67,125,074.5	19.07 (17.00, 21.39)
25-34 years	130,023,810	355,985.8	54,887,060	34,683,937,219	94,959,444.8	34.24 (32.37, 36.22)
35-44 years	185,309,713	507,350.3	45,986,758	34,740,699,164	95,114,850.6	58.30 (56.24, 60.44)
45-54 years	266,150,152	728,679.4	43,985,738	37,174,347,542	101,777,816.7	96.22 (93.99, 98.49)
55-64 years	262,015,885	717,360.4	38,912,628	35,504,731,799	97,206,657.9	166.35 (163.39, 169.36)
≥ 65 years	1,085,510,946	2,971,967.0	57,772,784	92,552,818,528	253,395,807.1	236.58 (234.84, 238.33)
<b>Incident CD Cohort</b>						
18-24 years	27,171,143	74,390.5	41,190,555	24,517,395,777	67,124,971.3	20.03 (17.06, 23.52)
25-34 years	59,417,818	162,677.1	54,886,883	34,683,852,663	94,959,213.3	35.35 (32.57, 38.36)
35-44 years	80,251,422	219,716.4	45,986,567	34,740,595,822	95,114,567.6	61.26 (58.07, 64.62)
45-54 years	108,460,653	296,949.1	43,985,486	37,174,207,265	101,777,432.6	100.59 (97.05, 104.26)
55-64 years	99,775,948	273,171.7	38,912,382	35,504,571,174	97,206,218.1	167.04 (162.26, 171.96)
≥ 65 years	364,024,903	996,645.9	57,772,283	92,552,256,105	253,394,267.2	233.43 (230.45, 236.45)
<b>Incident UC Cohort</b>						
18-24 years	26,262,314	71,902.3	41,190,537	24,517,394,805	67,124,968.7	18.36 (15.48, 21.77)
25-34 years	66,567,518	182,251.9	54,886,868	34,683,862,107	94,959,239.2	33.25 (30.71, 36.01)
35-44 years	99,877,053	273,448.5	45,986,587	34,740,615,148	95,114,620.5	56.39 (53.65, 59.28)
45-54 years	150,770,107	412,786.1	43,985,538	37,174,246,092	101,777,538.9	92.71 (89.82, 95.70)
55-64 years	154,830,389	423,902.5	38,912,458	35,504,629,543	97,206,377.9	164.78 (160.96, 168.69)
≥ 65 years	691,491,027	1,893,199.3	57,772,458	92,552,525,120	253,395,003.8	238.32 (236.13, 240.53)

**Table 4. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Age Group**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Advanced Therapy Initiators with IBD</b>						
18-24 years	10,376,821	28,410.2	148,766	75,142,000	205,727.6	12.32 (8.85, 17.16)
25-34 years	17,865,466	48,913.0	322,102	181,030,086	495,633.4	29.03 (24.63, 34.22)
35-44 years	18,446,787	50,504.6	381,151	268,660,617	735,552.7	51.68 (45.77, 58.34)
45-54 years	17,638,270	48,291.0	465,648	365,832,929	1,001,596.0	79.10 (71.56, 87.45)
55-64 years	12,432,124	34,037.3	512,095	429,843,433	1,176,847.2	141.32 (129.23, 154.53)
≥ 65 years	24,580,263	67,297.1	1,193,730	1,520,373,544	4,162,555.9	225.57 (214.50, 237.20)
<b>Advanced Therapy Initiators with CD</b>						
18-24 years	5,871,628	16,075.6	73,737	34,855,491	95,429.1	14.93 (10.01, 22.27)
25-34 years	9,661,921	26,452.9	148,626	77,895,450	213,266.1	25.71 (20.27, 32.60)
35-44 years	9,582,581	26,235.7	168,130	110,252,170	301,854.0	58.32 (49.77, 68.33)
45-54 years	8,908,111	24,389.1	194,238	142,299,426	389,594.6	81.18 (70.63, 93.32)
55-64 years	5,859,482	16,042.4	198,745	157,869,885	432,224.2	143.99 (126.57, 163.81)
≥ 65 years	10,035,748	27,476.4	403,915	479,366,301	1,312,433.4	214.73 (198.08, 232.78)
<b>Advanced Therapy Initiators with UC</b>						
18-24 years	*****	*****	62,818	30,067,883	82,321.4	5.64 (1.82, 17.50)
25-34 years	*****	*****	151,744	81,515,308	223,176.8	20.53 (13.38, 31.48)
35-44 years	3,899,396	10,676.0	187,627	126,059,696	345,132.6	43.09 (32.27, 57.52)
45-54 years	3,879,580	10,621.7	241,908	180,845,253	495,127.3	65.90 (52.14, 83.30)
55-64 years	3,043,804	8,333.5	279,499	223,168,338	611,001.6	135.60 (112.77, 163.05)
≥ 65 years	7,301,317	19,989.9	728,380	873,581,982	2,391,737.1	245.12 (224.35, 267.82)

<sup>1</sup>Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	28,743	28,743	622,587	622,587	844	2,996
2007	37,095	37,095	549,628	549,628	1,313	4,240
2008	85,683	85,683	1,274,073	1,274,073	2,059	7,506
2009	78,754	78,754	823,896	823,896	1,747	6,150
2010	170,395	170,395	4,499,457	4,499,457	15,758	73,277
2011	161,485	161,485	2,291,784	2,291,784	14,073	62,045
2012	144,460	144,460	1,894,519	1,894,519	11,417	49,651
2013	161,873	161,873	2,337,511	2,337,511	11,679	49,788
2014	169,957	169,957	2,234,439	2,234,439	10,907	45,749
2015	183,208	183,208	2,237,439	2,237,439	11,281	44,357
2016	199,849	199,849	2,580,633	2,580,633	9,940	37,514
2017	194,272	194,272	2,099,662	2,099,662	8,345	30,756
2018	179,946	179,946	1,750,184	1,750,184	7,095	23,217
2019	181,699	181,699	1,565,618	1,565,618	6,240	19,781
2020	174,265	174,265	1,292,175	1,292,175	4,723	15,272
2021	140,460	140,460	879,036	879,036	3,505	9,171
2022	136,467	136,467	534,519	534,519	1,692	3,475
2023	10,930	10,930	22,799	22,799	18	45
<b>Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	13,265	13,265	344,763	344,763	*****	1,211
2007	15,321	15,321	277,190	277,190	585	1,506
2008	37,128	37,128	667,235	667,235	870	2,749
2009	31,746	31,746	382,162	382,162	705	2,500
2010	74,257	74,257	2,605,414	2,605,414	7,009	32,599
2011	63,911	63,911	1,114,936	1,114,936	5,329	22,718
2012	57,357	57,357	927,470	927,470	4,370	18,558

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2013	65,227	65,227	1,149,883	1,149,883	4,481	19,292
2014	70,778	70,778	1,114,002	1,114,002	4,274	17,546
2015	76,003	76,003	1,127,791	1,127,791	4,168	16,284
2016	85,045	85,045	1,349,326	1,349,326	3,800	13,601
2017	78,535	78,535	1,038,668	1,038,668	2,990	10,453
2018	69,614	69,614	825,142	825,142	2,413	7,824
2019	69,261	69,261	744,521	744,521	2,107	6,612
2020	67,455	67,455	606,684	606,684	1,610	4,974
2021	49,453	49,453	383,243	383,243	1,135	2,864
2022	48,117	48,117	216,381	216,381	504	1,057
2023	4,242	4,242	9,281	9,281	*****	27
<b>Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	13,396	13,396	180,237	180,237	396	1,564
2007	19,967	19,967	191,746	191,746	662	2,453
2008	43,210	43,210	414,665	414,665	1,060	4,239
2009	43,207	43,207	319,716	319,716	982	3,475
2010	86,349	86,349	1,214,447	1,214,447	7,772	35,610
2011	91,394	91,394	855,776	855,776	8,242	36,999
2012	82,007	82,007	704,026	704,026	6,738	29,819
2013	90,061	90,061	862,620	862,620	6,788	28,787
2014	92,721	92,721	827,659	827,659	6,319	27,032
2015	100,530	100,530	828,242	828,242	6,828	27,188
2016	105,500	105,500	925,568	925,568	5,797	22,859
2017	100,602	100,602	784,758	784,758	4,673	17,363
2018	95,630	95,630	691,473	691,473	4,107	13,290
2019	97,642	97,642	624,135	624,135	3,640	11,676
2020	93,200	93,200	526,303	526,303	2,764	9,089

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2021	80,872	80,872	389,236	389,236	2,115	5,713
2022	78,614	78,614	260,750	260,750	1,091	2,261
2023	5,868	5,868	11,403	11,403	11	18
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	13,067	13,067	144,892	144,892	362	1,393
2007	24,274	24,274	225,737	225,737	801	2,649
2008	47,565	47,565	394,732	394,732	1,279	4,916
2009	55,760	55,760	403,077	403,077	1,373	5,071
2010	97,145	97,145	1,021,747	1,021,747	8,003	36,958
2011	121,777	121,777	1,075,311	1,075,311	10,861	47,710
2012	111,899	111,899	886,428	886,428	9,320	39,043
2013	116,079	116,079	934,641	934,641	9,069	37,863
2014	122,198	122,198	948,552	948,552	8,825	36,392
2015	132,517	132,517	959,941	959,941	9,310	36,111
2016	135,467	135,467	1,022,618	1,022,618	8,048	29,879
2017	139,671	139,671	965,047	965,047	6,864	25,530
2018	133,256	133,256	862,323	862,323	5,890	19,379
2019	133,369	133,369	755,590	755,590	5,056	15,751
2020	124,588	124,588	631,829	631,829	3,805	12,495
2021	103,734	103,734	464,639	464,639	2,890	7,551
2022	98,701	98,701	316,618	316,618	1,408	2,932
2023	7,315	7,315	14,478	14,478	14	35
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	5,258	5,258	62,725	62,725	*****	465
2007	9,395	9,395	94,688	94,688	323	893
2008	18,647	18,647	165,237	165,237	489	1,712
2009	21,613	21,613	165,473	165,473	516	1,920

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2010	37,518	37,518	442,145	442,145	3,004	14,082
2011	45,987	45,987	439,287	439,287	3,978	17,206
2012	42,428	42,428	349,875	349,875	3,435	13,972
2013	44,263	44,263	368,889	368,889	3,293	13,925
2014	47,944	47,944	383,056	383,056	3,319	13,354
2015	51,012	51,012	384,230	384,230	3,236	12,402
2016	52,564	52,564	434,980	434,980	2,876	10,228
2017	51,940	51,940	398,606	398,606	2,291	8,331
2018	47,223	47,223	330,579	330,579	1,841	6,097
2019	45,882	45,882	285,624	285,624	1,563	4,897
2020	43,080	43,080	235,735	235,735	1,139	3,749
2021	32,414	32,414	158,196	158,196	852	2,198
2022	30,728	30,728	102,891	102,891	369	780
2023	2,561	2,561	5,105	5,105	*****	27
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	7,586	7,586	65,626	65,626	*****	*****
2007	14,566	14,566	103,754	103,754	468	1,647
2008	28,199	28,199	184,081	184,081	768	3,179
2009	33,190	33,190	188,331	188,331	840	3,073
2010	58,403	58,403	465,471	465,471	4,927	22,653
2011	74,404	74,404	516,380	516,380	6,777	30,188
2012	68,238	68,238	435,346	435,346	5,803	24,795
2013	70,557	70,557	464,114	464,114	5,687	23,588
2014	72,949	72,949	464,392	464,392	5,426	22,727
2015	80,175	80,175	479,853	479,853	5,993	23,499
2016	79,908	79,908	491,793	491,793	5,012	19,220
2017	78,203	78,203	452,601	452,601	4,057	14,902



**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2018	76,253	76,253	426,073	426,073	3,585	11,519
2019	77,758	77,758	380,593	380,593	3,111	9,729
2020	73,006	73,006	326,127	326,127	2,399	7,837
2021	64,716	64,716	255,773	255,773	1,857	4,949
2022	61,745	61,745	184,511	184,511	969	2,038
2023	4,268	4,268	8,266	8,266	*****	*****
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	2,589	2,589	129,646	129,646	93	312
2007	2,464	2,464	112,071	112,071	*****	*****
2008	8,980	8,980	347,145	347,145	178	543
2009	6,863	6,863	235,748	235,748	135	467
2010	15,400	15,400	1,151,184	1,151,184	1,281	6,568
2011	10,592	10,592	572,851	572,851	691	3,364
2012	11,170	11,170	594,282	594,282	598	3,255
2013	15,562	15,562	758,843	758,843	778	3,388
2014	18,765	18,765	779,990	779,990	737	3,425
2015	21,311	21,311	793,177	793,177	738	3,103
2016	27,442	27,442	934,377	934,377	717	3,161
2017	27,223	27,223	832,021	832,021	637	2,909
2018	26,203	26,203	735,195	735,195	598	2,319
2019	28,481	28,481	676,416	676,416	550	1,864
2020	28,991	28,991	512,105	512,105	398	1,285
2021	20,966	20,966	340,520	340,520	316	673
2022	21,656	21,656	175,312	175,312	151	318
2023	2,150	2,150	5,975	5,975	*****	*****

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	1,919	1,919	94,007	94,007	69	218
2007	1,621	1,621	74,244	74,244	*****	*****
2008	5,916	5,916	230,604	230,604	116	396
2009	4,112	4,112	138,926	138,926	74	250
2010	9,916	9,916	801,703	801,703	849	4,529
2011	6,092	6,092	342,894	342,894	349	1,627
2012	6,279	6,279	349,409	349,409	326	1,830
2013	8,742	8,742	445,890	445,890	387	1,798
2014	10,628	10,628	454,488	454,488	383	1,974
2015	12,141	12,141	467,341	467,341	382	1,177
2016	15,800	15,800	561,999	561,999	342	1,305
2017	15,146	15,146	483,064	483,064	306	1,332
2018	14,128	14,128	405,697	405,697	278	931
2019	15,432	15,432	376,708	376,708	290	978
2020	16,089	16,089	292,452	292,452	199	627
2021	11,013	11,013	182,210	182,210	134	230
2022	11,326	11,326	91,978	91,978	53	96
2023	1,158	1,158	3,257	3,257	*****	*****
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	224	224	8,234	8,234	*****	53
2007	344	344	11,076	11,076	*****	85
2008	1,363	1,363	39,393	39,393	26	57
2009	1,185	1,185	31,547	31,547	31	113
2010	2,560	2,560	111,631	111,631	231	1,047
2011	2,117	2,117	73,706	73,706	187	1,000
2012	2,282	2,282	81,074	81,074	145	851

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2013	3,502	3,502	117,116	117,116	229	986
2014	4,405	4,405	126,387	126,387	200	970
2015	5,139	5,139	135,416	135,416	237	1,452
2016	7,060	7,060	172,554	172,554	232	1,224
2017	7,148	7,148	156,248	156,248	202	855
2018	6,900	6,900	144,226	144,226	187	830
2019	7,576	7,576	135,549	135,549	161	581
2020	7,626	7,626	103,519	103,519	120	453
2021	6,174	6,174	78,843	78,843	118	313
2022	6,625	6,625	44,705	44,705	63	151
2023	656	656	1,654	1,654	0	0
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	58	58	971	971	*****	35
2007	122	122	1,861	1,861	*****	84
2008	374	374	5,400	5,400	20	110
2009	447	447	4,576	4,576	18	117
2010	884	884	17,766	17,766	96	605
2011	1,019	1,019	16,352	16,352	133	788
2012	1,068	1,068	12,800	12,800	107	697
2013	1,348	1,348	18,205	18,205	141	932
2014	1,586	1,586	21,072	21,072	139	670
2015	1,836	1,836	21,037	21,037	143	654
2016	2,271	2,271	27,956	27,956	144	656
2017	2,369	2,369	25,186	25,186	133	833
2018	2,413	2,413	24,878	24,878	111	426
2019	2,574	2,574	21,955	21,955	111	478
2020	2,792	2,792	20,714	20,714	81	349

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2021	2,393	2,393	14,087	14,087	68	147
2022	2,501	2,501	9,737	9,737	43	84
2023	217	217	449	449	0	0
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	41	41	740	740	0	0
2007	66	66	1,082	1,082	*****	21
2008	246	246	4,330	4,330	*****	80
2009	292	292	3,140	3,140	11	102
2010	523	523	12,537	12,537	51	386
2011	573	573	11,464	11,464	69	406
2012	567	567	7,924	7,924	53	469
2013	757	757	11,901	11,901	60	436
2014	928	928	13,647	13,647	75	417
2015	1,025	1,025	13,240	13,240	54	164
2016	1,263	1,263	18,411	18,411	48	163
2017	1,266	1,266	15,222	15,222	52	382
2018	1,243	1,243	14,611	14,611	46	140
2019	1,333	1,333	12,648	12,648	49	241
2020	1,477	1,477	12,249	12,249	23	116
2021	1,098	1,098	7,915	7,915	22	41
2022	1,181	1,181	4,895	4,895	12	14
2023	132	132	293	293	0	0
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	16	16	92	92	*****	35
2007	53	53	617	617	*****	63
2008	127	127	593	593	*****	30
2009	147	147	921	921	*****	15

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2010	352	352	3,413	3,413	45	219
2011	434	434	3,876	3,876	62	376
2012	490	490	3,763	3,763	54	228
2013	580	580	4,935	4,935	81	496
2014	640	640	5,211	5,211	64	253
2015	794	794	6,190	6,190	88	467
2016	971	971	7,570	7,570	95	492
2017	1,011	1,011	7,775	7,775	78	329
2018	1,061	1,061	7,944	7,944	62	280
2019	1,144	1,144	7,622	7,622	55	218
2020	1,202	1,202	6,939	6,939	53	228
2021	1,197	1,197	5,262	5,262	39	93
2022	1,218	1,218	4,083	4,083	30	69
2023	81	81	135	135	0	0
<b>Prevalent IBD Cohort</b>						
2006	28,743	28,743	638,461	638,461	848	3,010
2007	37,101	37,101	561,717	561,717	1,321	4,261
2008	85,708	85,708	1,303,088	1,303,088	2,070	7,545
2009	78,774	78,774	843,066	843,066	1,754	6,166
2010	170,481	170,481	4,732,466	4,732,466	15,950	75,281
2011	161,549	161,549	2,397,177	2,397,177	14,166	62,632
2012	144,537	144,537	2,008,729	2,008,729	11,500	50,093
2013	161,966	161,966	2,523,150	2,523,150	11,827	50,633
2014	170,097	170,097	2,455,129	2,455,129	11,052	46,724
2015	183,816	183,816	2,505,197	2,505,197	11,439	45,091
2016	201,516	201,516	2,918,347	2,918,347	10,116	38,492
2017	196,408	196,408	2,395,976	2,395,976	8,512	31,738

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2018	182,077	182,077	2,007,743	2,007,743	7,243	23,863
2019	184,793	184,793	1,813,517	1,813,517	6,404	20,419
2020	178,128	178,128	1,489,931	1,489,931	4,846	15,679
2021	143,791	143,791	997,533	997,533	3,593	9,411
2022	140,264	140,264	583,091	583,091	1,725	3,574
2023	11,238	11,238	23,790	23,790	19	46
<b>Prevalent CD Cohort</b>						
2006	13,265	13,265	354,870	354,870	*****	1,225
2007	15,326	15,326	283,790	283,790	589	1,513
2008	37,145	37,145	684,917	684,917	877	2,774
2009	31,759	31,759	391,202	391,202	707	2,505
2010	74,316	74,316	2,760,267	2,760,267	7,122	33,783
2011	63,947	63,947	1,176,528	1,176,528	5,378	22,998
2012	57,410	57,410	993,270	993,270	4,418	18,820
2013	65,278	65,278	1,247,063	1,247,063	4,542	19,648
2014	70,855	70,855	1,230,147	1,230,147	4,344	18,009
2015	76,338	76,338	1,271,000	1,271,000	4,243	16,560
2016	85,986	85,986	1,528,126	1,528,126	3,897	14,013
2017	79,650	79,650	1,183,609	1,183,609	3,065	10,791
2018	70,614	70,614	940,802	940,802	2,485	8,150
2019	70,651	70,651	856,425	856,425	2,176	6,855
2020	69,182	69,182	696,204	696,204	1,674	5,144
2021	50,878	50,878	435,125	435,125	1,165	2,975
2022	49,667	49,667	236,287	236,287	522	1,082
2023	4,362	4,362	9,745	9,745	*****	28

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent UC Cohort</b>						
2006	13,396	13,396	183,432	183,432	396	1,564
2007	19,968	19,968	195,462	195,462	665	2,459
2008	43,214	43,214	421,085	421,085	1,063	4,249
2009	43,214	43,214	325,409	325,409	987	3,486
2010	86,368	86,368	1,248,662	1,248,662	7,828	36,246
2011	91,416	91,416	879,374	879,374	8,281	37,230
2012	82,027	82,027	729,824	729,824	6,769	29,966
2013	90,099	90,099	913,132	913,132	6,850	29,134
2014	92,769	92,769	890,939	890,939	6,375	27,334
2015	100,686	100,686	902,067	902,067	6,884	27,480
2016	105,988	105,988	1,024,117	1,024,117	5,853	23,277
2017	101,304	101,304	881,791	881,791	4,743	17,911
2018	96,452	96,452	786,423	786,423	4,172	13,568
2019	98,928	98,928	719,472	719,472	3,720	12,024
2020	94,809	94,809	600,762	600,762	2,816	9,284
2021	82,392	82,392	437,111	437,111	2,161	5,821
2022	80,456	80,456	282,001	282,001	1,101	2,290
2023	6,019	6,019	11,785	11,785	11	18
<b>Incident IBD Cohort</b>						
2006	13,067	13,067	148,098	148,098	363	1,402
2007	24,277	24,277	229,861	229,861	805	2,656
2008	47,574	47,574	400,403	400,403	1,281	4,925
2009	55,769	55,769	409,154	409,154	1,377	5,079
2010	97,169	97,169	1,050,802	1,050,802	8,038	37,374
2011	121,816	121,816	1,105,491	1,105,491	10,904	47,925
2012	111,945	111,945	919,706	919,706	9,355	39,171

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2013	116,128	116,128	982,240	982,240	9,128	38,221
2014	122,253	122,253	1,009,267	1,009,267	8,864	36,640
2015	132,585	132,585	1,026,503	1,026,503	9,355	36,364
2016	135,563	135,563	1,094,357	1,094,357	8,090	30,218
2017	139,789	139,789	1,041,662	1,041,662	6,922	25,944
2018	133,371	133,371	939,037	939,037	5,941	19,565
2019	133,558	133,558	822,196	822,196	5,111	16,015
2020	124,793	124,793	676,481	676,481	3,839	12,624
2021	103,910	103,910	491,887	491,887	2,920	7,613
2022	98,876	98,876	323,434	323,434	1,415	2,954
2023	7,334	7,334	14,564	14,564	14	35
<b>Incident CD Cohort</b>						
2006	5,258	5,258	64,294	64,294	*****	474
2007	9,398	9,398	96,441	96,441	326	896
2008	18,652	18,652	167,716	167,716	490	1,713
2009	21,616	21,616	167,262	167,262	517	1,921
2010	37,527	37,527	457,626	457,626	3,017	14,178
2011	46,008	46,008	453,287	453,287	4,001	17,286
2012	42,458	42,458	362,736	362,736	3,455	14,019
2013	44,281	44,281	388,774	388,774	3,316	14,060
2014	47,972	47,972	406,002	406,002	3,334	13,454
2015	51,054	51,054	409,003	409,003	3,251	12,454
2016	52,613	52,613	461,408	461,408	2,900	10,347
2017	51,985	51,985	425,025	425,025	2,310	8,413
2018	47,274	47,274	355,593	355,593	1,862	6,154
2019	45,952	45,952	308,466	308,466	1,583	4,957
2020	43,140	43,140	249,276	249,276	1,153	3,816



**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2021	32,464	32,464	166,761	166,761	860	2,212
2022	30,770	30,770	104,969	104,969	370	781
2023	2,565	2,565	5,128	5,128	*****	27
<b>Incident UC Cohort</b>						
2006	7,586	7,586	66,746	66,746	*****	*****
2007	14,566	14,566	105,452	105,452	469	1,651
2008	28,203	28,203	186,400	186,400	769	3,186
2009	33,196	33,196	191,214	191,214	843	3,080
2010	58,418	58,418	474,823	474,823	4,948	22,972
2011	74,422	74,422	527,005	527,005	6,797	30,323
2012	68,254	68,254	448,382	448,382	5,818	24,876
2013	70,587	70,587	483,308	483,308	5,723	23,811
2014	72,975	72,975	491,785	491,785	5,449	22,870
2015	80,200	80,200	510,759	510,759	6,019	23,685
2016	79,954	79,954	526,118	526,118	5,029	19,438
2017	78,271	78,271	487,697	487,697	4,088	15,170
2018	76,312	76,312	462,970	462,970	3,615	11,648
2019	77,867	77,867	414,182	414,182	3,143	9,930
2020	73,140	73,140	349,263	349,263	2,418	7,888
2021	64,834	64,834	269,833	269,833	1,877	4,995
2022	61,873	61,873	188,315	188,315	975	2,059
2023	4,283	4,283	8,317	8,317	*****	*****
<b>Advanced Therapy Initiators with IBD</b>						
2006	352	352	4,837	4,840	*****	*****
2007	1,112	1,112	17,410	17,430	25	37
2008	2,315	2,315	39,640	39,695	39	99
2009	3,652	3,652	64,691	64,730	61	124

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2010	4,484	4,484	77,569	77,602	149	658
2011	5,254	5,254	100,101	100,120	224	836
2012	5,642	5,642	109,445	109,478	207	758
2013	6,411	6,411	119,055	119,142	211	844
2014	8,417	8,417	155,138	155,316	272	1,069
2015	9,565	9,565	165,423	165,567	263	1,026
2016	11,467	11,467	194,386	194,674	275	836
2017	13,301	13,301	209,751	210,066	257	944
2018	13,739	13,739	205,491	205,822	250	874
2019	14,213	14,213	183,146	183,515	220	577
2020	14,013	14,013	131,266	131,544	167	421
2021	9,485	9,485	95,421	95,716	122	223
2022	9,574	9,574	49,150	49,393	59	125
2023	1,065	1,065	2,465	2,470	*****	*****
<b>Advanced Therapy Initiators with CD</b>						
2006	195	195	2,652	2,655	*****	*****
2007	683	683	11,198	11,215	*****	20
2008	1,325	1,325	23,613	23,661	22	49
2009	1,999	1,999	36,564	36,590	30	56
2010	2,358	2,358	42,705	42,733	77	209
2011	2,728	2,728	53,595	53,602	89	333
2012	2,816	2,816	57,106	57,128	95	239
2013	3,080	3,080	60,598	60,645	89	401
2014	4,041	4,041	75,014	75,102	126	445
2015	4,625	4,625	79,879	79,953	131	368
2016	5,597	5,597	93,802	93,958	115	392
2017	6,582	6,582	104,420	104,576	124	508

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
2018	6,607	6,607	99,026	99,165	103	343
2019	6,628	6,628	82,324	82,487	91	215
2020	6,652	6,652	60,176	60,280	74	229
2021	4,093	4,093	41,176	41,279	52	80
2022	4,063	4,063	20,933	21,026	20	39
2023	479	479	1,075	1,076	*****	*****
<b>Advanced Therapy Initiators with UC</b>						
2006	56	56	612	612	*****	*****
2007	162	162	1,855	1,858	*****	*****
2008	397	397	6,242	6,246	*****	*****
2009	629	629	9,902	9,908	*****	30
2010	883	883	12,395	12,395	31	314
2011	993	993	17,304	17,306	61	203
2012	1,084	1,084	19,414	19,419	46	242
2013	1,365	1,365	22,780	22,796	56	141
2014	2,038	2,038	35,234	35,270	77	388
2015	2,436	2,436	40,225	40,257	65	305
2016	3,179	3,179	52,018	52,090	93	288
2017	3,509	3,509	53,722	53,803	58	211
2018	3,498	3,498	50,425	50,533	64	202
2019	3,824	3,824	50,074	50,206	70	208
2020	3,824	3,824	36,266	36,358	43	103
2021	2,828	2,828	28,645	28,764	37	92
2022	2,963	2,963	15,272	15,368	18	48
2023	325	325	746	749	0	0

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	46,583,737	127,539.3	8,506,942	1,356,890,273	3,714,963.1	66.18 (61.86, 70.79)
2007	57,520,931	157,483.7	12,117,058	3,144,547,875	8,609,302.9	83.37 (78.98, 88.01)
2008	109,709,437	300,368.1	28,039,870	6,036,373,628	16,526,690.3	68.55 (65.65, 71.58)
2009	96,598,777	264,473.0	29,362,000	8,205,066,714	22,464,248.4	66.06 (63.03, 69.23)
2010	327,406,857	896,391.1	44,463,691	10,657,097,134	29,177,541.8	175.79 (173.07, 178.56)
2011	289,733,644	793,247.5	44,790,309	13,377,529,547	36,625,679.8	177.41 (174.50, 180.37)
2012	241,445,843	661,042.7	45,059,024	13,513,876,659	36,998,977.8	172.71 (169.57, 175.91)
2013	256,545,921	702,384.5	50,523,325	14,530,034,738	39,781,067.0	166.28 (163.29, 169.32)
2014	244,080,348	668,255.6	57,320,232	16,220,879,525	44,410,347.8	163.22 (160.18, 166.31)
2015	235,007,389	643,415.2	64,597,849	18,277,264,844	50,040,423.9	175.33 (172.12, 178.60)
2016	227,762,759	623,580.4	80,729,025	21,639,654,140	59,246,144.1	159.40 (156.30, 162.57)
2017	201,057,259	550,464.8	84,117,176	24,200,193,078	66,256,517.7	151.60 (148.38, 154.89)
2018	165,106,476	452,036.9	82,585,647	24,235,199,177	66,352,359.1	156.96 (153.35, 160.65)
2019	135,432,868	370,795.0	84,262,499	24,457,388,026	66,960,679.1	168.29 (164.16, 172.51)
2020	92,811,256	254,103.4	85,862,165	25,514,353,367	69,854,492.4	185.87 (180.64, 191.25)
2021	62,637,604	171,492.4	53,889,521	16,350,189,284	44,764,378.6	204.38 (197.73, 211.26)
2022	25,587,048	70,053.5	54,288,421	16,295,886,585	44,615,705.9	241.53 (230.29, 253.32)
2023	474,707	1,299.7	21,174,745	1,441,639,029	3,946,992.6	138.50 (87.26, 219.82)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	*****	*****	8,490,516	1,355,068,522	3,709,975.4	66.50 (60.16, 73.52)
2007	23,030,959	63,055.3	12,100,495	3,141,676,130	8,601,440.5	92.78 (85.55, 100.61)
2008	46,195,124	126,475.4	27,995,439	6,030,334,763	16,510,156.8	68.79 (64.37, 73.51)
2009	37,881,194	103,713.1	29,328,910	8,198,745,708	22,446,942.4	67.98 (63.14, 73.18)
2010	143,297,725	392,327.8	44,377,798	10,644,966,263	29,144,329.3	178.65 (174.52, 182.88)
2011	113,657,353	311,176.9	44,726,179	13,363,415,885	36,587,038.7	171.25 (166.72, 175.91)
2012	95,777,622	262,224.8	45,000,307	13,500,931,287	36,963,535.4	166.65 (161.78, 171.67)
2013	102,537,565	280,732.6	50,451,269	14,515,860,386	39,742,259.8	159.62 (155.01, 164.36)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2014	99,553,419	272,562.4	57,246,682	16,205,996,600	44,369,600.5	156.81 (152.18, 161.58)
2015	95,579,701	261,683.0	64,521,015	18,261,802,869	49,998,091.4	159.28 (154.51, 164.19)
2016	93,724,505	256,603.7	80,637,572	21,622,262,017	59,198,527.1	148.09 (143.45, 152.87)
2017	78,673,590	215,396.6	84,031,356	24,182,686,806	66,208,588.1	138.81 (133.93, 143.88)
2018	62,391,017	170,817.3	82,505,509	24,218,413,505	66,306,402.5	141.26 (135.74, 147.01)
2019	50,181,350	137,389.0	84,179,778	24,440,427,726	66,914,244.3	153.36 (146.95, 160.05)
2020	34,596,202	94,719.2	85,778,979	25,496,836,514	69,806,533.9	169.98 (161.87, 178.49)
2021	22,345,923	61,179.8	53,829,175	16,337,929,276	44,730,812.5	185.52 (175.03, 196.63)
2022	9,099,068	24,911.9	54,227,132	16,283,692,761	44,582,321.0	202.31 (185.40, 220.77)
2023	*****	*****	21,159,084	1,440,685,723	3,944,382.5	138.61 (66.08, 290.74)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	22,265,260	60,959.0	8,490,639	1,355,421,228	3,710,941.1	64.96 (58.87, 71.69)
2007	31,799,340	87,061.8	12,102,922	3,142,492,762	8,603,676.3	76.04 (70.46, 82.06)
2008	56,979,515	156,001.4	27,998,772	6,031,840,420	16,514,279.0	67.95 (63.98, 72.16)
2009	54,414,848	148,979.7	29,334,333	8,200,535,183	22,451,841.7	65.92 (61.92, 70.17)
2010	163,974,556	448,937.9	44,384,016	10,648,020,227	29,152,690.6	173.12 (169.31, 177.01)
2011	165,096,003	452,008.2	44,738,956	13,367,939,172	36,599,422.8	182.34 (178.45, 186.32)
2012	137,717,567	377,050.1	45,012,095	13,505,123,896	36,975,014.1	178.70 (174.49, 183.02)
2013	143,932,010	394,064.4	50,464,570	14,520,285,034	39,754,373.8	172.26 (168.21, 176.40)
2014	135,995,265	372,334.7	57,257,057	16,210,386,001	44,381,618.1	169.71 (165.58, 173.95)
2015	131,495,233	360,014.3	64,528,662	18,265,799,254	50,009,032.9	189.66 (185.21, 194.21)
2016	124,232,461	340,129.9	80,643,625	21,626,278,739	59,209,524.3	170.43 (166.10, 174.88)
2017	106,406,915	291,326.3	84,039,531	24,186,721,040	66,219,633.2	160.40 (155.87, 165.07)
2018	89,061,528	243,837.2	82,514,775	24,222,360,506	66,317,208.8	168.43 (163.36, 173.66)
2019	74,000,282	202,601.7	84,188,166	24,444,271,150	66,924,767.0	179.66 (173.92, 185.60)
2020	50,936,761	139,457.3	85,787,026	25,500,575,448	69,816,770.6	198.20 (190.94, 205.73)
2021	35,670,637	97,660.9	53,840,274	16,341,580,762	44,740,809.8	216.57 (207.53, 225.99)
2022	14,663,569	40,146.7	54,238,502	16,287,357,418	44,592,354.3	271.75 (256.10, 288.37)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2023	254,722	697.4	21,162,277	1,440,909,520	3,944,995.3	157.73 (87.35, 284.82)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	21,074,407	57,698.6	8,476,332	1,353,768,241	3,706,415.4	62.74 (56.60, 69.55)
2007	37,644,554	103,065.2	12,088,022	3,139,834,403	8,596,398.1	77.72 (72.52, 83.29)
2008	62,659,810	171,553.2	27,959,713	6,026,297,425	16,499,103.1	74.55 (70.58, 78.75)
2009	70,557,705	193,176.5	29,304,519	8,194,686,872	22,435,829.9	71.07 (67.41, 74.94)
2010	170,867,575	467,809.9	44,307,456	10,636,802,775	29,121,978.9	171.07 (167.37, 174.86)
2011	215,618,406	590,331.0	44,680,344	13,354,729,344	36,563,256.2	183.98 (180.55, 187.47)
2012	188,007,997	514,737.8	44,958,505	13,493,000,801	36,941,822.9	181.06 (177.42, 184.78)
2013	184,644,179	505,528.2	50,399,231	14,507,036,199	39,718,100.5	179.40 (175.74, 183.13)
2014	179,498,288	491,439.5	57,190,009	16,196,447,320	44,343,456.0	179.57 (175.87, 183.36)
2015	174,213,101	476,969.5	64,458,674	18,251,320,949	49,969,393.4	195.19 (191.27, 199.20)
2016	160,058,275	438,215.7	80,560,190	21,609,965,595	59,164,861.3	183.65 (179.68, 187.71)
2017	148,812,232	407,425.7	83,961,902	24,170,398,215	66,174,943.8	168.47 (164.53, 172.51)
2018	124,169,837	339,958.5	82,442,984	24,206,933,619	66,274,972.3	173.26 (168.89, 177.74)
2019	100,420,711	274,936.9	84,114,711	24,428,848,746	66,882,542.8	183.90 (178.90, 189.04)
2020	66,456,560	181,948.1	85,713,558	25,484,795,338	69,773,567.0	209.13 (202.59, 215.88)
2021	46,056,800	126,096.6	53,786,422	16,330,499,107	44,710,469.8	229.19 (220.98, 237.70)
2022	18,365,801	50,282.8	54,183,946	16,276,392,421	44,562,333.8	280.02 (265.77, 295.03)
2023	309,674	847.8	21,148,334	1,440,063,908	3,942,680.1	165.13 (97.79, 278.81)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	*****	*****	8,476,281	1,353,760,431	3,706,394.1	58.05 (48.95, 68.85)
2007	14,201,093	38,880.5	12,087,953	3,139,819,521	8,596,357.3	83.08 (74.49, 92.65)
2008	23,913,782	65,472.4	27,959,564	6,026,268,504	16,499,024.0	74.69 (68.35, 81.61)
2009	26,851,698	73,515.9	29,304,456	8,194,652,723	22,435,736.4	70.19 (64.39, 76.51)
2010	65,143,698	178,353.7	44,307,345	10,636,743,140	29,121,815.6	168.43 (162.51, 174.56)
2011	81,246,396	222,440.5	44,680,226	13,354,653,550	36,563,048.7	178.83 (173.36, 184.48)
2012	71,811,679	196,609.7	44,958,364	13,492,931,326	36,941,632.7	174.71 (168.97, 180.65)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2013	70,626,628	193,365.2	50,399,032	14,506,964,381	39,717,903.8	170.30 (164.58, 176.22)
2014	70,100,094	191,923.6	57,189,863	16,196,373,061	44,343,252.7	172.93 (167.15, 178.92)
2015	66,939,884	183,271.4	64,458,543	18,251,239,432	49,969,170.2	176.57 (170.59, 182.76)
2016	60,512,811	165,675.0	80,560,045	21,609,882,686	59,164,634.3	173.59 (167.36, 180.05)
2017	54,204,450	148,403.7	83,961,711	24,170,310,479	66,174,703.6	154.38 (148.18, 160.83)
2018	43,181,392	118,224.2	82,442,815	24,206,847,573	66,274,736.7	155.72 (148.77, 163.00)
2019	33,654,686	92,141.5	84,114,544	24,428,761,246	66,882,303.2	169.63 (161.43, 178.25)
2020	22,068,233	60,419.5	85,713,384	25,484,713,823	69,773,343.8	188.52 (177.88, 199.79)
2021	14,677,380	40,184.5	53,786,323	16,330,427,765	44,710,274.5	212.02 (198.25, 226.75)
2022	5,765,491	15,785.1	54,183,824	16,276,324,436	44,562,147.7	233.77 (211.09, 258.88)
2023	*****	*****	21,148,313	1,440,059,153	3,942,667.1	238.98 (113.93, 501.30)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
2006	*****	*****	8,476,288	1,353,762,760	3,706,400.4	65.43 (57.38, 74.61)
2007	22,991,594	62,947.6	12,088,000	3,139,824,695	8,596,371.5	74.35 (67.91, 81.40)
2008	37,764,989	103,394.9	27,959,608	6,026,278,056	16,499,050.1	74.28 (69.21, 79.72)
2009	42,485,674	116,319.4	29,304,487	8,194,664,298	22,435,768.1	72.21 (67.49, 77.27)
2010	103,748,129	284,046.9	44,307,360	10,636,764,027	29,121,872.8	173.46 (168.68, 178.37)
2011	131,982,219	361,347.6	44,680,270	13,354,681,968	36,563,126.5	187.55 (183.14, 192.07)
2012	114,311,660	312,968.3	44,958,402	13,492,957,135	36,941,703.3	185.42 (180.71, 190.25)
2013	112,109,425	306,938.9	50,399,117	14,506,990,674	39,717,975.8	185.28 (180.53, 190.16)
2014	107,551,166	294,459.0	57,189,878	16,196,398,063	44,343,321.2	184.27 (179.43, 189.24)
2015	105,529,556	288,924.2	64,458,539	18,251,268,603	49,969,250.1	207.42 (202.24, 212.74)
2016	96,044,104	262,954.4	80,560,070	21,609,910,033	59,164,709.2	190.60 (185.40, 195.95)
2017	83,912,706	229,740.5	83,961,752	24,170,336,743	66,174,775.5	176.59 (171.24, 182.11)
2018	71,446,279	195,609.3	82,442,846	24,206,876,609	66,274,816.2	183.27 (177.37, 189.37)
2019	58,969,329	161,449.2	84,114,586	24,428,793,132	66,882,390.5	192.69 (186.04, 199.58)
2020	39,578,077	108,358.9	85,713,408	25,484,743,749	69,773,425.7	221.39 (212.71, 230.43)
2021	28,336,653	77,581.5	53,786,349	16,330,460,084	44,710,363.0	239.36 (228.72, 250.50)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2022	11,440,291	31,321.8	54,183,878	16,276,355,462	44,562,232.6	309.37 (290.49, 329.47)
2023	*****	*****	21,148,320	1,440,060,861	3,942,671.8	139.83 (66.66, 293.31)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	3,963,519	10,851.5	10,882	1,357,659	3,717.1	85.70 (69.94, 105.02)
2007	*****	*****	16,141	3,509,068	9,607.3	83.65 (66.81, 104.74)
2008	10,985,832	30,077.6	46,846	8,117,260	22,223.8	59.18 (51.09, 68.55)
2009	7,699,773	21,080.8	53,962	12,773,991	34,973.3	64.04 (54.10, 75.81)
2010	30,089,611	82,380.9	119,063	23,293,810	63,775.0	155.50 (147.21, 164.25)
2011	16,969,070	46,458.8	130,379	35,454,335	97,068.7	148.73 (138.05, 160.25)
2012	17,261,343	47,259.0	144,283	40,037,393	109,616.4	126.54 (116.79, 137.10)
2013	22,490,249	61,574.9	177,863	47,139,518	129,061.0	126.35 (117.78, 135.55)
2014	23,349,564	63,927.6	208,325	55,548,494	152,083.5	115.29 (107.26, 123.92)
2015	23,716,164	64,931.3	243,929	65,348,720	178,915.0	113.66 (105.75, 122.16)
2016	27,198,191	74,464.6	302,307	79,097,839	216,558.1	96.29 (89.49, 103.60)
2017	24,418,757	66,854.9	337,376	91,521,661	250,572.7	95.28 (88.16, 102.98)
2018	21,689,050	59,381.4	361,408	100,186,846	274,296.6	100.70 (92.95, 109.11)
2019	19,295,483	52,828.2	402,007	110,488,962	302,502.3	104.11 (95.76, 113.19)
2020	14,012,620	38,364.5	433,517	122,183,053	334,519.0	103.74 (94.03, 114.45)
2021	9,329,139	25,541.8	356,713	101,663,376	278,339.2	123.72 (110.80, 138.14)
2022	4,144,708	11,347.6	377,277	107,573,814	294,521.1	133.07 (113.45, 156.08)
2023	*****	*****	115,041	7,399,224	20,258.0	39.89 (5.62, 283.21)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	2,858,196	7,825.3	10,171	1,338,380	3,664.3	88.18 (69.64, 111.64)
2007	*****	*****	15,243	3,479,198	9,525.5	79.81 (59.78, 106.55)
2008	7,102,498	19,445.6	43,603	8,006,790	21,921.4	59.65 (49.73, 71.56)
2009	4,482,937	12,273.6	50,968	12,655,490	34,648.8	60.29 (48.01, 75.72)
2010	19,777,316	54,147.3	113,196	23,062,463	63,141.6	156.79 (146.59, 167.70)
2011	9,669,259	26,473.0	125,532	35,215,064	96,413.6	131.83 (118.70, 146.42)



**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2012	9,748,394	26,689.6	138,906	39,767,536	108,877.6	122.14 (109.58, 136.15)
2013	12,582,422	34,448.8	170,212	46,729,735	127,939.0	112.34 (101.69, 124.11)
2014	13,018,807	35,643.6	199,013	55,024,274	150,648.3	107.45 (97.21, 118.77)
2015	13,382,512	36,639.3	233,238	64,675,025	177,070.6	104.26 (94.31, 115.26)
2016	15,572,643	42,635.6	288,471	78,174,866	214,031.1	80.21 (72.15, 89.18)
2017	13,554,720	37,110.8	322,869	90,495,990	247,764.5	82.46 (73.72, 92.23)
2018	11,735,932	32,131.2	346,679	99,107,345	271,341.1	86.52 (76.92, 97.31)
2019	10,453,762	28,620.8	385,963	109,260,434	299,138.8	101.32 (90.31, 113.68)
2020	7,799,256	21,353.2	417,256	120,801,924	330,737.6	93.19 (81.11, 107.09)
2021	4,948,936	13,549.4	344,295	100,558,657	275,314.6	98.90 (83.49, 117.14)
2022	2,188,439	5,991.6	364,174	106,385,012	291,266.3	88.46 (67.58, 115.79)
2023	*****	*****	112,847	7,309,368	20,012.0	72.61 (10.23, 515.50)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	*****	*****	8,356	1,282,227	3,510.5	88.13 (45.86, 169.38)
2007	*****	*****	13,838	3,439,610	9,417.1	143.08 (92.31, 221.78)
2008	1,787,361	4,893.5	38,518	7,824,892	21,423.4	53.13 (36.18, 78.03)
2009	1,443,908	3,953.2	47,700	12,524,732	34,290.8	78.42 (55.15, 111.51)
2010	4,879,596	13,359.6	105,128	22,772,857	62,348.7	172.91 (151.99, 196.71)
2011	3,504,369	9,594.4	120,932	35,030,072	95,907.1	194.90 (168.88, 224.94)
2012	3,601,330	9,859.9	134,268	39,583,756	108,374.4	147.06 (124.97, 173.06)
2013	5,213,918	14,274.9	164,312	46,499,104	127,307.6	160.42 (140.93, 182.60)
2014	5,587,859	15,298.7	192,109	54,740,395	149,871.0	130.73 (113.81, 150.16)
2015	5,749,157	15,740.3	225,392	64,341,169	176,156.5	150.57 (132.57, 171.01)
2016	7,018,546	19,215.7	278,562	77,783,247	212,958.9	120.73 (106.16, 137.31)
2017	6,236,652	17,075.0	313,915	90,160,143	246,845.0	118.30 (103.06, 135.79)
2018	5,631,112	15,417.1	338,424	98,813,469	270,536.5	121.29 (105.10, 139.99)
2019	5,100,597	13,964.7	377,043	108,932,501	298,240.9	115.29 (98.79, 134.55)
2020	3,671,074	10,050.9	407,916	120,460,353	329,802.5	119.39 (99.83, 142.79)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2021	2,685,042	7,351.2	339,103	100,494,593	275,139.2	160.52 (134.02, 192.26)
2022	1,240,606	3,396.6	359,152	106,324,156	291,099.7	185.48 (144.90, 237.43)
2023	26,966	73.8	112,238	7,292,893	19,966.9	0.00 (0.00, 0.00)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	*****	*****	8,106	1,273,232	3,485.9	49.89 (7.03, 354.17)
2007	*****	*****	13,483	3,420,779	9,365.6	219.04 (124.40, 385.71)
2008	472,814	1,294.5	37,031	7,759,550	21,244.5	154.50 (99.68, 239.48)
2009	517,023	1,415.5	46,396	12,454,236	34,097.8	127.16 (80.12, 201.83)
2010	1,613,283	4,416.9	102,369	22,624,698	61,943.0	217.35 (177.94, 265.48)
2011	1,820,027	4,983.0	118,695	34,865,847	95,457.5	266.91 (225.19, 316.35)
2012	1,840,238	5,038.3	131,759	39,399,327	107,869.5	212.37 (175.72, 256.68)
2013	2,171,335	5,944.8	160,268	46,209,249	126,514.0	237.18 (201.09, 279.75)
2014	2,226,958	6,097.1	186,890	54,354,791	148,815.3	227.98 (193.06, 269.21)
2015	2,362,501	6,468.2	219,181	63,842,957	174,792.5	221.08 (187.66, 260.46)
2016	2,553,037	6,989.8	269,873	77,078,607	211,029.7	206.01 (174.97, 242.57)
2017	2,366,888	6,480.2	304,892	89,370,710	244,683.7	205.24 (173.16, 243.26)
2018	2,231,889	6,110.6	329,597	97,987,819	268,276.0	181.65 (150.82, 218.79)
2019	1,866,214	5,109.4	367,293	108,003,504	295,697.5	217.25 (180.37, 261.67)
2020	1,488,094	4,074.2	397,825	119,414,232	326,938.3	198.81 (159.91, 247.19)
2021	1,068,543	2,925.5	331,033	99,620,188	272,745.2	232.44 (183.27, 294.80)
2022	468,211	1,281.9	350,361	105,378,465	288,510.5	335.44 (248.78, 452.30)
2023	8,819	24.1	110,650	7,222,557	19,774.3	0.00 (0.00, 0.00)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	48,620	133.1	8,105	1,273,215	3,485.9	0.00 (0.00, 0.00)
2007	*****	*****	13,476	3,420,723	9,365.4	108.57 (35.01, 336.63)
2008	*****	*****	37,022	7,759,422	21,244.1	115.28 (62.03, 214.26)
2009	317,558	869.4	46,382	12,454,081	34,097.4	126.52 (70.07, 228.46)
2010	935,997	2,562.6	102,331	22,624,337	61,942.1	199.02 (151.25, 261.87)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2011	1,015,105	2,779.2	118,673	34,865,401	95,456.3	248.27 (196.09, 314.34)
2012	1,023,902	2,803.3	131,731	39,398,826	107,868.1	189.06 (144.44, 247.48)
2013	1,173,453	3,212.7	160,253	46,208,658	126,512.4	186.76 (145.01, 240.53)
2014	1,227,862	3,361.7	186,855	54,354,133	148,813.5	223.10 (177.91, 279.76)
2015	1,269,994	3,477.1	219,151	63,842,146	174,790.3	155.30 (118.95, 202.78)
2016	1,343,694	3,678.8	269,821	77,077,599	211,027.0	130.48 (98.33, 173.14)
2017	1,219,485	3,338.8	304,832	89,369,607	244,680.6	155.75 (118.68, 204.39)
2018	1,092,818	2,992.0	329,517	97,986,649	268,272.8	153.74 (115.16, 205.26)
2019	935,550	2,561.4	367,216	108,002,263	295,694.1	191.30 (144.58, 253.12)
2020	757,114	2,072.9	397,756	119,412,917	326,934.7	110.96 (73.73, 166.97)
2021	501,820	1,373.9	330,987	99,618,893	272,741.7	160.13 (105.44, 243.19)
2022	231,356	633.4	350,303	105,377,145	288,506.9	189.45 (107.59, 333.59)
2023	5,398	14.8	110,641	7,222,472	19,774.1	0.00 (0.00, 0.00)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
2006	*****	*****	8,096	1,273,190	3,485.8	168.66 (23.76, 1,197.37)
2007	*****	*****	13,466	3,420,710	9,365.4	362.06 (188.38, 695.85)
2008	*****	*****	37,000	7,759,303	21,243.8	235.99 (126.97, 438.60)
2009	*****	*****	46,353	12,453,936	34,097.0	138.15 (65.86, 289.79)
2010	660,992	1,809.7	102,306	22,624,166	61,941.6	248.66 (185.66, 333.04)
2011	783,982	2,146.4	118,647	34,865,262	95,455.9	288.85 (225.20, 370.49)
2012	797,819	2,184.3	131,713	39,398,749	107,867.9	247.22 (189.34, 322.79)
2013	985,209	2,697.4	160,214	46,208,481	126,511.9	300.29 (241.53, 373.36)
2014	973,112	2,664.2	186,815	54,353,845	148,812.7	240.22 (188.02, 306.91)
2015	1,076,544	2,947.4	219,114	63,841,915	174,789.6	298.57 (242.27, 367.94)
2016	1,166,767	3,194.4	269,796	77,077,307	211,026.2	297.39 (243.22, 363.63)
2017	1,036,176	2,836.9	304,801	89,369,352	244,680.0	274.95 (220.23, 343.27)
2018	1,023,410	2,801.9	329,489	97,986,467	268,272.3	221.27 (172.52, 283.82)
2019	851,199	2,330.5	367,182	108,002,074	295,693.6	236.01 (181.19, 307.40)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2020	655,911	1,795.8	397,716	119,412,642	326,934.0	295.14 (225.47, 386.32)
2021	525,205	1,437.9	330,973	99,618,992	272,741.9	271.22 (198.16, 371.22)
2022	218,403	598.0	350,304	105,377,182	288,507.0	501.71 (350.79, 717.57)
2023	3,279	9.0	110,645	7,222,421	19,773.9	0.00 (0.00, 0.00)
<b>Prevalent IBD Cohort</b>						
2006	46,913,145	128,441.2	8,506,948	1,356,899,529	3,714,988.4	66.02 (61.72, 70.62)
2007	57,792,868	158,228.2	12,117,380	3,144,696,857	8,609,710.8	83.49 (79.10, 88.11)
2008	110,268,912	301,899.8	28,042,039	6,036,976,982	16,528,342.2	68.57 (65.67, 71.58)
2009	97,018,337	265,621.7	29,364,952	8,206,103,886	22,467,088.0	66.03 (63.01, 69.20)
2010	331,317,558	907,098.0	44,470,792	10,658,912,885	29,182,513.0	175.84 (173.13, 178.59)
2011	291,817,484	798,952.7	44,798,860	13,380,544,800	36,633,935.1	177.31 (174.41, 180.25)
2012	243,587,263	666,905.6	45,069,592	13,517,614,975	37,009,212.8	172.44 (169.32, 175.62)
2013	260,282,241	712,613.9	50,536,813	14,534,538,124	39,793,396.6	165.97 (163.00, 168.98)
2014	248,474,831	680,287.0	57,335,614	16,226,057,111	44,424,523.2	162.46 (159.46, 165.52)
2015	240,235,234	657,728.2	64,615,396	18,282,999,378	50,056,124.2	173.92 (170.76, 177.13)
2016	234,318,974	641,530.4	80,749,769	21,646,122,661	59,263,854.0	157.69 (154.64, 160.79)
2017	207,163,940	567,184.0	84,139,769	24,207,173,232	66,275,628.3	150.07 (146.92, 153.30)
2018	170,335,328	466,352.7	82,608,661	24,242,265,827	66,371,706.6	155.31 (151.78, 158.93)
2019	140,548,470	384,800.7	84,287,367	24,464,683,159	66,980,652.0	166.42 (162.40, 170.55)
2020	96,681,754	264,700.2	85,887,786	25,521,792,215	69,874,858.9	183.08 (177.99, 188.30)
2021	64,984,281	177,917.3	53,910,494	16,356,067,961	44,780,473.5	201.95 (195.45, 208.66)
2022	26,527,010	72,627.0	54,309,352	16,301,535,253	44,631,171.1	237.51 (226.57, 248.99)
2023	490,119	1,341.9	21,180,650	1,442,006,755	3,947,999.3	141.59 (90.31, 221.99)
<b>Prevalent CD Cohort</b>						
2006	*****	*****	8,490,522	1,355,077,778	3,710,000.8	66.55 (60.23, 73.53)
2007	23,167,752	63,429.8	12,100,816	3,141,824,779	8,601,847.4	92.86 (85.65, 100.67)
2008	46,494,896	127,296.1	27,997,598	6,030,936,441	16,511,804.1	68.89 (64.48, 73.61)
2009	38,064,200	104,214.1	29,331,853	8,199,780,479	22,449,775.4	67.84 (63.02, 73.03)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2010	145,731,929	398,992.3	44,384,874	10,646,778,397	29,149,290.6	178.50 (174.40, 182.69)
2011	114,770,773	314,225.3	44,734,708	13,366,425,916	36,595,279.7	171.15 (166.64, 175.79)
2012	96,904,670	265,310.5	45,010,853	13,504,664,061	36,973,755.1	166.52 (161.68, 171.51)
2013	104,374,126	285,760.8	50,464,726	14,520,356,637	39,754,569.8	158.94 (154.39, 163.63)
2014	101,635,494	278,262.8	57,262,017	16,211,166,401	44,383,754.7	156.11 (151.54, 160.82)
2015	98,149,302	268,718.1	64,538,285	18,267,523,599	50,013,753.9	157.90 (153.22, 162.72)
2016	96,912,828	265,332.9	80,657,574	21,628,701,101	59,216,156.3	146.87 (142.33, 151.56)
2017	81,487,416	223,100.4	84,052,915	24,189,629,328	66,227,595.7	137.38 (132.60, 142.33)
2018	64,570,615	176,784.7	82,527,331	24,225,438,228	66,325,635.1	140.57 (135.15, 146.20)
2019	52,330,866	143,274.1	84,202,880	24,447,661,867	66,934,050.3	151.88 (145.63, 158.39)
2020	36,220,339	99,165.9	85,802,426	25,504,191,609	69,826,671.1	168.81 (160.91, 177.09)
2021	23,303,412	63,801.3	53,848,154	16,343,738,984	44,746,718.6	182.60 (172.41, 193.39)
2022	9,467,002	25,919.2	54,245,704	16,289,264,929	44,597,576.8	201.39 (184.84, 219.43)
2023	*****	*****	21,164,753	1,441,046,395	3,945,370.0	152.96 (76.49, 305.86)
<b>Prevalent UC Cohort</b>						
2006	22,361,990	61,223.8	8,490,645	1,355,430,484	3,710,966.4	64.68 (58.61, 71.38)
2007	31,922,723	87,399.7	12,103,242	3,142,641,335	8,604,083.1	76.09 (70.52, 82.10)
2008	57,172,756	156,530.5	28,000,924	6,032,442,030	16,515,926.2	67.91 (63.95, 72.12)
2009	54,618,615	149,537.6	29,337,268	8,201,569,485	22,454,673.5	66.00 (62.01, 70.25)
2010	164,981,031	451,693.4	44,391,046	10,649,831,253	29,157,648.9	173.30 (169.51, 177.19)
2011	165,837,879	454,039.4	44,747,470	13,370,949,526	36,607,664.7	182.39 (178.50, 186.36)
2012	138,525,383	379,261.8	45,022,622	13,508,856,725	36,985,234.0	178.48 (174.28, 182.78)
2013	145,428,605	398,161.8	50,478,006	14,524,782,859	39,766,688.2	172.04 (168.01, 176.16)
2014	137,848,629	377,409.0	57,272,355	16,215,556,535	44,395,774.2	168.91 (164.82, 173.11)
2015	133,531,390	365,589.0	64,545,766	18,271,518,210	50,024,690.5	188.30 (183.90, 192.80)
2016	126,875,980	347,367.5	80,663,180	21,632,711,871	59,227,137.2	168.50 (164.23, 172.87)
2017	109,013,191	298,461.9	84,060,640	24,193,657,274	66,238,623.6	158.91 (154.46, 163.50)
2018	91,526,552	250,586.0	82,536,392	24,229,385,690	66,336,442.7	166.49 (161.51, 171.62)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2019	76,404,661	209,184.6	84,211,155	24,451,510,967	66,944,588.5	177.83 (172.21, 183.64)
2020	52,728,298	144,362.2	85,810,320	25,507,939,833	69,836,933.1	195.06 (187.99, 202.40)
2021	36,806,615	100,771.0	53,859,326	16,347,405,646	44,756,757.4	214.45 (205.59, 223.68)
2022	15,135,973	41,440.0	54,257,276	16,292,948,451	44,607,661.7	265.69 (250.45, 281.85)
2023	261,819	716.8	21,167,984	1,441,272,065	3,945,987.9	153.46 (84.98, 277.10)
<b>Incident IBD Cohort</b>						
2006	21,152,496	57,912.4	8,476,338	1,353,777,497	3,706,440.8	62.68 (56.55, 69.47)
2007	37,764,904	103,394.7	12,088,341	3,139,982,646	8,596,804.0	77.86 (72.66, 83.43)
2008	62,814,053	171,975.5	27,961,859	6,026,897,603	16,500,746.3	74.49 (70.52, 78.68)
2009	70,726,290	193,638.0	29,307,447	8,195,719,148	22,438,656.1	71.11 (67.45, 74.97)
2010	171,494,499	469,526.3	44,314,471	10,638,611,110	29,126,929.8	171.19 (167.49, 174.98)
2011	216,396,721	592,461.9	44,688,842	13,357,735,246	36,571,486.0	184.05 (180.62, 187.53)
2012	188,772,208	516,830.1	44,969,015	13,496,728,554	36,952,028.9	181.01 (177.38, 184.71)
2013	185,815,838	508,736.0	50,412,640	14,511,527,347	39,730,396.6	179.43 (175.78, 183.14)
2014	180,929,742	495,358.6	57,205,268	16,201,610,600	44,357,592.3	178.94 (175.25, 182.71)
2015	175,790,438	481,288.0	64,475,613	18,257,029,162	49,985,021.7	194.37 (190.48, 198.35)
2016	161,756,756	442,865.9	80,579,236	21,616,375,245	59,182,410.0	182.67 (178.74, 186.70)
2017	150,634,774	412,415.5	83,982,290	24,177,305,084	66,193,853.8	167.84 (163.93, 171.84)
2018	125,884,441	344,652.8	82,463,727	24,213,925,837	66,294,115.9	172.38 (168.05, 176.82)
2019	101,933,628	279,079.1	84,136,360	24,436,040,521	66,902,232.8	183.14 (178.19, 188.23)
2020	67,428,193	184,608.3	85,735,214	25,492,094,159	69,793,550.1	207.95 (201.48, 214.64)
2021	46,637,391	127,686.2	53,803,872	16,336,268,319	44,726,265.1	228.69 (220.54, 237.13)
2022	18,513,830	50,688.1	54,200,796	16,281,919,119	44,577,465.1	279.16 (264.99, 294.09)
2023	311,505	852.9	21,153,847	1,440,420,522	3,943,656.5	164.15 (97.22, 277.17)
<b>Incident CD Cohort</b>						
2006	*****	*****	8,476,287	1,353,769,687	3,706,419.4	58.21 (49.11, 68.99)
2007	14,255,758	39,030.1	12,088,272	3,139,967,764	8,596,763.2	83.53 (74.93, 93.10)
2008	23,979,374	65,651.9	27,961,710	6,026,868,678	16,500,667.2	74.64 (68.31, 81.55)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2009	26,898,952	73,645.3	29,307,384	8,195,684,993	22,438,562.6	70.20 (64.40, 76.52)
2010	65,443,804	179,175.4	44,314,360	10,638,551,460	29,126,766.5	168.38 (162.48, 174.50)
2011	81,604,766	223,421.7	44,688,724	13,357,659,434	36,571,278.4	179.08 (173.61, 184.71)
2012	72,111,593	197,430.8	44,968,874	13,496,659,063	36,951,838.6	175.00 (169.26, 180.93)
2013	71,106,655	194,679.4	50,412,441	14,511,455,498	39,730,199.9	170.33 (164.63, 176.23)
2014	70,643,476	193,411.3	57,205,122	16,201,536,314	44,357,389.0	172.38 (166.63, 178.33)
2015	67,569,151	184,994.3	64,475,482	18,256,947,619	49,984,798.4	175.74 (169.80, 181.88)
2016	61,139,933	167,392.0	80,579,091	21,616,292,289	59,182,182.9	173.25 (167.05, 179.67)
2017	54,870,894	150,228.3	83,982,097	24,177,217,275	66,193,613.3	153.77 (147.62, 160.17)
2018	43,777,609	119,856.6	82,463,558	24,213,839,727	66,293,880.2	155.35 (148.45, 162.57)
2019	34,179,025	93,577.1	84,136,193	24,435,952,902	66,901,992.9	169.17 (161.03, 177.71)
2020	22,382,831	61,280.9	85,735,040	25,492,012,499	69,793,326.5	188.15 (177.60, 199.33)
2021	14,873,895	40,722.5	53,803,773	16,336,196,851	44,726,069.4	211.19 (197.53, 225.78)
2022	5,810,432	15,908.1	54,200,674	16,281,851,001	44,577,278.6	232.59 (210.05, 257.53)
2023	*****	*****	21,153,826	1,440,415,752	3,943,643.4	237.44 (113.19, 498.05)
<b>Incident UC Cohort</b>						
2006	*****	*****	8,476,294	1,353,772,016	3,706,425.8	65.24 (57.21, 74.39)
2007	23,057,279	63,127.4	12,088,319	3,139,972,935	8,596,777.4	74.29 (67.87, 81.33)
2008	37,848,036	103,622.3	27,961,754	6,026,878,229	16,500,693.3	74.21 (69.15, 79.65)
2009	42,598,893	116,629.4	29,307,415	8,195,696,571	22,438,594.3	72.28 (67.56, 77.33)
2010	104,065,794	284,916.6	44,314,375	10,638,572,353	29,126,823.7	173.66 (168.89, 178.57)
2011	132,388,036	362,458.7	44,688,768	13,357,687,849	36,571,356.2	187.52 (183.12, 192.04)
2012	114,754,766	314,181.4	44,968,912	13,496,684,858	36,951,909.3	185.18 (180.48, 190.00)
2013	112,771,914	308,752.7	50,412,526	14,511,481,803	39,730,271.9	185.36 (180.62, 190.22)
2014	108,405,229	296,797.3	57,205,137	16,201,561,314	44,357,457.4	183.59 (178.78, 188.53)
2015	106,443,942	291,427.6	64,475,478	18,256,976,773	49,984,878.2	206.53 (201.38, 211.82)
2016	97,077,869	265,784.7	80,579,115	21,616,319,633	59,182,257.7	189.21 (184.06, 194.52)
2017	84,961,331	232,611.4	83,982,140	24,177,243,562	66,193,685.3	175.74 (170.44, 181.21)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2018	72,477,976	198,433.9	82,463,589	24,213,868,771	66,293,959.7	182.18 (176.33, 188.21)
2019	59,885,128	163,956.5	84,136,235	24,435,984,827	66,902,080.3	191.70 (185.11, 198.52)
2020	40,175,742	109,995.2	85,735,064	25,492,042,499	69,793,408.6	219.83 (211.24, 228.77)
2021	28,682,828	78,529.3	53,803,799	16,336,229,238	44,726,158.1	239.02 (228.45, 250.08)
2022	11,534,754	31,580.4	54,200,728	16,281,882,113	44,577,363.8	308.74 (289.95, 328.74)
2023	*****	*****	21,153,833	1,440,417,471	3,943,648.1	138.97 (66.25, 291.51)
<b>Advanced Therapy Initiators with IBD</b>						
2006	*****	*****	40,271	5,272,093	14,434.2	149.74 (93.09, 240.87)
2007	1,236,488	3,385.3	74,126	16,641,615	45,562.3	73.85 (49.90, 109.29)
2008	2,316,161	6,341.3	166,128	33,459,011	91,605.8	61.50 (44.93, 84.18)
2009	3,635,246	9,952.8	210,391	52,604,337	144,022.8	61.29 (47.69, 78.77)
2010	5,122,903	14,025.7	367,560	77,702,599	212,738.1	106.23 (90.47, 124.74)
2011	6,507,190	17,815.7	456,856	119,616,599	327,492.4	125.73 (110.30, 143.32)
2012	6,736,532	18,443.6	521,462	142,824,391	391,031.9	112.23 (97.94, 128.61)
2013	7,139,072	19,545.7	609,159	166,271,554	455,226.7	107.95 (94.33, 123.55)
2014	8,711,522	23,850.8	686,355	189,568,410	519,010.0	114.04 (101.26, 128.43)
2015	8,875,265	24,299.2	762,630	212,312,250	581,279.3	108.23 (95.91, 122.14)
2016	9,763,859	26,732.0	853,718	237,530,649	650,323.5	102.87 (91.41, 115.78)
2017	10,565,265	28,926.1	906,423	256,985,338	703,587.5	88.85 (78.62, 100.40)
2018	9,978,860	27,320.6	934,026	268,451,857	734,981.1	91.51 (80.84, 103.58)
2019	8,608,967	23,570.1	976,702	279,214,902	764,448.7	93.34 (81.78, 106.52)
2020	5,856,472	16,034.1	991,493	289,628,253	792,958.9	104.15 (89.50, 121.21)
2021	4,051,427	11,092.2	812,094	237,809,462	651,086.8	109.99 (92.10, 131.34)
2022	1,776,523	4,863.9	815,257	240,118,832	657,409.5	121.30 (93.98, 156.56)
2023	*****	*****	231,199	14,870,457	40,713.1	84.34 (11.88, 598.76)



**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Advanced Therapy Initiators with CD</b>						
2006	*****	*****	17,293	2,222,027	6,083.6	136.44 (68.23, 272.82)
2007	*****	*****	30,426	6,590,760	18,044.5	84.31 (52.41, 135.62)
2008	1,308,832	3,583.4	67,061	12,916,095	35,362.3	61.39 (40.42, 93.24)
2009	1,981,619	5,425.4	82,225	19,713,418	53,972.4	55.30 (38.66, 79.09)
2010	2,693,686	7,374.9	145,361	29,327,126	80,293.3	104.41 (83.51, 130.54)
2011	3,376,028	9,243.1	175,869	44,683,320	122,336.3	96.29 (78.22, 118.52)
2012	3,417,209	9,355.8	195,968	52,138,062	142,746.2	101.54 (83.04, 124.16)
2013	3,476,309	9,517.6	226,188	59,960,985	164,164.2	93.51 (75.97, 115.10)
2014	4,201,658	11,503.5	255,952	68,302,999	187,003.4	109.53 (91.98, 130.43)
2015	4,297,282	11,765.3	284,730	76,787,802	210,233.5	111.34 (93.82, 132.14)
2016	4,773,861	13,070.1	320,335	86,243,865	236,122.8	87.99 (73.29, 105.63)
2017	5,313,979	14,548.9	336,388	92,879,577	254,290.4	85.23 (71.47, 101.63)
2018	4,858,761	13,302.6	338,067	95,120,034	260,424.5	77.43 (63.83, 93.92)
2019	3,980,159	10,897.1	349,275	97,526,394	267,012.7	83.51 (68.00, 102.56)
2020	2,720,386	7,448.0	349,295	100,043,631	273,904.5	99.36 (79.11, 124.78)
2021	1,777,816	4,867.4	266,332	76,938,214	210,645.3	106.83 (81.41, 140.20)
2022	771,791	2,113.0	263,216	76,149,968	208,487.2	94.65 (61.06, 146.71)
2023	*****	*****	78,375	4,994,446	13,674.0	187.66 (26.43, 1,332.29)
<b>Advanced Therapy Initiators with UC</b>						
2006	*****	*****	21,019	2,691,265	7,368.3	223.63 (83.93, 595.86)
2007	*****	*****	39,682	8,665,803	23,725.7	60.99 (19.67, 189.11)
2008	*****	*****	88,980	17,661,999	48,355.9	71.36 (35.68, 142.69)
2009	*****	*****	113,201	27,872,486	76,310.7	50.60 (26.33, 97.24)
2010	1,016,138	2,782.0	197,424	41,058,062	112,410.8	111.43 (78.36, 158.45)
2011	1,289,078	3,529.3	248,433	63,657,371	174,284.4	172.84 (134.48, 222.14)
2012	1,266,555	3,467.6	283,352	76,370,642	209,091.4	132.66 (99.36, 177.10)
2013	1,506,862	4,125.6	331,045	89,251,262	244,356.6	135.74 (104.46, 176.38)

**Table 5. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Year**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>1</sup>	Total Eligible Member-Days <sup>1</sup>	Total Eligible Member-Years <sup>1</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
2014	2,002,800	5,483.4	370,750	101,737,664	278,542.5	140.42 (112.32, 175.57)
2015	2,200,069	6,023.5	410,895	113,610,169	311,047.7	107.91 (84.62, 137.61)
2016	2,600,555	7,119.9	457,359	127,242,358	348,370.6	130.62 (106.60, 160.06)
2017	2,647,520	7,248.5	480,486	136,465,813	373,623.0	80.02 (61.86, 103.50)
2018	2,396,457	6,561.1	494,419	141,772,396	388,151.7	97.54 (76.35, 124.62)
2019	2,264,726	6,200.5	514,815	146,897,840	402,184.4	112.89 (89.32, 142.70)
2020	1,582,401	4,332.4	522,974	152,236,224	416,800.1	99.25 (73.61, 133.83)
2021	1,180,619	3,232.4	444,591	128,880,579	352,855.8	114.47 (82.94, 157.99)
2022	531,762	1,455.9	448,654	131,205,539	359,221.2	123.64 (77.90, 196.24)
2023	12,973	35.5	123,481	7,960,988	21,796.0	0.00 (0.00, 0.00)

<sup>1</sup>Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	7,569	7,569	83,271	83,271	476	1,820
Asian	28,421	28,421	212,109	212,109	1,588	7,454
Black or African American	141,072	141,072	1,862,889	1,862,889	7,902	30,391
Multi-racial	5,882	5,882	64,178	64,178	53	138
Native Hawaiian or Other Pacific Islander	2,090	2,090	23,613	23,613	83	300
Unknown	1,029,879	1,029,879	11,030,100	11,030,100	19,103	64,112
White	1,224,628	1,224,628	16,213,799	16,213,799	93,431	380,775
<b>Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	3,141	3,141	43,329	43,329	194	717
Asian	9,677	9,677	80,102	80,102	598	2,644
Black or African American	59,730	59,730	1,066,861	1,066,861	2,992	11,657
Multi-racial	2,464	2,464	32,476	32,476	24	67
Native Hawaiian or Other Pacific Islander	804	804	11,054	11,054	31	127
Unknown	428,333	428,333	5,388,128	5,388,128	7,562	24,204
White	472,566	472,566	8,262,142	8,262,142	35,338	142,959
<b>Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	3,995	3,995	28,241	28,241	259	1,029
Asian	17,221	17,221	104,191	104,191	931	4,624
Black or African American	73,486	73,486	527,525	527,525	4,537	17,146
Multi-racial	3,039	3,039	23,452	23,452	27	60
Native Hawaiian or Other Pacific Islander	1,148	1,148	9,746	9,746	48	167
Unknown	538,513	538,513	4,076,145	4,076,145	10,529	36,638
White	683,368	683,368	5,843,460	5,843,460	53,654	219,771

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	5,804	5,804	37,168	37,168	363	1,432
Asian	23,478	23,478	105,035	105,035	1,405	6,638
Black or African American	104,261	104,261	660,030	660,030	6,430	24,763
Multi-racial	3,873	3,873	28,341	28,341	36	91
Native Hawaiian or Other Pacific Islander	1,522	1,522	7,960	7,960	68	224
Unknown	682,147	682,147	4,649,693	4,649,693	14,187	48,131
White	897,297	897,297	6,539,973	6,539,973	70,689	280,379
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	2,263	2,263	16,154	16,154	127	508
Asian	8,050	8,050	33,055	33,055	534	2,318
Black or African American	39,337	39,337	285,808	285,808	2,251	9,047
Multi-racial	1,514	1,514	11,985	11,985	14	31
Native Hawaiian or Other Pacific Islander	573	573	2,955	2,955	24	105
Unknown	264,873	264,873	1,904,981	1,904,981	5,211	17,193
White	313,847	313,847	2,552,383	2,552,383	24,502	97,036
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	3,329	3,329	17,535	17,535	226	870
Asian	14,476	14,476	60,799	60,799	830	4,213
Black or African American	61,397	61,397	306,715	306,715	4,010	14,993
Multi-racial	2,180	2,180	13,242	13,242	20	49
Native Hawaiian or Other Pacific Islander	878	878	4,323	4,323	42	115
Unknown	393,564	393,564	2,205,233	2,205,233	8,547	29,606
White	548,300	548,300	3,285,238	3,285,238	44,234	176,603

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	738	738	23,593	23,593	31	64
Asian	1,864	1,864	57,032	57,032	48	160
Black or African American	15,508	15,508	671,428	671,428	487	2,120
Multi-racial	1,232	1,232	31,959	31,959	*****	25
Native Hawaiian or Other Pacific Islander	167	167	4,845	4,845	*****	11
Unknown	168,633	168,633	4,364,642	4,364,642	2,003	6,629
White	108,666	108,666	4,533,359	4,533,359	6,093	28,142
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	360	360	13,968	13,968	*****	33
Asian	861	861	30,877	30,877	20	70
Black or African American	9,920	9,920	452,909	452,909	280	1,338
Multi-racial	693	693	18,913	18,913	*****	23
Native Hawaiian or Other Pacific Islander	84	84	2,833	2,833	*****	11
Unknown	94,440	94,440	2,501,786	2,501,786	1,068	3,206
White	61,100	61,100	2,775,585	2,775,585	3,186	14,710
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	229	229	4,376	4,376	*****	*****
Asian	657	657	12,832	12,832	*****	37
Black or African American	2,737	2,737	63,017	63,017	100	420
Multi-racial	341	341	6,399	6,399	*****	*****
Native Hawaiian or Other Pacific Islander	55	55	862	862	0	0
Unknown	41,617	41,617	796,149	796,149	525	2,099
White	27,250	27,250	689,243	689,243	1,749	8,436

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	109	109	1,076	1,076	*****	18
Asian	216	216	1,559	1,559	*****	35
Black or African American	1,239	1,239	13,694	13,694	88	644
Multi-racial	106	106	1,119	1,119	0	0
Native Hawaiian or Other Pacific Islander	19	19	140	140	0	0
Unknown	12,217	12,217	121,008	121,008	272	1,212
White	12,366	12,366	126,406	126,406	1,123	5,756
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	*****	*****	709	709	*****	*****
Asian	98	98	828	828	*****	*****
Black or African American	687	687	9,426	9,426	*****	*****
Multi-racial	59	59	743	743	0	0
Native Hawaiian or Other Pacific Islander	*****	*****	22	22	0	0
Unknown	7,193	7,193	80,018	80,018	120	594
White	5,921	5,921	74,503	74,503	470	2,573
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	58	58	312	312	*****	11
Asian	110	110	582	582	*****	27
Black or African American	523	523	3,401	3,401	44	241
Multi-racial	44	44	316	316	0	0
Native Hawaiian or Other Pacific Islander	13	13	118	118	0	0
Unknown	4,703	4,703	31,334	31,334	147	608
White	6,067	6,067	40,878	40,878	631	3,004

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent IBD Cohort</b>						
American Indian or Alaska Native	7,599	7,599	88,801	88,801	480	1,877
Asian	28,593	28,593	229,635	229,635	1,593	7,475
Black or African American	141,938	141,938	1,995,695	1,995,695	7,977	30,793
Multi-racial	6,027	6,027	74,082	74,082	56	142
Native Hawaiian or Other Pacific Islander	2,109	2,109	25,249	25,249	84	302
Unknown	1,041,098	1,041,098	12,064,102	12,064,102	19,430	65,379
White	1,233,623	1,233,623	17,720,544	17,720,544	94,765	388,690
<b>Prevalent CD Cohort</b>						
American Indian or Alaska Native	3,150	3,150	46,873	46,873	195	719
Asian	9,727	9,727	86,454	86,454	600	2,657
Black or African American	60,207	60,207	1,151,498	1,151,498	3,026	11,842
Multi-racial	2,515	2,515	36,979	36,979	24	67
Native Hawaiian or Other Pacific Islander	813	813	11,882	11,882	31	127
Unknown	433,094	433,094	5,848,990	5,848,990	7,695	24,645
White	477,123	477,123	9,096,701	9,096,701	36,027	146,816
<b>Prevalent UC Cohort</b>						
American Indian or Alaska Native	4,011	4,011	29,581	29,581	261	1,079
Asian	17,308	17,308	112,298	112,298	933	4,626
Black or African American	73,753	73,753	549,670	549,670	4,566	17,310
Multi-racial	3,121	3,121	27,068	27,068	30	64
Native Hawaiian or Other Pacific Islander	1,157	1,157	10,484	10,484	49	169
Unknown	543,422	543,422	4,451,361	4,451,361	10,680	37,310
White	686,733	686,733	6,252,386	6,252,386	54,156	222,783

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Incident IBD Cohort</b>						
American Indian or Alaska Native	5,809	5,809	38,581	38,581	363	1,481
Asian	23,487	23,487	108,689	108,689	1,407	6,645
Black or African American	104,356	104,356	676,797	676,797	6,448	24,875
Multi-racial	3,879	3,879	31,060	31,060	36	91
Native Hawaiian or Other Pacific Islander	1,524	1,524	8,078	8,078	68	224
Unknown	682,692	682,692	4,919,303	4,919,303	14,295	48,666
White	898,030	898,030	6,902,635	6,902,635	71,105	282,743
<b>Incident CD Cohort</b>						
American Indian or Alaska Native	2,266	2,266	16,856	16,856	127	509
Asian	8,054	8,054	33,822	33,822	534	2,318
Black or African American	39,373	39,373	293,228	293,228	2,256	9,066
Multi-racial	1,515	1,515	12,952	12,952	14	31
Native Hawaiian or Other Pacific Islander	574	574	2,968	2,968	24	105
Unknown	265,077	265,077	1,992,159	1,992,159	5,246	17,295
White	314,128	314,128	2,697,782	2,697,782	24,684	97,838
<b>Incident UC Cohort</b>						
American Indian or Alaska Native	3,331	3,331	18,021	18,021	226	918
Asian	14,481	14,481	63,087	63,087	831	4,214
Black or African American	61,450	61,450	313,045	313,045	4,022	15,083
Multi-racial	2,185	2,185	14,604	14,604	20	49
Native Hawaiian or Other Pacific Islander	879	879	4,425	4,425	42	115
Unknown	393,890	393,890	2,340,483	2,340,483	8,614	30,018
White	548,725	548,725	3,438,904	3,438,904	44,455	178,091



**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Advanced Therapy Initiators with IBD</b>						
American Indian or Alaska Native	387	387	3,991	3,992	*****	13
Asian	866	866	10,274	10,275	*****	19
Black or African American	7,635	7,635	87,830	87,876	173	479
Multi-racial	526	526	9,659	9,664	*****	*****
Native Hawaiian or Other Pacific Islander	78	78	1,000	1,000	*****	*****
Unknown	74,222	74,222	1,124,822	1,127,246	711	1,882
White	50,347	50,347	686,809	687,067	1,909	7,091
<b>Advanced Therapy Initiators with CD</b>						
American Indian or Alaska Native	166	166	1,689	1,689	*****	*****
Asian	336	336	4,358	4,358	*****	*****
Black or African American	4,283	4,283	48,546	48,568	81	278
Multi-racial	256	256	5,107	5,108	*****	*****
Native Hawaiian or Other Pacific Islander	38	38	420	420	*****	*****
Unknown	34,921	34,921	542,148	543,274	307	591
White	24,551	24,551	343,588	343,714	861	3,050
<b>Advanced Therapy Initiators with UC</b>						
American Indian or Alaska Native	132	132	1,402	1,402	*****	*****
Asian	311	311	3,382	3,383	*****	*****
Black or African American	1,320	1,320	14,330	14,339	*****	95
Multi-racial	155	155	2,462	2,466	*****	*****
Native Hawaiian or Other Pacific Islander	29	29	414	414	0	0
Unknown	19,712	19,712	276,305	277,039	188	647
White	12,334	12,334	154,836	154,895	514	2,042

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	8,137,440	22,279.1	1,082,264	1,245,214,815	3,409,212.4	213.65 (195.30, 233.74)
Asian	31,492,766	86,222.5	4,702,327	5,050,379,178	13,827,184.6	184.17 (175.34, 193.46)
Black or African American	145,725,278	398,974.1	16,617,044	17,970,999,813	49,201,916.0	198.06 (193.74, 202.47)
Multi-racial	6,261,381	17,142.7	817,589	849,987,027	2,327,137.7	30.92 (23.62, 40.47)
Native Hawaiian or Other Pacific Islander	2,092,200	5,728.1	437,051	445,175,596	1,218,824.4	144.90 (116.85, 179.68)
Unknown	984,060,307	2,694,210.3	134,833,404	131,433,765,266	359,846,037.7	70.90 (69.91, 71.92)
White	1,637,733,489	4,483,869.9	70,670,862	102,458,541,928	280,516,199.7	208.37 (207.04, 209.71)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	3,550,982	9,722.1	1,080,960	1,244,544,753	3,407,377.8	199.55 (173.35, 229.70)
Asian	11,503,623	31,495.2	4,697,271	5,047,580,610	13,819,522.5	189.87 (175.25, 205.71)
Black or African American	63,473,451	173,780.8	16,592,542	17,958,529,304	49,167,773.6	172.17 (166.11, 178.45)
Multi-racial	2,634,489	7,212.8	816,214	849,576,468	2,326,013.6	33.27 (22.30, 49.64)
Native Hawaiian or Other Pacific Islander	782,139	2,141.4	436,587	444,986,970	1,218,307.9	144.77 (101.81, 205.85)
Unknown	403,918,648	1,105,869.0	134,590,761	131,349,193,654	359,614,493.2	68.38 (66.86, 69.94)
White	643,823,560	1,762,692.8	70,446,899	102,347,320,982	280,211,693.3	200.48 (198.40, 202.58)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	4,152,337	11,368.5	1,080,849	1,244,689,664	3,407,774.6	227.82 (201.70, 257.33)
Asian	18,621,008	50,981.5	4,698,787	5,048,075,989	13,820,878.8	182.62 (171.25, 194.73)
Black or African American	74,624,865	204,311.7	16,586,346	17,961,381,983	49,175,583.8	222.06 (215.69, 228.62)
Multi-racial	3,289,016	9,004.8	816,169	849,598,767	2,326,074.7	29.98 (20.56, 43.72)
Native Hawaiian or Other Pacific Islander	1,203,698	3,295.5	436,653	445,035,654	1,218,441.2	145.65 (109.76, 193.28)
Unknown	525,328,165	1,438,270.1	134,583,420	131,366,594,584	359,662,134.4	73.21 (71.82, 74.62)
White	911,677,383	2,496,036.6	70,441,607	102,382,521,119	280,308,066.0	214.96 (213.15, 216.78)

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	5,956,212	16,307.2	1,079,730	1,244,066,937	3,406,069.6	222.60 (200.84, 246.72)
Asian	25,927,498	70,985.6	4,694,274	5,045,489,066	13,813,796.2	197.93 (187.84, 208.55)
Black or African American	104,991,959	287,452.3	16,565,653	17,949,867,043	49,144,057.6	223.69 (218.29, 229.22)
Multi-racial	4,379,750	11,991.1	814,977	849,222,215	2,325,043.7	30.02 (21.66, 41.62)
Native Hawaiian or Other Pacific Islander	1,522,018	4,167.1	436,249	444,855,714	1,217,948.6	163.18 (128.66, 206.97)
Unknown	668,338,647	1,829,811.5	134,375,070	131,289,292,739	359,450,493.5	77.53 (76.27, 78.82)
White	1,158,319,828	3,171,306.9	70,244,744	102,279,027,564	280,024,716.1	222.90 (221.26, 224.55)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	2,485,787	6,805.7	1,079,724	1,244,063,396	3,406,059.9	186.61 (156.82, 222.06)
Asian	9,660,066	26,447.8	4,694,257	5,045,473,636	13,813,754.0	201.91 (185.49, 219.78)
Black or African American	41,372,441	113,271.6	16,565,593	17,949,802,110	49,143,879.8	198.73 (190.68, 207.11)
Multi-racial	1,737,824	4,757.9	814,975	849,219,856	2,325,037.3	29.42 (17.43, 49.68)
Native Hawaiian or Other Pacific Islander	572,003	1,566.1	436,247	444,854,765	1,217,946.0	153.25 (102.72, 228.64)
Unknown	259,042,994	709,221.1	134,374,363	131,288,875,417	359,449,350.9	73.47 (71.51, 75.50)
White	418,440,157	1,145,626.7	70,244,248	102,278,444,050	280,023,118.5	213.87 (211.21, 216.57)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
American Indian or Alaska Native	3,322,078	9,095.4	1,079,729	1,244,064,462	3,406,062.9	248.48 (218.11, 283.08)
Asian	15,518,021	42,486.0	4,694,269	5,045,480,064	13,813,771.6	195.36 (182.51, 209.11)
Black or African American	60,911,521	166,766.7	16,565,589	17,949,824,173	49,143,940.2	240.46 (233.13, 248.01)
Multi-racial	2,494,061	6,828.4	814,974	849,220,522	2,325,039.1	29.29 (18.90, 45.40)
Native Hawaiian or Other Pacific Islander	906,154	2,480.9	436,248	444,855,070	1,217,946.8	169.29 (125.11, 229.08)
Unknown	390,268,965	1,068,498.2	134,374,544	131,289,004,119	359,449,703.3	79.99 (78.31, 81.70)
White	707,411,923	1,936,788.3	70,244,316	102,278,678,542	280,023,760.6	228.39 (226.27, 230.53)

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	751,784	2,058.3	6,707	7,242,215	19,828.1	150.61 (105.92, 214.16)
Asian	1,605,263	4,395.0	13,661	13,353,421	36,559.7	109.22 (82.30, 144.93)
Black or African American	14,653,939	40,120.3	66,857	59,314,920	162,395.4	121.38 (111.07, 132.66)
Multi-racial	*****	*****	4,598	3,066,222	8,394.9	26.46 (13.23, 52.91)
Native Hawaiian or Other Pacific Islander	*****	*****	1,219	970,919	2,658.2	80.83 (26.07, 250.62)
Unknown	135,533,607	371,070.8	607,870	418,406,926	1,145,535.7	53.98 (51.67, 56.40)
White	126,238,361	345,621.8	474,168	510,340,400	1,397,235.9	176.29 (171.92, 180.77)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	*****	*****	6,352	7,203,115	19,721.1	196.92 (128.39, 302.02)
Asian	792,848	2,170.7	12,685	13,267,144	36,323.5	92.14 (59.44, 142.81)
Black or African American	9,599,007	26,280.6	61,412	58,831,261	161,071.2	106.54 (94.77, 119.78)
Multi-racial	*****	*****	4,064	3,020,191	8,268.8	35.70 (16.04, 79.46)
Native Hawaiian or Other Pacific Islander	*****	*****	1,140	964,480	2,640.6	159.53 (51.45, 494.66)
Unknown	76,628,558	209,797.6	533,586	413,131,672	1,131,092.9	50.91 (47.94, 54.05)
White	72,939,103	199,696.4	429,311	505,629,688	1,384,338.6	159.54 (154.10, 165.18)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	*****	*****	6,224	7,210,844	19,742.2	114.18 (54.43, 239.50)
Asian	*****	*****	12,478	13,265,184	36,318.1	104.09 (62.75, 172.67)
Black or African American	2,374,322	6,500.5	53,940	58,456,843	160,046.1	153.83 (126.45, 187.14)
Multi-racial	*****	*****	3,718	3,005,969	8,229.9	24.26 (6.07, 97.01)
Native Hawaiian or Other Pacific Islander	48,126	131.8	1,101	962,022	2,633.9	0.00 (0.00, 0.00)
Unknown	31,354,616	85,844.3	480,474	410,663,067	1,124,334.2	61.16 (56.14, 66.62)
White	29,433,219	80,583.8	394,722	504,736,240	1,381,892.5	217.04 (207.10, 227.46)

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	*****	*****	6,011	7,178,092	19,652.5	180.00 (80.86, 400.66)
Asian	*****	*****	11,855	13,194,943	36,125.8	212.38 (120.61, 373.97)
Black or African American	1,228,742	3,364.1	51,402	58,111,094	159,099.5	261.58 (212.26, 322.37)
Multi-racial	101,586	278.1	3,387	2,975,008	8,145.1	0.00 (0.00, 0.00)
Native Hawaiian or Other Pacific Islander	16,382	44.9	1,051	957,465	2,621.4	0.00 (0.00, 0.00)
Unknown	9,655,846	26,436.3	438,833	406,884,392	1,113,988.8	102.89 (91.36, 115.87)
White	14,018,503	38,380.6	370,103	500,979,754	1,371,607.8	292.60 (275.97, 310.22)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	*****	*****	6,011	7,178,030	19,652.4	209.84 (67.68, 650.63)
Asian	*****	*****	11,847	13,194,825	36,125.5	111.42 (35.94, 345.48)
Black or African American	*****	*****	51,392	58,110,542	159,098.0	217.37 (160.64, 294.13)
Multi-racial	52,824	144.6	3,385	2,974,961	8,145.0	0.00 (0.00, 0.00)
Native Hawaiian or Other Pacific Islander	4,947	13.5	1,051	957,452	2,621.4	0.00 (0.00, 0.00)
Unknown	5,622,646	15,394.0	438,520	406,879,368	1,113,975.0	77.95 (65.18, 93.23)
White	6,980,767	19,112.3	369,795	500,973,309	1,371,590.2	245.91 (224.66, 269.18)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
American Indian or Alaska Native	*****	*****	6,010	7,178,041	19,652.4	171.79 (55.40, 532.65)
Asian	*****	*****	11,847	13,194,837	36,125.5	283.82 (141.94, 567.54)
Black or African American	496,748	1,360.0	51,338	58,110,378	159,097.5	323.52 (240.76, 434.74)
Multi-racial	47,945	131.3	3,379	2,974,946	8,145.0	0.00 (0.00, 0.00)
Native Hawaiian or Other Pacific Islander	11,435	31.3	1,051	957,459	2,621.4	0.00 (0.00, 0.00)
Unknown	3,796,824	10,395.1	438,236	406,876,878	1,113,968.2	141.41 (120.30, 166.22)
White	6,690,613	18,317.9	369,720	500,973,455	1,371,590.6	344.47 (318.62, 372.43)

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort</b>						
American Indian or Alaska Native	8,249,005	22,584.5	1,082,353	1,245,457,692	3,409,877.3	212.53 (194.35, 232.42)
Asian	31,833,457	87,155.3	4,702,590	5,050,675,028	13,827,994.6	182.78 (174.02, 191.98)
Black or African American	147,827,468	404,729.5	16,620,654	17,979,121,616	49,224,152.3	197.09 (192.82, 201.47)
Multi-racial	6,478,133	17,736.2	817,829	850,193,910	2,327,704.1	31.57 (24.30, 41.03)
Native Hawaiian or Other Pacific Islander	2,126,498	5,822.0	437,081	445,228,190	1,218,968.4	144.28 (116.50, 178.68)
Unknown	1,005,512,803	2,752,944.0	134,853,122	131,459,202,375	359,915,680.7	70.58 (69.59, 71.58)
White	1,666,730,385	4,563,259.1	70,690,886	102,497,112,779	280,621,800.9	207.67 (206.35, 209.00)
<b>Prevalent CD Cohort</b>						
American Indian or Alaska Native	3,616,783	9,902.2	1,081,035	1,244,787,139	3,408,041.4	196.93 (171.14, 226.60)
Asian	11,607,519	31,779.7	4,697,422	5,047,872,639	13,820,322.1	188.80 (174.28, 204.53)
Black or African American	64,697,978	177,133.4	16,595,840	17,966,630,388	49,189,953.1	170.83 (164.85, 177.03)
Multi-racial	2,709,503	7,418.2	816,362	849,778,488	2,326,566.7	32.35 (21.68, 48.27)
Native Hawaiian or Other Pacific Islander	796,898	2,181.8	436,609	445,039,075	1,218,450.6	142.09 (99.92, 202.04)
Unknown	412,815,115	1,130,226.2	134,605,073	131,374,404,267	359,683,516.1	68.08 (66.58, 69.62)
White	658,717,441	1,803,470.1	70,463,076	102,385,694,933	280,316,755.5	199.76 (197.71, 201.84)
<b>Prevalent UC Cohort</b>						
American Indian or Alaska Native	4,189,908	11,471.3	1,080,929	1,244,932,413	3,408,439.2	227.52 (201.53, 256.87)
Asian	18,819,996	51,526.3	4,698,971	5,048,369,514	13,821,682.4	181.07 (169.82, 193.07)
Black or African American	75,222,841	205,948.9	16,589,414	17,969,480,359	49,197,755.9	221.71 (215.37, 228.23)
Multi-racial	3,403,888	9,319.3	816,350	849,804,098	2,326,636.8	32.19 (22.51, 46.04)
Native Hawaiian or Other Pacific Islander	1,222,017	3,345.7	436,676	445,087,760	1,218,583.9	146.46 (110.69, 193.78)
Unknown	535,378,582	1,465,786.7	134,597,611	131,391,829,072	359,731,222.6	72.86 (71.49, 74.26)
White	922,744,858	2,526,337.7	70,456,465	102,420,907,023	280,413,160.9	214.37 (212.57, 216.18)

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Incident IBD Cohort</b>						
American Indian or Alaska Native	5,989,716	16,398.9	1,079,799	1,244,309,275	3,406,733.1	221.36 (199.72, 245.34)
Asian	26,014,127	71,222.8	4,694,379	5,045,779,596	13,814,591.6	197.55 (187.49, 208.15)
Black or African American	105,440,885	288,681.4	16,568,510	17,957,947,342	49,166,180.3	223.36 (217.97, 228.88)
Multi-racial	4,451,406	12,187.3	815,077	849,423,078	2,325,593.6	29.54 (21.31, 40.95)
Native Hawaiian or Other Pacific Islander	1,527,665	4,182.5	436,265	444,907,392	1,218,090.1	162.58 (128.19, 206.20)
Unknown	674,823,196	1,847,565.2	134,385,168	131,314,352,762	359,519,104.1	77.37 (76.11, 78.65)
White	1,166,510,712	3,193,732.3	70,256,704	102,317,248,274	280,129,358.7	222.64 (221.01, 224.28)
<b>Incident CD Cohort</b>						
American Indian or Alaska Native	2,503,580	6,854.4	1,079,793	1,244,305,732	3,406,723.4	185.28 (155.70, 220.48)
Asian	9,685,585	26,517.7	4,694,362	5,045,764,161	13,814,549.4	201.38 (185.00, 219.20)
Black or African American	41,567,713	113,806.2	16,568,450	17,957,882,350	49,166,002.3	198.23 (190.22, 206.58)
Multi-racial	1,755,617	4,806.6	815,075	849,420,714	2,325,587.2	29.13 (17.25, 49.18)
Native Hawaiian or Other Pacific Islander	572,509	1,567.4	436,263	444,906,442	1,218,087.5	153.12 (102.63, 228.44)
Unknown	261,259,486	715,289.5	134,384,460	131,313,935,099	359,517,960.6	73.34 (71.38, 75.35)
White	421,757,397	1,154,708.8	70,256,207	102,316,664,308	280,127,759.9	213.77 (211.12, 216.45)
<b>Incident UC Cohort</b>						
American Indian or Alaska Native	3,337,729	9,138.2	1,079,798	1,244,306,797	3,406,726.3	247.31 (217.08, 281.75)
Asian	15,573,929	42,639.1	4,694,374	5,045,770,590	13,814,567.0	194.89 (182.08, 208.60)
Black or African American	61,149,176	167,417.3	16,568,446	17,957,904,430	49,166,062.8	240.24 (232.93, 247.78)
Multi-racial	2,542,612	6,961.3	815,074	849,421,384	2,325,589.0	28.73 (18.54, 44.53)
Native Hawaiian or Other Pacific Islander	911,295	2,495.0	436,264	444,906,747	1,218,088.3	168.34 (124.40, 227.79)
Unknown	394,277,259	1,079,472.3	134,384,642	131,314,063,923	359,518,313.3	79.80 (78.13, 81.50)
White	712,006,408	1,949,367.3	70,256,276	102,316,898,944	280,128,402.3	228.05 (225.94, 230.18)

**Table 6. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Race<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Advanced Therapy Initiators with IBD</b>						
American Indian or Alaska Native	*****	*****	8,260	8,546,333	23,398.6	110.75 (55.38, 221.45)
Asian	*****	*****	30,880	34,722,543	95,065.1	67.89 (36.53, 126.18)
Black or African American	5,339,447	14,618.6	151,770	154,176,571	422,112.4	118.34 (101.96, 137.36)
Multi-racial	*****	*****	5,937	5,929,795	16,234.9	49.32 (22.16, 109.78)
Native Hawaiian or Other Pacific Islander	*****	*****	2,314	2,254,646	6,172.9	147.20 (36.81, 588.57)
Unknown	52,116,434	142,687.0	1,091,898	1,030,378,310	2,821,022.1	49.83 (46.30, 53.63)
White	42,588,031	116,599.7	1,271,250	1,604,874,411	4,393,906.7	163.72 (156.54, 171.23)
<b>Advanced Therapy Initiators with CD</b>						
American Indian or Alaska Native	*****	*****	3,419	3,403,037	9,317.0	152.75 (63.58, 366.99)
Asian	*****	*****	10,697	12,233,315	33,493.0	68.71 (25.79, 183.07)
Black or African American	3,011,273	8,244.4	62,902	59,052,426	161,676.7	98.25 (79.02, 122.15)
Multi-racial	*****	*****	2,387	2,154,086	5,897.6	62.33 (23.39, 166.07)
Native Hawaiian or Other Pacific Islander	*****	*****	898	781,154	2,138.7	318.93 (79.76, 1,275.24)
Unknown	25,167,709	68,905.4	440,367	369,168,514	1,010,728.3	44.55 (39.84, 49.83)
White	21,150,976	57,908.2	485,951	555,746,191	1,521,550.1	148.68 (139.08, 158.95)
<b>Advanced Therapy Initiators with UC</b>						
American Indian or Alaska Native	*****	*****	4,438	4,219,949	11,553.6	84.84 (21.22, 339.24)
Asian	*****	*****	18,686	19,654,701	53,811.6	59.82 (19.29, 185.49)
Black or African American	*****	*****	81,416	78,670,423	215,387.9	144.43 (103.20, 202.13)
Multi-racial	*****	*****	3,232	3,078,326	8,428.0	68.21 (17.06, 272.76)
Native Hawaiian or Other Pacific Islander	18,158	49.7	1,283	1,240,393	3,396.0	0.00 (0.00, 0.00)
Unknown	12,838,849	35,150.9	596,088	543,793,332	1,488,825.0	53.48 (46.36, 61.70)
White	9,709,484	26,583.1	722,568	864,581,336	2,367,094.7	193.36 (177.34, 210.82)

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>2</sup>Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.



**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	60,629	60,629	550,351	550,351	2,427	9,237
No	1,324,958	1,324,958	17,630,743	17,630,743	101,558	414,988
Unknown	1,053,954	1,053,954	11,308,865	11,308,865	18,651	60,765
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	20,910	20,910	225,474	225,474	804	2,943
No	514,264	514,264	9,086,427	9,086,427	38,425	156,116
Unknown	441,541	441,541	5,572,191	5,572,191	7,510	23,316
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	35,534	35,534	240,349	240,349	1,511	5,891
No	736,978	736,978	6,223,419	6,223,419	58,343	239,323
Unknown	548,258	548,258	4,148,992	4,148,992	10,131	34,221
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	46,681	46,681	244,494	244,494	2,102	8,014
No	982,986	982,986	7,059,103	7,059,103	77,657	309,577
Unknown	688,715	688,715	4,724,603	4,724,603	13,419	44,067
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	15,434	15,434	84,139	84,139	687	2,541
No	346,196	346,196	2,776,612	2,776,612	26,987	107,821
Unknown	268,827	268,827	1,946,570	1,946,570	4,989	15,876
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	28,994	28,994	134,824	134,824	1,355	5,285
No	599,106	599,106	3,528,213	3,528,213	48,542	194,307
Unknown	396,024	396,024	2,230,048	2,230,048	8,012	26,857

**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	6,650	6,650	179,290	179,290	121	562
No	115,236	115,236	5,027,294	5,027,294	6,515	30,097
Unknown	174,922	174,922	4,480,274	4,480,274	2,037	6,492
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	3,142	3,142	88,429	88,429	47	180
No	65,444	65,444	3,119,187	3,119,187	3,444	15,962
Unknown	98,872	98,872	2,589,255	2,589,255	1,093	3,249
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	2,124	2,124	41,413	41,413	52	287
No	27,936	27,936	719,576	719,576	1,820	8,801
Unknown	42,826	42,826	811,889	811,889	526	1,933
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	693	693	5,414	5,414	32	200
No	12,953	12,953	133,786	133,786	1,209	6,393
Unknown	12,626	12,626	125,802	125,802	260	1,072
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	343	343	2,906	2,906	12	28
No	6,171	6,171	79,612	79,612	510	2,947
Unknown	7,497	7,497	83,731	83,731	116	603
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	324	324	2,001	2,001	20	172
No	6,383	6,383	42,763	42,763	674	3,260
Unknown	4,811	4,811	32,177	32,177	139	459

**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same-Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Prevalent IBD Cohort</b>						
Yes	61,063	61,063	595,873	595,873	2,441	9,304
No	1,333,565	1,333,565	19,201,752	19,201,752	102,922	423,229
Unknown	1,066,359	1,066,359	12,400,483	12,400,483	19,022	62,125
<b>Prevalent CD Cohort</b>						
Yes	21,073	21,073	245,621	245,621	808	2,956
No	518,696	518,696	9,969,984	9,969,984	39,128	160,091
Unknown	446,860	446,860	6,063,772	6,063,772	7,662	23,826
<b>Prevalent UC Cohort</b>						
Yes	35,740	35,740	256,465	256,465	1,517	5,900
No	740,105	740,105	6,633,644	6,633,644	58,855	242,498
Unknown	553,660	553,660	4,542,739	4,542,739	10,303	34,943
<b>Incident IBD Cohort</b>						
Yes	46,719	46,719	252,539	252,539	2,106	8,021
No	983,783	983,783	7,423,944	7,423,944	78,083	312,081
Unknown	689,275	689,275	5,008,660	5,008,660	13,533	44,623
<b>Incident CD Cohort</b>						
Yes	15,449	15,449	87,013	87,013	688	2,543
No	346,507	346,507	2,925,143	2,925,143	27,172	108,641
Unknown	269,031	269,031	2,037,611	2,037,611	5,025	15,978
<b>Incident UC Cohort</b>						
Yes	29,014	29,014	139,040	139,040	1,358	5,290
No	599,561	599,561	3,680,315	3,680,315	48,769	195,909
Unknown	396,366	396,366	2,373,214	2,373,214	8,083	27,289

**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Number of Patients	Number of Assessment Episodes	Number of Assessment Episode Defining-Codes (Adjusted for Same-Day Codes)	Number of Assessment Episode Defining-Codes (Not Adjusted for Same- Day Codes)	Number of Assessment Episodes with an Interstitial Lung Disease (ILD) Event	Total Number of ILD Events
<b>Advanced Therapy Initiators with IBD</b>						
Yes	3,208	3,208	33,455	33,472	41	196
No	55,003	55,003	715,463	715,750	2,054	7,514
Unknown	75,850	75,850	1,175,467	1,177,898	724	1,787
<b>Advanced Therapy Initiators with CD</b>						
Yes	1,304	1,304	13,398	13,404	13	63
No	27,363	27,363	364,050	364,187	936	3,327
Unknown	35,884	35,884	568,408	569,540	315	556
<b>Advanced Therapy Initiators with UC</b>						
Yes	1,071	1,071	10,545	10,551	16	51
No	12,898	12,898	153,969	154,035	535	2,106
Unknown	20,024	20,024	288,617	289,352	192	641

**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	53,131,828	145,467.0	12,790,604	10,900,286,459	29,843,357.9	166.84 (160.33, 173.61)
No	1,754,092,043	4,802,442.3	85,010,422	119,038,633,025	325,910,015.1	211.47 (210.17, 212.78)
Unknown	1,008,278,990	2,760,517.4	131,359,515	129,515,144,139	354,593,139.3	67.56 (66.60, 68.54)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	18,778,250	51,412.0	12,776,784	10,893,617,880	29,825,100.3	156.38 (145.94, 167.58)
No	694,478,271	1,901,377.9	84,775,966	118,917,234,142	325,577,643.1	202.09 (200.08, 204.12)
Unknown	416,430,371	1,140,124.2	131,108,484	129,430,880,719	354,362,438.7	65.87 (64.40, 67.38)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	31,178,111	85,361.0	12,779,624	10,895,901,030	29,831,351.2	177.01 (168.31, 186.17)
No	971,902,045	2,660,922.8	84,765,224	118,954,294,367	325,679,108.5	219.26 (217.49, 221.04)
Unknown	535,816,316	1,466,985.1	131,098,983	129,447,702,363	354,408,493.8	69.06 (67.73, 70.42)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	41,120,941	112,583.0	12,767,693	10,889,746,206	29,814,500.2	186.71 (178.89, 194.86)
No	1,250,560,194	3,423,847.2	84,560,029	118,841,294,218	325,369,730.9	226.81 (225.22, 228.41)
Unknown	677,754,777	1,855,591.4	130,882,975	129,370,780,854	354,197,894.2	72.32 (71.10, 73.55)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	14,156,947	38,759.6	12,767,653	10,889,714,953	29,814,414.7	177.25 (164.48, 191.01)
No	455,263,669	1,246,444.0	84,559,485	118,840,657,366	325,367,987.3	216.51 (213.94, 219.11)
Unknown	263,890,656	722,493.2	130,882,269	129,370,360,911	354,196,744.5	69.05 (67.16, 71.00)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use</b>						
Yes	25,419,398	69,594.5	12,767,669	10,889,728,515	29,814,451.8	194.70 (184.60, 205.35)
No	760,800,460	2,082,958.1	84,559,578	118,840,910,309	325,368,679.8	233.04 (230.98, 235.13)
Unknown	394,612,865	1,080,391.1	130,882,422	129,370,488,128	354,197,092.8	74.16 (72.55, 75.80)

**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	4,731,661	12,954.6	41,959	35,615,760	97,510.6	93.40 (78.16, 111.62)
No	134,136,895	367,246.8	518,888	563,156,825	1,541,839.4	177.40 (173.15, 181.76)
Unknown	141,154,351	386,459.6	614,233	413,922,438	1,133,257.9	52.71 (50.47, 55.05)
<b>Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	2,254,936	6,173.7	38,447	35,267,455	96,557.0	76.13 (57.20, 101.33)
No	78,284,247	214,330.6	471,884	558,149,834	1,528,131.0	160.69 (155.41, 166.14)
Unknown	80,492,411	220,376.2	538,219	408,630,262	1,118,768.7	49.60 (46.74, 52.63)
<b>Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	1,489,777	4,078.8	37,431	35,260,368	96,537.6	127.49 (97.15, 167.31)
No	30,397,601	83,224.1	433,351	557,048,571	1,525,115.9	218.69 (208.87, 228.97)
Unknown	32,374,271	88,635.9	481,875	405,991,230	1,111,543.4	59.34 (54.48, 64.64)
<b>Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	591,581	1,619.7	35,306	34,985,106	95,784.0	197.57 (139.72, 279.38)
No	14,804,597	40,532.8	408,207	553,082,581	1,514,257.6	298.28 (281.93, 315.57)
Unknown	9,953,007	27,249.8	439,129	402,213,061	1,101,199.3	95.41 (84.49, 107.75)
<b>Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	279,552	765.4	35,292	34,984,756	95,783.0	156.79 (89.04, 276.08)
No	7,389,387	20,231.0	407,902	553,075,799	1,514,239.0	252.09 (231.13, 274.94)
Unknown	5,848,543	16,012.4	438,807	402,207,932	1,101,185.3	72.44 (60.39, 86.90)
<b>Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy</b>						
Yes	284,306	778.4	35,282	34,984,737	95,783.0	256.94 (165.77, 398.27)
No	7,048,109	19,296.7	407,793	553,076,011	1,514,239.6	349.28 (323.88, 376.67)
Unknown	3,877,887	10,617.1	438,506	402,205,246	1,101,177.9	130.92 (110.87, 154.60)

**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Prevalent IBD Cohort</b>						
Yes	53,915,921	147,613.7	12,791,778	10,902,349,677	29,849,006.6	165.36 (158.93, 172.06)
No	1,783,587,035	4,883,195.2	85,031,786	119,083,754,393	326,033,550.7	210.77 (209.48, 212.06)
Unknown	1,031,254,793	2,823,421.7	131,380,951	129,540,887,520	354,663,620.9	67.37 (66.42, 68.34)
<b>Prevalent CD Cohort</b>						
Yes	19,076,389	52,228.3	12,777,727	10,895,671,018	29,830,721.5	154.71 (144.40, 165.75)
No	709,871,052	1,943,521.0	84,793,771	118,962,161,583	325,700,647.7	201.33 (199.34, 203.33)
Unknown	426,013,796	1,166,362.2	131,123,919	129,456,374,328	354,432,236.4	65.69 (64.24, 67.18)
<b>Prevalent UC Cohort</b>						
Yes	31,556,752	86,397.7	12,780,594	10,897,951,000	29,836,963.7	175.58 (166.97, 184.65)
No	982,888,015	2,691,000.7	84,781,613	118,999,229,572	325,802,134.4	218.71 (216.95, 220.48)
Unknown	546,537,323	1,496,337.6	131,114,209	129,473,229,667	354,478,383.8	68.85 (67.54, 70.20)
<b>Incident IBD Cohort</b>						
Yes	41,296,041	113,062.4	12,768,493	10,891,788,225	29,820,091.0	186.27 (178.48, 194.40)
No	1,258,781,364	3,446,355.5	84,573,779	118,886,064,716	325,492,305.9	226.57 (224.98, 228.16)
Unknown	684,680,302	1,874,552.5	130,893,630	129,396,114,778	354,267,254.7	72.19 (70.99, 73.42)
<b>Incident CD Cohort</b>						
Yes	14,219,130	38,929.9	12,768,453	10,891,756,949	29,820,005.3	176.73 (164.00, 190.44)
No	458,653,673	1,255,725.3	84,573,234	118,885,427,378	325,490,560.9	216.38 (213.83, 218.97)
Unknown	266,229,084	728,895.5	130,892,923	129,395,694,479	354,266,104.0	68.94 (67.06, 70.87)
<b>Incident UC Cohort</b>						
Yes	25,527,444	69,890.3	12,768,469	10,891,770,516	29,820,042.5	194.30 (184.24, 204.92)
No	765,358,918	2,095,438.5	84,573,328	118,885,680,465	325,491,253.8	232.74 (230.68, 234.81)
Unknown	398,912,046	1,092,161.7	130,893,077	129,395,821,834	354,266,452.7	74.01 (72.41, 75.64)

**Table 7. Summary of Outcomes of Interest in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023, by Hispanic Origin<sup>1</sup>**

	Total Days at Risk	Total Years at Risk	Number of Eligible Members <sup>2</sup>	Total Eligible Member-Days <sup>2</sup>	Total Eligible Member-Years <sup>2</sup>	ILD Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)
<b>Advanced Therapy Initiators with IBD</b>						
Yes	1,808,805	4,952.2	68,861	60,300,037	165,092.5	82.79 (60.96, 112.44)
No	45,651,149	124,986.0	1,383,227	1,734,793,186	4,749,604.9	164.34 (157.38, 171.60)
Unknown	53,879,777	147,514.8	1,110,221	1,045,789,386	2,863,215.3	49.08 (45.63, 52.79)
<b>Advanced Therapy Initiators with CD</b>						
Yes	734,569	2,011.1	23,672	19,670,928	53,856.1	64.64 (37.53, 111.32)
No	23,000,028	62,970.6	532,798	606,893,752	1,661,584.5	148.64 (139.42, 158.47)
Unknown	26,184,874	71,690.3	450,151	375,974,043	1,029,360.8	43.94 (39.35, 49.07)
<b>Advanced Therapy Initiators with UC</b>						
Yes	572,271	1,566.8	40,980	34,590,272	94,703.0	102.12 (62.56, 166.69)
No	10,033,842	27,471.2	782,559	930,457,672	2,547,454.3	194.75 (178.93, 211.97)
Unknown	13,196,586	36,130.3	604,172	550,190,516	1,506,339.5	53.14 (46.13, 61.22)

<sup>1</sup>Hispanic origin data may not be completely populated at all Data Partners; therefore, data about Hispanic origin may be incomplete.

<sup>2</sup>Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use		Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use		Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	476,013,417	N/A	476,013,417	N/A	476,013,417	N/A
Had required coverage type (medical and/or drug coverage)	348,851,929	127,161,488	348,851,929	127,161,488	348,851,929	127,161,488
Enrolled during specified age range	283,150,628	65,701,301	283,150,628	65,701,301	283,150,628	65,701,301
Met demographic requirements (sex, race, and Hispanic origin)	282,942,908	207,720	282,942,908	207,720	282,942,908	207,720
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	2,964,531	279,978,377	1,423,987	281,518,921	1,832,593	281,110,315
Claim recorded during specified age range	2,931,852	32,679	1,400,180	23,807	1,816,511	16,082
Episode defining index claim recorded during the query period	2,931,852	0	1,400,180	0	1,816,511	0
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	2,554,503	377,349	1,212,340	187,840	1,583,771	232,740
Met inclusion and exclusion criteria <sup>1</sup>	2,532,812	21,691	1,006,552	205,788	1,379,061	204,710
<i>Prior vedolizumab or natalizumab exclusion</i>						
Evidence of natalizumab	N/A	1,138	N/A	800	N/A	751
Evidence of vedolizumab	N/A	20,646	N/A	22,514	N/A	19,883
<i>IBD subtype exclusion criteria</i>						
Evidence of UC or indeterminate colitis (CD subtype exclusion)	N/A	N/A	N/A	197,281	N/A	N/A
Evidence of CD or indeterminate colitis (UC subtype exclusion)	N/A	N/A	N/A	N/A	N/A	197,013

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use		Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use		Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Advanced therapy inclusion for IBD-indexed cohorts</i>						
<i>No evidence of adalimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of certolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of etrasimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of golimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of infliximab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of mirikizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ozanimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of risankizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of tofacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of upadacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ustekinumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>IBD inclusion for advanced therapy-indexed cohorts</i>						
<i>Evidence of IBD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of CD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of UC</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Other IBD treatment exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of amiodarone</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of azathioprine</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of bleomycin</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cyclophosphamide</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of methotrexate</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of sulfasalazine</i>	N/A	N/A	N/A	N/A	N/A	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent Inflammatory Bowel Disease (IBD) Cohort Excluding Prior Vedolizumab/Natalizumab Use		Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use		Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Cancer immunotherapy exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of atezolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of avelumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cemiplimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of dostarlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of durvalumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of ipilimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of nivolumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of pembrolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of retifanlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tyrosine kinase inhibitors<sup>2</sup></i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tremelimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
Excluded due to interstitial lung disease (ILD) prior to the index date	2,439,541	93,271	976,715	29,837	1,320,770	58,291
<b>Final cohort</b>						
Number of members	2,439,541	N/A	976,715	N/A	1,320,770	N/A
Number of episodes	2,439,541	N/A	976,715	N/A	1,320,770	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use		Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use		Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	476,013,417	N/A	476,013,417	N/A	476,013,417	N/A
Had required coverage type (medical and/or drug coverage)	348,851,929	127,161,488	348,851,929	127,161,488	348,851,929	127,161,488
Enrolled during specified age range	283,150,628	65,701,301	283,150,628	65,701,301	283,150,628	65,701,301
Met demographic requirements (sex, race, and Hispanic origin)	282,942,908	207,720	282,942,908	207,720	282,942,908	207,720
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	2,964,531	279,978,377	1,423,987	281,518,921	1,832,593	281,110,315
Claim recorded during specified age range	2,931,852	32,679	1,400,180	23,807	1,816,511	16,082
Episode defining index claim recorded during the query period	2,905,743	26,109	1,382,517	17,663	1,806,826	9,685
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	1,803,991	1,101,752	800,358	582,159	1,227,714	579,112
Met inclusion and exclusion criteria <sup>1</sup>	1,802,535	1,456	656,373	143,985	1,078,480	149,234
<i>Prior vedolizumab or natalizumab exclusion</i>						
Evidence of natalizumab	N/A	752	N/A	389	N/A	581
Evidence of vedolizumab	N/A	704	N/A	4,063	N/A	4,445
<i>IBD subtype exclusion criteria</i>						
Evidence of UC or indeterminate colitis (CD subtype exclusion)	N/A	N/A	N/A	143,435	N/A	N/A
Evidence of CD or indeterminate colities (UC subtype exclusion)	N/A	N/A	N/A	N/A	N/A	148,379

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use		Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use		Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Advanced therapy inclusion for IBD-indexed cohorts</i>						
<i>No evidence of adalimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of certolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of etrasimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of golimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of infliximab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of mirikizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ozanimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of risankizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of tofacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of upadacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ustekinumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>IBD inclusion for advanced therapy-indexed cohorts</i>						
<i>Evidence of IBD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of CD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of UC</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Other IBD treatment exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of amiodarone</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of azathioprine</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of bleomycin</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cyclophosphamide</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of methotrexate</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of sulfasalazine</i>	N/A	N/A	N/A	N/A	N/A	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use		Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use		Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Cancer immunotherapy exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of atezolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of avelumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cemiplimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of dostarlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of durvalumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of ipilimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of nivolumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of pembrolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of retifanlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tyrosine kinase inhibitors<sup>2</sup></i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tremelimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
Excluded due to interstitial lung disease (ILD) prior to the index date	1,718,382	84,153	630,457	25,916	1,024,124	54,356
<b>Final cohort</b>						
Number of members	1,718,382	N/A	630,457	N/A	1,024,124	N/A
Number of episodes	1,718,382	N/A	630,457	N/A	1,024,124	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	476,013,417	N/A	476,013,417	N/A	476,013,417	N/A
Had required coverage type (medical and/or drug coverage)	348,851,929	127,161,488	348,851,929	127,161,488	348,851,929	127,161,488
Enrolled during specified age range	283,150,628	65,701,301	283,150,628	65,701,301	283,150,628	65,701,301
Met demographic requirements (sex, race, and Hispanic origin)	282,942,908	207,720	282,942,908	207,720	282,942,908	207,720
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	2,964,531	279,978,377	1,423,987	281,518,921	1,832,593	281,110,315
Claim recorded during specified age range	2,931,852	32,679	1,400,180	23,807	1,816,511	16,082
Episode defining index claim recorded during the query period	2,931,852	0	1,400,180	0	1,816,511	0
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	2,554,503	377,349	1,212,340	187,840	1,583,771	232,740
Met inclusion and exclusion criteria <sup>1</sup>	302,928	2,251,575	169,973	1,042,367	75,071	1,508,700
<i>Prior vedolizumab or natalizumab exclusion</i>						
Evidence of natalizumab	N/A	1,423	N/A	984	N/A	835
Evidence of vedolizumab	N/A	44,634	N/A	33,006	N/A	33,384
<i>IBD subtype exclusion criteria</i>						
Evidence of UC or indeterminate colitis (CD subtype exclusion)	N/A	N/A	N/A	262,913	N/A	N/A
Evidence of CD or indeterminate colities (UC subtype exclusion)	N/A	N/A	N/A	N/A	N/A	271,453

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Advanced therapy inclusion for IBD-indexed cohorts</i>						
<i>No evidence of adalimumab</i>	N/A	2,250,490	N/A	1,029,683	N/A	1,491,772
<i>No evidence of certolizumab</i>	N/A	2,251,425	N/A	1,040,857	N/A	1,505,014
<i>No evidence of etrasimod</i>	N/A	2,251,575	N/A	1,042,367	N/A	1,508,700
<i>No evidence of golimumab</i>	N/A	2,251,498	N/A	1,041,505	N/A	1,508,176
<i>No evidence of infliximab</i>	N/A	2,250,137	N/A	1,021,386	N/A	1,485,508
<i>No evidence of mirikizumab</i>	N/A	2,251,575	N/A	1,042,367	N/A	1,508,700
<i>No evidence of ozanimod</i>	N/A	2,251,569	N/A	1,042,353	N/A	1,508,689
<i>No evidence of risankizumab</i>	N/A	2,251,568	N/A	1,042,335	N/A	1,508,673
<i>No evidence of tofacitinib</i>	N/A	2,251,446	N/A	1,041,876	N/A	1,508,337
<i>No evidence of upadacitinib</i>	N/A	2,251,558	N/A	1,042,336	N/A	1,508,657
<i>No evidence of ustekinumab</i>	N/A	2,250,987	N/A	1,039,954	N/A	1,505,048
<i>IBD inclusion for advanced therapy-indexed cohorts</i>						
<i>Evidence of IBD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of CD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of UC</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Other IBD treatment exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of amiodarone</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of azathioprine</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of bleomycin</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cyclophosphamide</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of methotrexate</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of sulfasalazine</i>	N/A	N/A	N/A	N/A	N/A	N/A



**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Cancer immunotherapy exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of atezolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of avelumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cemiplimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of dostarlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of durvalumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of ipilimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of nivolumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of pembrolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of retifanlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tyrosine kinase inhibitors<sup>2</sup></i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tremelimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
Excluded due to interstitial lung disease (ILD) prior to the index date	296,808	6,120	167,458	2,515	72,886	2,185
<b>Final cohort</b>						
Number of members	296,808	N/A	167,458	N/A	72,886	N/A
Number of episodes	296,808	N/A	167,458	N/A	72,886	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	476,013,417	N/A	476,013,417	N/A	476,013,417	N/A
Had required coverage type (medical and/or drug coverage)	348,851,929	127,161,488	348,851,929	127,161,488	348,851,929	127,161,488
Enrolled during specified age range	283,150,628	65,701,301	283,150,628	65,701,301	283,150,628	65,701,301
Met demographic requirements (sex, race, and Hispanic origin)	282,942,908	207,720	282,942,908	207,720	282,942,908	207,720
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	2,964,531	279,978,377	1,423,987	281,518,921	1,832,593	281,110,315
Claim recorded during specified age range	2,931,852	32,679	1,400,180	23,807	1,816,511	16,082
Episode defining index claim recorded during the query period	2,905,743	26,109	1,382,517	17,663	1,806,826	9,685
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	1,803,991	1,101,752	800,358	582,159	1,227,714	579,112
Met inclusion and exclusion criteria <sup>1</sup>	28,197	1,775,794	14,711	785,647	12,635	1,215,079
<i>Prior vedolizumab or natalizumab exclusion</i>						
<i>Evidence of natalizumab</i>	N/A	752	N/A	389	N/A	581
<i>Evidence of vedolizumab</i>	N/A	704	N/A	4,063	N/A	4,445
<i>IBD subtype exclusion criteria</i>						
<i>Evidence of UC or indeterminate colitis (CD subtype exclusion)</i>	N/A	N/A	N/A	143,435	N/A	N/A
<i>Evidence of CD or indeterminate colities (UC subtype exclusion)</i>	N/A	N/A	N/A	N/A	N/A	148,379

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Advanced therapy inclusion for IBD-indexed cohorts</i>						
<i>No evidence of adalimumab</i>	N/A	1,775,762	N/A	779,312	N/A	1,202,738
<i>No evidence of certolizumab</i>	N/A	1,775,793	N/A	785,155	N/A	1,212,090
<i>No evidence of etrasimod</i>	N/A	1,775,794	N/A	785,647	N/A	1,215,079
<i>No evidence of golimumab</i>	N/A	1,775,789	N/A	784,953	N/A	1,214,774
<i>No evidence of infliximab</i>	N/A	1,775,755	N/A	775,397	N/A	1,201,409
<i>No evidence of mirikizumab</i>	N/A	1,775,794	N/A	785,647	N/A	1,215,079
<i>No evidence of ozanimod</i>	N/A	1,775,794	N/A	785,637	N/A	1,215,078
<i>No evidence of risankizumab</i>	N/A	1,775,794	N/A	785,630	N/A	1,215,056
<i>No evidence of tofacitinib</i>	N/A	1,775,788	N/A	785,269	N/A	1,214,934
<i>No evidence of upadacitinib</i>	N/A	1,775,794	N/A	785,633	N/A	1,215,062
<i>No evidence of ustekinumab</i>	N/A	1,775,787	N/A	784,889	N/A	1,212,342
<i>IBD inclusion for advanced therapy-indexed cohorts</i>						
<i>Evidence of IBD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of CD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of UC</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Other IBD treatment exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of amiodarone</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of azathioprine</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of bleomycin</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cyclophosphamide</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of methotrexate</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of sulfasalazine</i>	N/A	N/A	N/A	N/A	N/A	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy		Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Cancer immunotherapy exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of atezolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of avelumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cemiplimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of dostarlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of durvalumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of ipilimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of nivolumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of pembrolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of retifanlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tyrosine kinase inhibitors<sup>2</sup></i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tremelimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
Excluded due to interstitial lung disease (ILD) prior to the index date	26,272	1,925	14,011	700	11,518	1,117
<b>Final cohort</b>						
Number of members	26,272	N/A	14,011	N/A	11,518	N/A
Number of episodes	26,272	N/A	14,011	N/A	11,518	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent IBD Cohort		Prevalent CD Cohort		Prevalent UC Cohort	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	476,013,417	N/A	476,013,417	N/A	476,013,417	N/A
Had required coverage type (medical and/or drug coverage)	348,851,929	127,161,488	348,851,929	127,161,488	348,851,929	127,161,488
Enrolled during specified age range	283,150,628	65,701,301	283,150,628	65,701,301	283,150,628	65,701,301
Met demographic requirements (sex, race, and Hispanic origin)	282,942,908	207,720	282,942,908	207,720	282,942,908	207,720
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	2,964,531	279,978,377	1,423,987	281,518,921	1,832,593	281,110,315
Claim recorded during specified age range	2,931,852	32,679	1,400,180	23,807	1,816,511	16,082
Episode defining index claim recorded during the query period	2,931,852	0	1,400,180	0	1,816,511	0
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	2,554,503	377,349	1,212,340	187,840	1,583,771	232,740
Met inclusion and exclusion criteria <sup>1</sup>	2,554,503	0	1,016,568	195,772	1,387,898	195,873
<i>Prior vedolizumab or natalizumab exclusion</i>						
Evidence of natalizumab	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of vedolizumab	N/A	N/A	N/A	N/A	N/A	N/A
<i>IBD subtype exclusion criteria</i>						
Evidence of UC or indeterminate colitis (CD subtype exclusion)	N/A	N/A	N/A	195,772	N/A	N/A
Evidence of CD or indeterminate colities (UC subtype exclusion)	N/A	N/A	N/A	N/A	N/A	195,873

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent IBD Cohort		Prevalent CD Cohort		Prevalent UC Cohort	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Advanced therapy inclusion for IBD-indexed cohorts</i>						
<i>No evidence of adalimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of certolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of etrasimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of golimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of infliximab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of mirikizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ozanimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of risankizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of tofacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of upadacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ustekinumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>IBD inclusion for advanced therapy-indexed cohorts</i>						
<i>Evidence of IBD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of CD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of UC</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Other IBD treatment exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of amiodarone</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of azathioprine</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of bleomycin</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cyclophosphamide</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of methotrexate</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of sulfasalazine</i>	N/A	N/A	N/A	N/A	N/A	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Prevalent IBD Cohort		Prevalent CD Cohort		Prevalent UC Cohort	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Cancer immunotherapy exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of atezolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of avelumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cemiplimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of dostarlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of durvalumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of ipilimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of nivolumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of pembrolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of retifanlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tyrosine kinase inhibitors<sup>2</sup></i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tremelimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
Excluded due to interstitial lung disease (ILD) prior to the index date	2,460,987	93,516	986,629	29,939	1,329,505	58,393
<b>Final cohort</b>						
Number of members	2,460,987	N/A	986,629	N/A	1,329,505	N/A
Number of episodes	2,460,987	N/A	986,629	N/A	1,329,505	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort		Incident CD Cohort		Incident UC Cohort	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	476,013,417	N/A	476,013,417	N/A	476,013,417	N/A
Had required coverage type (medical and/or drug coverage)	348,851,929	127,161,488	348,851,929	127,161,488	348,851,929	127,161,488
Enrolled during specified age range	283,150,628	65,701,301	283,150,628	65,701,301	283,150,628	65,701,301
Met demographic requirements (sex, race, and Hispanic origin)	282,942,908	207,720	282,942,908	207,720	282,942,908	207,720
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	2,964,531	279,978,377	1,423,987	281,518,921	1,832,593	281,110,315
Claim recorded during specified age range	2,931,852	32,679	1,400,180	23,807	1,816,511	16,082
Episode defining index claim recorded during the query period	2,905,743	26,109	1,382,517	17,663	1,806,826	9,685
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	1,803,991	1,101,752	800,358	582,159	1,227,714	579,112
Met inclusion and exclusion criteria <sup>1</sup>	1,803,991	0	656,923	143,435	1,079,335	148,379
<i>Prior vedolizumab or natalizumab exclusion</i>						
Evidence of natalizumab	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of vedolizumab	N/A	N/A	N/A	N/A	N/A	N/A
<i>IBD subtype exclusion criteria</i>						
Evidence of UC or indeterminate colitis (CD subtype exclusion)	N/A	N/A	N/A	143,435	N/A	N/A
Evidence of CD or indeterminate colities (UC subtype exclusion)	N/A	N/A	N/A	N/A	N/A	148,379



**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort		Incident CD Cohort		Incident UC Cohort	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Advanced therapy inclusion for IBD-indexed cohorts</i>						
<i>No evidence of adalimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of certolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of etrasimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of golimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of infliximab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of mirikizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ozanimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of risankizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of tofacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of upadacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ustekinumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>IBD inclusion for advanced therapy-indexed cohorts</i>						
<i>Evidence of IBD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of CD</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of UC</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Other IBD treatment exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of amiodarone</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of azathioprine</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of bleomycin</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cyclophosphamide</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of methotrexate</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of sulfasalazine</i>	N/A	N/A	N/A	N/A	N/A	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Incident IBD Cohort		Incident CD Cohort		Incident UC Cohort	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Cancer immunotherapy exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of atezolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of avelumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of cemiplimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of dostarlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of durvalumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of ipilimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of nivolumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of pembrolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of retifanlimab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tyrosine kinase inhibitors<sup>2</sup></i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>Evidence of tremelimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
Excluded due to interstitial lung disease (ILD) prior to the index date	1,719,777	84,214	630,987	25,936	1,024,941	54,394
<b>Final cohort</b>						
Number of members	1,719,777	N/A	630,987	N/A	1,024,941	N/A
Number of episodes	1,719,777	N/A	630,987	N/A	1,024,941	N/A

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Advanced Therapy Initiators with IBD		Advanced Therapy Initiators with CD		Advanced Therapy Initiators with UC	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	476,013,417	N/A	476,013,417	N/A	476,013,417	N/A
Had required coverage type (medical and/or drug coverage)	348,851,929	127,161,488	348,851,929	127,161,488	348,851,929	127,161,488
Enrolled during specified age range	283,150,628	65,701,301	283,150,628	65,701,301	283,150,628	65,701,301
Met demographic requirements (sex, race, and Hispanic origin)	282,942,908	207,720	282,942,908	207,720	282,942,908	207,720
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	1,284,709	281,658,199	1,284,709	281,658,199	1,284,709	281,658,199
Claim recorded during specified age range	1,272,740	11,969	1,272,740	11,969	1,272,740	11,969
Episode defining index claim recorded during the query period	1,261,726	11,014	1,261,726	11,014	1,261,726	11,014
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	743,457	518,269	743,457	518,269	743,457	518,269
Met inclusion and exclusion criteria <sup>1</sup>	137,989	605,468	66,122	677,335	35,133	708,324
<i>Prior vedolizumab or natalizumab exclusion</i>						
<i>Evidence of natalizumab</i>	N/A	124	N/A	130	N/A	151
<i>Evidence of vedolizumab</i>	N/A	9,704	N/A	11,693	N/A	11,883
<i>IBD subtype exclusion criteria</i>						
<i>Evidence of UC or indeterminate colitis (CD subtype exclusion)</i>	N/A	N/A	N/A	92,782	N/A	N/A
<i>Evidence of CD or indeterminate colities (UC subtype exclusion)</i>	N/A	N/A	N/A	N/A	N/A	126,648

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Advanced Therapy Initiators with IBD		Advanced Therapy Initiators with CD		Advanced Therapy Initiators with UC	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Advanced therapy inclusion for IBD-indexed cohorts</i>						
<i>No evidence of adalimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of certolizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of etrasimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of golimumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of infliximab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of mirikizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ozanimod</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of risankizumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of tofacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of upadacitinib</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>No evidence of ustekinumab</i>	N/A	N/A	N/A	N/A	N/A	N/A
<i>IBD inclusion for advanced therapy-indexed cohorts</i>						
<i>Evidence of IBD</i>	N/A	571,685	N/A	N/A	N/A	N/A
<i>Evidence of CD</i>	N/A	N/A	N/A	619,027	N/A	N/A
<i>Evidence of UC</i>	N/A	N/A	N/A	N/A	N/A	652,924
<i>Other IBD treatment exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of amiodarone</i>	N/A	6,299	N/A	6,377	N/A	6,399
<i>Evidence of azathioprine</i>	N/A	18,314	N/A	19,362	N/A	19,989
<i>Evidence of bleomycin</i>	N/A	*****	N/A	*****	N/A	*****
<i>Evidence of cyclophosphamide</i>	N/A	55	N/A	55	N/A	56
<i>Evidence of methotrexate</i>	N/A	164,968	N/A	165,943	N/A	166,295
<i>Evidence of sulfasalazine</i>	N/A	28,261	N/A	28,694	N/A	28,750

**Table 8. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2006 to April 30, 2023**

	Advanced Therapy Initiators with IBD		Advanced Therapy Initiators with CD		Advanced Therapy Initiators with UC	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<i>Cancer immunotherapy exclusion (Advanced therapy-indexed cohorts)</i>						
<i>Evidence of atezolizumab</i>	N/A	60	N/A	60	N/A	60
<i>Evidence of avelumab</i>	N/A	*****	N/A	*****	N/A	*****
<i>Evidence of cemiplimab</i>	N/A	18	N/A	18	N/A	18
<i>Evidence of dostarlimab</i>	N/A	0	N/A	0	N/A	0
<i>Evidence of durvalumab</i>	N/A	67	N/A	67	N/A	67
<i>Evidence of ipilimumab</i>	N/A	926	N/A	933	N/A	928
<i>Evidence of nivolumab</i>	N/A	1,165	N/A	1,172	N/A	1,167
<i>Evidence of pembrolizumab</i>	N/A	653	N/A	658	N/A	655
<i>Evidence of retifanlimab</i>	N/A	0	N/A	0	N/A	0
<i>Evidence of tyrosine kinase inhibitors<sup>2</sup></i>	N/A	351	N/A	354	N/A	354
<i>Evidence of tremelimumab</i>	N/A	0	N/A	0	N/A	0
Excluded due to interstitial lung disease (ILD) prior to the index date	134,061	3,928	64,551	1,571	33,993	1,140
<b>Final cohort</b>						
Number of members	134,061	N/A	64,551	N/A	33,993	N/A
Number of episodes	134,061	N/A	64,551	N/A	33,993	N/A

N/A: Not applicable

<sup>1</sup>Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

<sup>2</sup>Tyrosine kinase inhibitors include selpercatinib, pirtobrutinib, dasatinib, deucravacitinib, imatinib, bosutinib, axitinib, dacomitinib, lorlatinib, sunitinib, crizotinib, nilotinib, ceritinib, pazopanib, lapatinib, midostaurin, capmatinib, asciminib, erlotinib, gefitinib, acalabrutinib, osimertinib, vandetanib, gilteritinib, afatinib, nintedanib, tepotinib, tivozanib, entrectinib, alectinib, pralsetinib, larotrectinib, pemigatinib, tucatinib, ibrutinib, fedratinib, erdafitinib, lenvatinib, mobocertinib, brigatinib, futibatinib, pexidartinib, quizartinib, neratinib, fostamatinib, avapritinib, pacritinib, zanubrutinib, infigratinib, ripretinib.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (February 16, 2024)**

Masked DP ID	DP Start Date	DP End Date <sup>1</sup>
DP01	01/01/2008	04/30/2023
DP02	01/01/2007	01/31/2023
DP03	01/01/2006	02/28/2023
DP04	01/01/2008	12/31/2022
DP05	01/01/2010	12/31/2022
DP06	01/01/2014	12/31/2020

<sup>1</sup>End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

**Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inflammatory Bowel Disease (IBD) Index Dates in this Request**

Code	Description	Code Category	Code Type
<b>Inflammatory Bowel Disease</b>			
555	Regional enteritis	Diagnosis	ICD-9-CM
555.0	Regional enteritis of small intestine	Diagnosis	ICD-9-CM
555.1	Regional enteritis of large intestine	Diagnosis	ICD-9-CM
555.2	Regional enteritis of small intestine with large intestine	Diagnosis	ICD-9-CM
555.9	Regional enteritis of unspecified site	Diagnosis	ICD-9-CM
556.0	Ulcerative (chronic) enterocolitis	Diagnosis	ICD-9-CM
556.1	Ulcerative (chronic) ileocolitis	Diagnosis	ICD-9-CM
556.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-9-CM
556.3	Ulcerative (chronic) proctosigmoiditis	Diagnosis	ICD-9-CM
556.5	Left sided ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.6	Universal ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.8	Other ulcerative colitis	Diagnosis	ICD-9-CM
556.9	Unspecified ulcerative colitis	Diagnosis	ICD-9-CM
K50	Crohn's disease [regional enteritis]	Diagnosis	ICD-10-CM
K50.0	Crohn's disease of small intestine	Diagnosis	ICD-10-CM
K50.00	Crohn's disease of small intestine without complications	Diagnosis	ICD-10-CM
K50.01	Crohn's disease of small intestine with complications	Diagnosis	ICD-10-CM
K50.011	Crohn's disease of small intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.012	Crohn's disease of small intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.013	Crohn's disease of small intestine with fistula	Diagnosis	ICD-10-CM
K50.014	Crohn's disease of small intestine with abscess	Diagnosis	ICD-10-CM
K50.018	Crohn's disease of small intestine with other complication	Diagnosis	ICD-10-CM
K50.019	Crohn's disease of small intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.1	Crohn's disease of large intestine	Diagnosis	ICD-10-CM
K50.10	Crohn's disease of large intestine without complications	Diagnosis	ICD-10-CM
K50.11	Crohn's disease of large intestine with complications	Diagnosis	ICD-10-CM
K50.111	Crohn's disease of large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.112	Crohn's disease of large intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.113	Crohn's disease of large intestine with fistula	Diagnosis	ICD-10-CM
K50.114	Crohn's disease of large intestine with abscess	Diagnosis	ICD-10-CM
K50.118	Crohn's disease of large intestine with other complication	Diagnosis	ICD-10-CM
K50.119	Crohn's disease of large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.8	Crohn's disease of both small and large intestine	Diagnosis	ICD-10-CM
K50.80	Crohn's disease of both small and large intestine without complications	Diagnosis	ICD-10-CM
K50.81	Crohn's disease of both small and large intestine with complications	Diagnosis	ICD-10-CM
K50.811	Crohn's disease of both small and large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.813	Crohn's disease of both small and large intestine with fistula	Diagnosis	ICD-10-CM
K50.814	Crohn's disease of both small and large intestine with abscess	Diagnosis	ICD-10-CM
K50.818	Crohn's disease of both small and large intestine with other complication	Diagnosis	ICD-10-CM

**Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inflammatory Bowel Disease (IBD) Index Dates in this Request**

Code	Description	Code Category	Code Type
K50.819	Crohn's disease of both small and large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.9	Crohn's disease, unspecified	Diagnosis	ICD-10-CM
K50.90	Crohn's disease, unspecified, without complications	Diagnosis	ICD-10-CM
K50.91	Crohn's disease, unspecified, with complications	Diagnosis	ICD-10-CM
K50.911	Crohn's disease, unspecified, with rectal bleeding	Diagnosis	ICD-10-CM
K50.912	Crohn's disease, unspecified, with intestinal obstruction	Diagnosis	ICD-10-CM
K50.913	Crohn's disease, unspecified, with fistula	Diagnosis	ICD-10-CM
K50.914	Crohn's disease, unspecified, with abscess	Diagnosis	ICD-10-CM
K50.918	Crohn's disease, unspecified, with other complication	Diagnosis	ICD-10-CM
K50.919	Crohn's disease, unspecified, with unspecified complications	Diagnosis	ICD-10-CM
K51.0	Ulcerative (chronic) pancolitis	Diagnosis	ICD-10-CM
K51.00	Ulcerative (chronic) pancolitis without complications	Diagnosis	ICD-10-CM
K51.01	Ulcerative (chronic) pancolitis with complications	Diagnosis	ICD-10-CM
K51.011	Ulcerative (chronic) pancolitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.012	Ulcerative (chronic) pancolitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.013	Ulcerative (chronic) pancolitis with fistula	Diagnosis	ICD-10-CM
K51.014	Ulcerative (chronic) pancolitis with abscess	Diagnosis	ICD-10-CM
K51.018	Ulcerative (chronic) pancolitis with other complication	Diagnosis	ICD-10-CM
K51.019	Ulcerative (chronic) pancolitis with unspecified complications	Diagnosis	ICD-10-CM
K51.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-10-CM
K51.20	Ulcerative (chronic) proctitis without complications	Diagnosis	ICD-10-CM
K51.21	Ulcerative (chronic) proctitis with complications	Diagnosis	ICD-10-CM
K51.211	Ulcerative (chronic) proctitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.213	Ulcerative (chronic) proctitis with fistula	Diagnosis	ICD-10-CM
K51.214	Ulcerative (chronic) proctitis with abscess	Diagnosis	ICD-10-CM
K51.218	Ulcerative (chronic) proctitis with other complication	Diagnosis	ICD-10-CM
K51.219	Ulcerative (chronic) proctitis with unspecified complications	Diagnosis	ICD-10-CM
K51.3	Ulcerative (chronic) rectosigmoiditis	Diagnosis	ICD-10-CM
K51.30	Ulcerative (chronic) rectosigmoiditis without complications	Diagnosis	ICD-10-CM
K51.31	Ulcerative (chronic) rectosigmoiditis with complications	Diagnosis	ICD-10-CM
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding	Diagnosis	ICD-10-CM
K51.312	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.313	Ulcerative (chronic) rectosigmoiditis with fistula	Diagnosis	ICD-10-CM
K51.314	Ulcerative (chronic) rectosigmoiditis with abscess	Diagnosis	ICD-10-CM
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication	Diagnosis	ICD-10-CM
K51.319	Ulcerative (chronic) rectosigmoiditis with unspecified complications	Diagnosis	ICD-10-CM
K51.8	Other ulcerative colitis	Diagnosis	ICD-10-CM
K51.80	Other ulcerative colitis without complications	Diagnosis	ICD-10-CM
K51.81	Other ulcerative colitis with complications	Diagnosis	ICD-10-CM
K51.811	Other ulcerative colitis with rectal bleeding	Diagnosis	ICD-10-CM



**Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inflammatory Bowel Disease (IBD) Index Dates in this Request**

Code	Description	Code Category	Code Type
K51.812	Other ulcerative colitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.813	Other ulcerative colitis with fistula	Diagnosis	ICD-10-CM
K51.814	Other ulcerative colitis with abscess	Diagnosis	ICD-10-CM
K51.818	Other ulcerative colitis with other complication	Diagnosis	ICD-10-CM
K51.819	Other ulcerative colitis with unspecified complications	Diagnosis	ICD-10-CM
K51.9	Ulcerative colitis, unspecified	Diagnosis	ICD-10-CM
K51.90	Ulcerative colitis, unspecified, without complications	Diagnosis	ICD-10-CM
K51.91	Ulcerative colitis, unspecified, with complications	Diagnosis	ICD-10-CM
K51.911	Ulcerative colitis, unspecified with rectal bleeding	Diagnosis	ICD-10-CM
K51.912	Ulcerative colitis, unspecified with intestinal obstruction	Diagnosis	ICD-10-CM
K51.913	Ulcerative colitis, unspecified with fistula	Diagnosis	ICD-10-CM
K51.914	Ulcerative colitis, unspecified with abscess	Diagnosis	ICD-10-CM
K51.918	Ulcerative colitis, unspecified with other complication	Diagnosis	ICD-10-CM
K51.919	Ulcerative colitis, unspecified with unspecified complications	Diagnosis	ICD-10-CM
K52.3	Indeterminate colitis	Diagnosis	ICD-10-CM
<b>Crohn's Disease</b>			
555	Regional enteritis	Diagnosis	ICD-9-CM
555.0	Regional enteritis of small intestine	Diagnosis	ICD-9-CM
555.1	Regional enteritis of large intestine	Diagnosis	ICD-9-CM
555.2	Regional enteritis of small intestine with large intestine	Diagnosis	ICD-9-CM
555.9	Regional enteritis of unspecified site	Diagnosis	ICD-9-CM
K50	Crohn's disease [regional enteritis]	Diagnosis	ICD-10-CM
K50.0	Crohn's disease of small intestine	Diagnosis	ICD-10-CM
K50.00	Crohn's disease of small intestine without complications	Diagnosis	ICD-10-CM
K50.01	Crohn's disease of small intestine with complications	Diagnosis	ICD-10-CM
K50.011	Crohn's disease of small intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.012	Crohn's disease of small intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.013	Crohn's disease of small intestine with fistula	Diagnosis	ICD-10-CM
K50.014	Crohn's disease of small intestine with abscess	Diagnosis	ICD-10-CM
K50.018	Crohn's disease of small intestine with other complication	Diagnosis	ICD-10-CM
K50.019	Crohn's disease of small intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.1	Crohn's disease of large intestine	Diagnosis	ICD-10-CM
K50.10	Crohn's disease of large intestine without complications	Diagnosis	ICD-10-CM
K50.11	Crohn's disease of large intestine with complications	Diagnosis	ICD-10-CM
K50.111	Crohn's disease of large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.112	Crohn's disease of large intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.113	Crohn's disease of large intestine with fistula	Diagnosis	ICD-10-CM
K50.114	Crohn's disease of large intestine with abscess	Diagnosis	ICD-10-CM
K50.118	Crohn's disease of large intestine with other complication	Diagnosis	ICD-10-CM
K50.119	Crohn's disease of large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.8	Crohn's disease of both small and large intestine	Diagnosis	ICD-10-CM

**Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inflammatory Bowel Disease (IBD) Index Dates in this Request**

Code	Description	Code Category	Code Type
K50.80	Crohn's disease of both small and large intestine without complications	Diagnosis	ICD-10-CM
K50.81	Crohn's disease of both small and large intestine with complications	Diagnosis	ICD-10-CM
K50.811	Crohn's disease of both small and large intestine with rectal bleeding	Diagnosis	ICD-10-CM
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction	Diagnosis	ICD-10-CM
K50.813	Crohn's disease of both small and large intestine with fistula	Diagnosis	ICD-10-CM
K50.814	Crohn's disease of both small and large intestine with abscess	Diagnosis	ICD-10-CM
K50.818	Crohn's disease of both small and large intestine with other complication	Diagnosis	ICD-10-CM
K50.819	Crohn's disease of both small and large intestine with unspecified complications	Diagnosis	ICD-10-CM
K50.9	Crohn's disease, unspecified	Diagnosis	ICD-10-CM
K50.90	Crohn's disease, unspecified, without complications	Diagnosis	ICD-10-CM
K50.91	Crohn's disease, unspecified, with complications	Diagnosis	ICD-10-CM
K50.911	Crohn's disease, unspecified, with rectal bleeding	Diagnosis	ICD-10-CM
K50.912	Crohn's disease, unspecified, with intestinal obstruction	Diagnosis	ICD-10-CM
K50.913	Crohn's disease, unspecified, with fistula	Diagnosis	ICD-10-CM
K50.914	Crohn's disease, unspecified, with abscess	Diagnosis	ICD-10-CM
K50.918	Crohn's disease, unspecified, with other complication	Diagnosis	ICD-10-CM
K50.919	Crohn's disease, unspecified, with unspecified complications	Diagnosis	ICD-10-CM
<b>Ulcerative Colitis</b>			
556.0	Ulcerative (chronic) enterocolitis	Diagnosis	ICD-9-CM
556.1	Ulcerative (chronic) ileocolitis	Diagnosis	ICD-9-CM
556.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-9-CM
556.3	Ulcerative (chronic) proctosigmoiditis	Diagnosis	ICD-9-CM
556.5	Left sided ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.6	Universal ulcerative (chronic) colitis	Diagnosis	ICD-9-CM
556.8	Other ulcerative colitis	Diagnosis	ICD-9-CM
556.9	Unspecified ulcerative colitis	Diagnosis	ICD-9-CM
K51.0	Ulcerative (chronic) pancolitis	Diagnosis	ICD-10-CM
K51.00	Ulcerative (chronic) pancolitis without complications	Diagnosis	ICD-10-CM
K51.01	Ulcerative (chronic) pancolitis with complications	Diagnosis	ICD-10-CM
K51.011	Ulcerative (chronic) pancolitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.012	Ulcerative (chronic) pancolitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.013	Ulcerative (chronic) pancolitis with fistula	Diagnosis	ICD-10-CM
K51.014	Ulcerative (chronic) pancolitis with abscess	Diagnosis	ICD-10-CM
K51.018	Ulcerative (chronic) pancolitis with other complication	Diagnosis	ICD-10-CM
K51.019	Ulcerative (chronic) pancolitis with unspecified complications	Diagnosis	ICD-10-CM
K51.2	Ulcerative (chronic) proctitis	Diagnosis	ICD-10-CM
K51.20	Ulcerative (chronic) proctitis without complications	Diagnosis	ICD-10-CM
K51.21	Ulcerative (chronic) proctitis with complications	Diagnosis	ICD-10-CM
K51.211	Ulcerative (chronic) proctitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.213	Ulcerative (chronic) proctitis with fistula	Diagnosis	ICD-10-CM

**Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inflammatory Bowel Disease (IBD) Index Dates in this Request**

Code	Description	Code Category	Code Type
K51.214	Ulcerative (chronic) proctitis with abscess	Diagnosis	ICD-10-CM
K51.218	Ulcerative (chronic) proctitis with other complication	Diagnosis	ICD-10-CM
K51.219	Ulcerative (chronic) proctitis with unspecified complications	Diagnosis	ICD-10-CM
K51.3	Ulcerative (chronic) rectosigmoiditis	Diagnosis	ICD-10-CM
K51.30	Ulcerative (chronic) rectosigmoiditis without complications	Diagnosis	ICD-10-CM
K51.31	Ulcerative (chronic) rectosigmoiditis with complications	Diagnosis	ICD-10-CM
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding	Diagnosis	ICD-10-CM
K51.312	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.313	Ulcerative (chronic) rectosigmoiditis with fistula	Diagnosis	ICD-10-CM
K51.314	Ulcerative (chronic) rectosigmoiditis with abscess	Diagnosis	ICD-10-CM
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication	Diagnosis	ICD-10-CM
K51.319	Ulcerative (chronic) rectosigmoiditis with unspecified complications	Diagnosis	ICD-10-CM
K51.8	Other ulcerative colitis	Diagnosis	ICD-10-CM
K51.80	Other ulcerative colitis without complications	Diagnosis	ICD-10-CM
K51.81	Other ulcerative colitis with complications	Diagnosis	ICD-10-CM
K51.811	Other ulcerative colitis with rectal bleeding	Diagnosis	ICD-10-CM
K51.812	Other ulcerative colitis with intestinal obstruction	Diagnosis	ICD-10-CM
K51.813	Other ulcerative colitis with fistula	Diagnosis	ICD-10-CM
K51.814	Other ulcerative colitis with abscess	Diagnosis	ICD-10-CM
K51.818	Other ulcerative colitis with other complication	Diagnosis	ICD-10-CM
K51.819	Other ulcerative colitis with unspecified complications	Diagnosis	ICD-10-CM
K51.9	Ulcerative colitis, unspecified	Diagnosis	ICD-10-CM
K51.90	Ulcerative colitis, unspecified, without complications	Diagnosis	ICD-10-CM
K51.91	Ulcerative colitis, unspecified, with complications	Diagnosis	ICD-10-CM
K51.911	Ulcerative colitis, unspecified with rectal bleeding	Diagnosis	ICD-10-CM
K51.912	Ulcerative colitis, unspecified with intestinal obstruction	Diagnosis	ICD-10-CM
K51.913	Ulcerative colitis, unspecified with fistula	Diagnosis	ICD-10-CM
K51.914	Ulcerative colitis, unspecified with abscess	Diagnosis	ICD-10-CM
K51.918	Ulcerative colitis, unspecified with other complication	Diagnosis	ICD-10-CM
K51.919	Ulcerative colitis, unspecified with unspecified complications	Diagnosis	ICD-10-CM

**Appendix C. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapy Exposures in this Request**

Non-Proprietary Name	Proprietary Name
<b>Infliximab</b>	
infliximab	Remicade
infliximab	infliximab
infliximab-abda	Renflexis
infliximab-axxq	Avsola
infliximab-dyyb	Inflectra
<b>Adalimumab</b>	
adalimumab	Humira
adalimumab	Humira Pediatric Crohns Start
adalimumab	Humira Pen
adalimumab	Humira Pen Crohns-UC-HS Start
adalimumab	Humira Pen Psor-Uveits-Adol HS
adalimumab	Humira(CF)
adalimumab	Humira(CF) Pedi Crohns Starter
adalimumab	Humira(CF) Pen
adalimumab	Humira(CF) Pen Crohns-UC-HS
adalimumab	Humira(CF) Pen Pediatric UC
adalimumab	Humira(CF) Pen Psor-Uv-Adol HS
adalimumab-aacf	Idacio(CF)
adalimumab-aacf	Idacio(CF) Pen
adalimumab-aacf	Idacio(CF) Pen Crohn-UC Startr
adalimumab-aacf	Idacio(CF) Pen Psoriasis Start
adalimumab-aaty	Yuflyma(CF)
adalimumab-aaty	Yuflyma(CF) Autoinjector
adalimumab-adaz	Hyrimoz
adalimumab-adaz	Hyrimoz Pen
adalimumab-adaz	Hyrimoz Pen Crohn's-UC Starter
adalimumab-adaz	Hyrimoz Pen Psoriasis Starter
adalimumab-adaz	Hyrimoz(CF)
adalimumab-adaz	Hyrimoz(CF) Pedi Crohn Starter
adalimumab-adaz	Hyrimoz(CF) Pen
adalimumab-adaz	adalimumab-adaz
adalimumab-adbm	Cyltezo(CF)
adalimumab-adbm	Cyltezo(CF) Pen
adalimumab-adbm	Cyltezo(CF) Pen Crohn's-UC-HS
adalimumab-adbm	Cyltezo(CF) Pen Psoriasis-UV
adalimumab-adbm	adalimumab-adbm
adalimumab-adbm	adalimumab-adbm(CF) pen Crohns
adalimumab-adbm	adalimumab-adbm(CF) pen PS-UV
adalimumab-afzb	Abrilada(CF)
adalimumab-afzb	Abrilada(CF) Pen

**Appendix C. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapy Exposures in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
adalimumab-aqvh	Yusimry(CF) Pen
adalimumab-atto	Amjevita(CF)
adalimumab-atto	Amjevita(CF) Autoinjector
adalimumab-bwwd	Hadlima
adalimumab-bwwd	Hadlima PushTouch
adalimumab-bwwd	Hadlima(CF)
adalimumab-bwwd	Hadlima(CF) PushTouch
adalimumab-fkjp	Hulio(CF)
adalimumab-fkjp	Hulio(CF) Pen
adalimumab-fkjp	adalimumab-fkjp
<b>Certolizumab</b>	
certolizumab pegol	Cimzia
certolizumab pegol	Cimzia Powder for Reconst
certolizumab pegol	Cimzia Starter Kit
<b>Golimumab</b>	
golimumab	Simponi
golimumab	Simponi ARIA
<b>Ustekinumab</b>	
ustekinumab	Stelara
<b>Risankizumab</b>	
risankizumab-rzaa	Skyrizi
<b>Mirikizumab</b>	
mirikizumab-mrkz	OmvoH
mirikizumab-mrkz	OmvoH Pen
<b>Ozanimod</b>	
ozanimod hydrochloride	Zeposia
ozanimod hydrochloride	Zeposia Starter Kit (28-day)
ozanimod hydrochloride	Zeposia Starter Kit (37-day)
ozanimod hydrochloride	Zeposia Starter Pack (7-day)
<b>Etrasimod</b>	
etrasimod arginine	Velsipity
<b>Tofacitinib</b>	
tofacitinib citrate	Xeljanz
tofacitinib citrate	Xeljanz XR
<b>Upadacitinib</b>	
upadacitinib	Rinvoq

**Appendix D. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapy Exposures in this Request**

Code	Description	Code Category	Code Type
<b>Infliximab</b>			
J1745	Injection, infliximab, excludes biosimilar, 10 mg	Procedure	HCPCS
Q5102	Injection, infliximab, biosimilar, 10 mg	Procedure	HCPCS
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg	Procedure	HCPCS
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg	Procedure	HCPCS
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg	Procedure	HCPCS
Q5121	Injection, infliximab-axxq, biosimilar, (AVSOLA), 10 mg	Procedure	HCPCS
<b>Adalimumab</b>			
J0135	Injection, adalimumab, 20 mg	Procedure	HCPCS
Q5131	Injection, adalimumab-aacf (Idacio), biosimilar, 20 mg	Procedure	HCPCS
<b>Certolizumab</b>			
C9249	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
J0717	Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J0718	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
<b>Golimumab</b>			
J1602	Injection, golimumab, 1 mg, for intravenous use	Procedure	HCPCS
<b>Ustekinumab</b>			
C9261	Injection, ustekinumab, 1 mg	Procedure	HCPCS
C9487	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
J3357	Ustekinumab, for subcutaneous injection, 1 mg	Procedure	HCPCS
J3358	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
Q9989	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
<b>Risankizumab</b>			
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg	Procedure	HCPCS

**Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request**

Code	Description	Code Category	Code Type
<b>Interstitial Lung Disease</b>			
515	Postinflammatory pulmonary fibrosis	Diagnosis	ICD-9-CM
516.30	Idiopathic interstitial pneumonia, not otherwise specified	Diagnosis	ICD-9-CM
516.31	Idiopathic pulmonary fibrosis	Diagnosis	ICD-9-CM
516.32	Idiopathic non-specific interstitial pneumonitis	Diagnosis	ICD-9-CM
516.33	Acute interstitial pneumonitis	Diagnosis	ICD-9-CM
516.34	Respiratory bronchiolitis interstitial lung disease	Diagnosis	ICD-9-CM
516.35	Idiopathic lymphoid interstitial pneumonia	Diagnosis	ICD-9-CM
516.36	Cryptogenic organizing pneumonia	Diagnosis	ICD-9-CM
516.37	Desquamative interstitial pneumonia	Diagnosis	ICD-9-CM
516.8	Other specified alveolar and parietoalveolar pneumonopathies	Diagnosis	ICD-9-CM
516.9	Unspecified alveolar and parietoalveolar pneumonopathy	Diagnosis	ICD-9-CM
J80	Acute respiratory distress syndrome	Diagnosis	ICD-10-CM
J84	Other interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.1	Other interstitial pulmonary diseases with fibrosis	Diagnosis	ICD-10-CM
J84.10	Pulmonary fibrosis, unspecified	Diagnosis	ICD-10-CM
J84.11	Idiopathic interstitial pneumonia	Diagnosis	ICD-10-CM
J84.111	Idiopathic interstitial pneumonia, not otherwise specified	Diagnosis	ICD-10-CM
J84.112	Idiopathic pulmonary fibrosis	Diagnosis	ICD-10-CM
J84.113	Idiopathic non-specific interstitial pneumonitis	Diagnosis	ICD-10-CM
J84.114	Acute interstitial pneumonitis	Diagnosis	ICD-10-CM
J84.115	Respiratory bronchiolitis interstitial lung disease	Diagnosis	ICD-10-CM
J84.116	Cryptogenic organizing pneumonia	Diagnosis	ICD-10-CM
J84.117	Desquamative interstitial pneumonia	Diagnosis	ICD-10-CM
J84.17	Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere	Diagnosis	ICD-10-CM
J84.2	Lymphoid interstitial pneumonia	Diagnosis	ICD-10-CM
J84.8	Other specified interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.89	Other specified interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.9	Interstitial pulmonary disease, unspecified	Diagnosis	ICD-10-CM

**Appendix F. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Vedolizumab and Natalizumab as Exclusion Criteria in this Request**

Non-Proprietary Name	Proprietary Name
Vedolizumab	
vedolizumab	Entyvio
vedolizumab	Entyvio Pen
Natalizumab	
natalizumab	Tysabri



**Appendix G. List of Current Procedural Terminology, Fourth Edition (CPT-4) and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Vedolizumab and Natalizumab as Exclusion Criteria in this Request**

Code	Description	Code Category	Code Type
<b>Vedolizumab</b>			
80280	Vedolizumab antibody assay	Procedure	CPT-4
C9026	Injection, vedolizumab, 1 mg	Procedure	HCPCS
J3380	Injection, vedolizumab, 1 mg	Procedure	HCPCS
<b>Natalizumab</b>			
C9126	Injection natalizumab per 5 mg	Procedure	HCPCS
J2323	Injection, natalizumab, 1 mg	Procedure	HCPCS
Q4079	Injection, natalizumab, 1 mg	Procedure	HCPCS

**Appendix H. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapies as Inclusion Criteria in this Request**

Non-Proprietary Name	Proprietary Name
<b>Infliximab</b>	
infliximab	Remicade
infliximab	infliximab
infliximab-abda	Renflexis
infliximab-axxq	Avsola
infliximab-dyyb	Inflectra
<b>Adalimumab</b>	
adalimumab	Humira
adalimumab	Humira Pediatric Crohns Start
adalimumab	Humira Pen
adalimumab	Humira Pen Crohns-UC-HS Start
adalimumab	Humira Pen Psor-Uveits-Adol HS
adalimumab	Humira(CF)
adalimumab	Humira(CF) Pedi Crohns Starter
adalimumab	Humira(CF) Pen
adalimumab	Humira(CF) Pen Crohns-UC-HS
adalimumab	Humira(CF) Pen Pediatric UC
adalimumab	Humira(CF) Pen Psor-Uv-Adol HS
adalimumab-aacf	Idacio(CF)
adalimumab-aacf	Idacio(CF) Pen
adalimumab-aacf	Idacio(CF) Pen Crohn-UC Startr
adalimumab-aacf	Idacio(CF) Pen Psoriasis Start
adalimumab-aaty	Yuflyma(CF)
adalimumab-aaty	Yuflyma(CF) Autoinjector
adalimumab-adaz	Hyrimoz
adalimumab-adaz	Hyrimoz Pen
adalimumab-adaz	Hyrimoz Pen Crohn's-UC Starter
adalimumab-adaz	Hyrimoz Pen Psoriasis Starter
adalimumab-adaz	Hyrimoz(CF)
adalimumab-adaz	Hyrimoz(CF) Pedi Crohn Starter
adalimumab-adaz	Hyrimoz(CF) Pen
adalimumab-adaz	adalimumab-adaz
adalimumab-adbm	Cyltezo(CF)
adalimumab-adbm	Cyltezo(CF) Pen
adalimumab-adbm	Cyltezo(CF) Pen Crohn's-UC-HS
adalimumab-adbm	Cyltezo(CF) Pen Psoriasis-UV
adalimumab-adbm	adalimumab-adbm
adalimumab-adbm	adalimumab-adbm(CF) pen Crohns
adalimumab-adbm	adalimumab-adbm(CF) pen PS-UV
adalimumab-afzb	Abrilada(CF)
adalimumab-afzb	Abrilada(CF) Pen

**Appendix H. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapies as Inclusion Criteria in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
adalimumab-aqvh	Yusimry(CF) Pen
adalimumab-atto	Amjevita(CF)
adalimumab-atto	Amjevita(CF) Autoinjector
adalimumab-bwwd	Hadlima
adalimumab-bwwd	Hadlima PushTouch
adalimumab-bwwd	Hadlima(CF)
adalimumab-bwwd	Hadlima(CF) PushTouch
adalimumab-fkjp	Hulio(CF)
adalimumab-fkjp	Hulio(CF) Pen
adalimumab-fkjp	adalimumab-fkjp
<b>Certolizumab</b>	
certolizumab pegol	Cimzia
certolizumab pegol	Cimzia Powder for Reconst
certolizumab pegol	Cimzia Starter Kit
<b>Golimumab</b>	
golimumab	Simponi
golimumab	Simponi ARIA
<b>Ustekinumab</b>	
ustekinumab	Stelara
<b>Risankizumab</b>	
risankizumab-rzaa	Skyrizi
<b>Mirikizumab</b>	
mirikizumab-mrkz	OmvoH
mirikizumab-mrkz	OmvoH Pen
<b>Ozanimod</b>	
ozanimod hydrochloride	Zeposia
ozanimod hydrochloride	Zeposia Starter Kit (28-day)
ozanimod hydrochloride	Zeposia Starter Kit (37-day)
ozanimod hydrochloride	Zeposia Starter Pack (7-day)
<b>Etrasimod</b>	
etrasimod arginine	Velsipity
<b>Tofacitinib</b>	
tofacitinib citrate	Xeljanz
tofacitinib citrate	Xeljanz XR
<b>Upadacitinib</b>	
upadacitinib	Rinvoq

**Appendix I. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Advanced Inflammatory Bowel Disease (IBD) Therapies as Inclusion Criteria in this Request**

Code	Description	Code Category	Code Type
<b>Infliximab</b>			
J1745	Injection, infliximab, excludes biosimilar, 10 mg	Procedure	HCPCS
Q5102	Injection, infliximab, biosimilar, 10 mg	Procedure	HCPCS
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg	Procedure	HCPCS
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg	Procedure	HCPCS
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg	Procedure	HCPCS
Q5121	Injection, infliximab-axxq, biosimilar, (AVSOLA), 10 mg	Procedure	HCPCS
<b>Adalimumab</b>			
J0135	Injection, adalimumab, 20 mg	Procedure	HCPCS
Q5131	Injection, adalimumab-aacf (Idacio), biosimilar, 20 mg	Procedure	HCPCS
<b>Certolizumab</b>			
C9249	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
J0717	Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J0718	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
<b>Golimumab</b>			
J1602	Injection, golimumab, 1 mg, for intravenous use	Procedure	HCPCS
<b>Ustekinumab</b>			
C9261	Injection, ustekinumab, 1 mg	Procedure	HCPCS
C9487	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
J3357	Ustekinumab, for subcutaneous injection, 1 mg	Procedure	HCPCS
J3358	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
Q9989	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
<b>Risankizumab</b>			
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg	Procedure	HCPCS

**Appendix J. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Other Inflammatory Bowel Disease (IBD) and Cancer Immunotherapy-Related Exclusion Criteria for this Request**

Non-Proprietary Name	Proprietary Name
<b>Methotrexate</b>	
methotrexate	Xatmep
methotrexate sodium	Methotrexate (Anti-Rheumatic)
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	Methotrexate LPF
methotrexate sodium/PF	methotrexate sodium (PF)
methotrexate/PF	Otrexup (PF)
methotrexate/PF	Rasuvo (PF)
methotrexate/PF	RediTrex (PF)
<b>Amiodarone</b>	
amiodarone HCl	Cordarone
amiodarone HCl	Cordarone IV
amiodarone HCl	Pacerone
amiodarone HCl	amiodarone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
<b>Bleomycin</b>	
bleomycin sulfate	Blenoxane
bleomycin sulfate	Bleo 15K
bleomycin sulfate	bleomycin
<b>Azathioprine</b>	
azathioprine	Azasan
azathioprine	Imuran
azathioprine	azathioprine
azathioprine sodium	azathioprine sodium
<b>Cyclophosphamide</b>	
cyclophosphamide	Cytosan
cyclophosphamide	Neosar
cyclophosphamide	cyclophosphamide
<b>Sulfasalazine</b>	
sulfasalazine	Azulfidine
sulfasalazine	Azulfidine EN-tabs
sulfasalazine	Sulfazine
sulfasalazine	sulfasalazine
<b>Tyrosine Kinase Inhibitors</b>	
acalabrutinib	Calquence
acalabrutinib maleate	Calquence (acalabrutinib mal)
afatinib dimaleate	Gilotrif
alectinib HCl	Alecensa

**Appendix J. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Other Inflammatory Bowel Disease (IBD) and Cancer Immunotherapy-Related Exclusion Criteria for this Request**

Non-Proprietary Name	Proprietary Name
asciminib hydrochloride	Scemblix
avapritinib	Ayvakit
axitinib	Inlyta
bosutinib	Bosulif
brigatinib	Alunbrig
capmatinib hydrochloride	Tabrecta
ceritinib	Zykadia
crizotinib	Xalkori
dacomitinib	Vizimpro
dasatinib	Sprycel
deucravacitinib	Sotyktu
entrectinib	Rozlytrek
erdafitinib	Balversa
erlotinib HCl	Tarceva
erlotinib HCl	erlotinib
fedratinib dihydrochloride	Inrebic
fostamatinib disodium	Tavalisse
futibatinib	Lytgobi
gefitinib	Iressa
gefitinib	gefitinib
gilteritinib fumarate	Xospata
ibrutinib	Imbruvica
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
infigratinib phosphate	Truseltiq
lapatinib ditosylate	Tykerb
lapatinib ditosylate	lapatinib
larotrectinib sulfate	Vittrakvi
lenvatinib mesylate	Lenvima
lorlatinib	Lorbrena
midostaurin	Rydapt
mobocertinib succinate	Exkivity
neratinib maleate	Nerlynx
nilotinib HCl	Tasigna
nintedanib esylate	Ofev
osimertinib mesylate	Tagrisso
pacritinib citrate	Vonjo
pazopanib HCl	Votrient
pazopanib HCl	pazopanib
pemigatinib	Pemazyre
pexidartinib hydrochloride	Turalio

**Appendix J. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Other Inflammatory Bowel Disease (IBD) and Cancer Immunotherapy-Related Exclusion Criteria for this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
pirtobrutinib	Jaypirca
pralsetinib	Gavreto
quizartinib dihydrochloride	Vanflyta
ripretinib	Qinlock
selpercatinib	Retevmo
sunitinib malate	Sutent
sunitinib malate	sunitinib malate
tepotinib HCl	Tepmetko
tivozanib HCl	Fotivda
tucatinib	Tukysa
vandetanib	Caprelsa
vandetanib	vandetanib
zanubrutinib	Brukinsa
<b>Atezolizumab</b>	
atezolizumab	Tecentriq
<b>Durvalumab</b>	
durvalumab	Imfinzi
<b>Avelumab</b>	
avelumab	Bavencio
<b>Cemiplimab</b>	
cemiplimab-rwlc	Libtayo
<b>Dostarlimab</b>	
dostarlimab-gxly	Jemperli
<b>Ipilimumab</b>	
ipilimumab	Yervoy
<b>Nivolumab</b>	
nivolumab	Opdivo
nivolumab-relatlimab-rmbw	Opdualag
<b>Pembrolizumab</b>	
pembrolizumab	Keytruda
<b>Tremelimumab</b>	
tremelimumab-actl	Imjudo
<b>Retifanlimab</b>	
retifanlimab-dlwr	Zynyz

**Appendix K. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Other Inflammatory Bowel Disease (IBD) and Cancer Immunotherapy-Related Exclusion Criteria for this Request**

Code	Description	Code Category	Code Type
<b>Methotrexate</b>			
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
<b>Amiodarone</b>			
J0282	Injection, amiodarone HCl, 30 mg	Procedure	HCPCS
J0283	Injection, amiodarone HCl (Nexterone), 30 mg	Procedure	HCPCS
<b>Bleomycin</b>			
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
<b>Azathioprine</b>			
C9436	Azathioprine, parenteral, brand name, per 100 mg	Procedure	HCPCS
J7500	Azathioprine, oral, 50 mg	Procedure	HCPCS
J7501	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
<b>Cyclophosphamide</b>			
C9087	Injection, cyclophosphamide, (AuroMedics), 10 mg	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9071	Injection, cyclophosphamide, (AuroMedics), 5 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS
<b>Tyrosine Kinase Inhibitors</b>			
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS
<b>Atezolizumab</b>			
C9483	Injection, atezolizumab, 10 mg	Procedure	HCPCS
J9022	Injection, atezolizumab, 10 mg	Procedure	HCPCS
XW033D6	Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous	Procedure	ICD-10-PCS
XW043D6	Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous	Procedure	ICD-10-PCS



**Appendix K. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Other Inflammatory Bowel Disease (IBD) and Cancer Immunotherapy-Related Exclusion Criteria for this Request**

Code	Description	Code Category	Code Type
<b>Durvalumab</b>			
C9492	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
XW03336	Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous	Procedure	ICD-10-PCS
XW04336	Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous	Procedure	ICD-10-PCS
<b>Avelumab</b>			
C9491	Injection, avelumab, 10 mg	Procedure	HCPCS
J9023	Injection, avelumab, 10 mg	Procedure	HCPCS
<b>Cemiplimab</b>			
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
J9119	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
<b>Dostarlimab</b>			
C9082	Injection, dostarlimab-gxly, 100 mg	Procedure	HCPCS
J9272	Injection, dostarlimab-gxly, 10 mg	Procedure	HCPCS
<b>Ipilimumab</b>			
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
<b>Nivolumab</b>			
C9453	Injection, nivolumab, 1 mg	Procedure	HCPCS
J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg	Procedure	HCPCS
J9299	Injection, nivolumab, 1 mg	Procedure	HCPCS
<b>Pembrolizumab</b>			
C9027	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
J9271	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
<b>Tremelimumab</b>			
C9147	Injection, tremelimumab-actl, 1 mg	Procedure	HCPCS
J9347	Injection, tremelimumab-actl, 1 mg	Procedure	HCPCS

**Appendix K.1. Half-Life Information for Other Inflammatory Bowel Disease (IBD) Therapies and Cancer Immunotherapies Used as Exclusion Criteria**

Drug	Half-Life	Approximation of Five Times the Half-Life (Days)	Five Times the Half-Life (Rounded Up to Next Integer) (Days)
IBD therapy			
Methotrexate	Low dose: 3-10 hours High dose: 8-15 hours	3.1	4
Amiodarone	142 days	710.0	710
Bleomycin	1 day	5.0	5
Azathioprine	5 hours	1.0	1
Cyclophosphamide	12 hours	2.5	3
Sulfasalazine	14.8 hours	3.1	4
Checkpoint inhibitors			
Ipilimumab	15.4 days	77.0	77
Tremelimumab	18.2 days	91.0	91
Nivolumab	26.7 days	133.5	134
Pembrolizumab	22 days	110.0	110
Cemiplimab	22 days	110.0	110
Dostarlimab	23.5 days	117.5	118
Retifanlimab	19 days	95.0	95
Atezolizumab	27 days	135.0	135
Durvalumab	21 days	105.0	105
Avelumab	6.1 days	30.5	31
Tyrosine kinase inhibitors*	4.5 days	22.5	23

\* Includes selpercatinib, pirtobrutinib, dasatinib, deucravacitinib, imatinib, bosutinib, axitinib, dacomitinib, lorlatinib, sunitinib, crizotinib, nilotinib, ceritinib, pazopanib, lapatinib, midostaurin, capmatinib, asciminib, erlotinib, gefitinib, acalabrutinib, osimertinib, vandetanib, gilteritinib, afatinib, nintedanib, tepotinib, tivozanib, entrectinib, alectinib, pralsetinib, larotrectinib, pemigatinib, tucatinib, ibrutinib, fedratinib, erdafitinib, lenvatinib, mobocertinib, brigatinib, futibatinib, pexidartinib, quizartinib, neratinib, fostamatinib, avapritinib, pacritinib, zanubrutinib, infigratinib, and ripretinib

**Appendix L. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Vedolizumab, Natalizumab, Other Inflammatory Bowel Disease (IBD) Therapies, and Cancer Immunotherapies as Censoring Criteria in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
<b>Vedolizumab</b>	
vedolizumab	Entyvio
vedolizumab	Entyvio Pen
<b>Natalizumab</b>	
natalizumab	Tysabri
<b>Methotrexate</b>	
methotrexate	Xatmep
methotrexate sodium	Methotrexate (Anti-Rheumatic)
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	Methotrexate LPF
methotrexate sodium/PF	methotrexate sodium (PF)
methotrexate/PF	Otrexup (PF)
methotrexate/PF	Rasuvo (PF)
methotrexate/PF	RediTrex (PF)
<b>Amiodarone</b>	
amiodarone HCl	Cordarone
amiodarone HCl	Cordarone IV
amiodarone HCl	Pacerone
amiodarone HCl	amiodarone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
<b>Bleomycin</b>	
bleomycin sulfate	Blenoxane
bleomycin sulfate	Bleo 15K
bleomycin sulfate	bleomycin
<b>Azathioprine</b>	
azathioprine	Azasan
azathioprine	Imuran
azathioprine	azathioprine
azathioprine sodium	azathioprine sodium
<b>Cyclophosphamide</b>	
cyclophosphamide	Cytoxan
cyclophosphamide	Neosar
cyclophosphamide	cyclophosphamide
<b>Sulfasalazine</b>	
sulfasalazine	Azulfidine
sulfasalazine	Azulfidine EN-tabs
sulfasalazine	Sulfazine
sulfasalazine	sulfasalazine

**Appendix L. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Vedolizumab, Natalizumab, Other Inflammatory Bowel Disease (IBD) Therapies, and Cancer Immunotherapies as Censoring Criteria in this Request**

Non-Proprietary Name	Proprietary Name
<b>Checkpoint Inhibitors</b>	
atezolizumab	Tecentriq
avelumab	Bavencio
cemiplimab-rwlc	Libtayo
dostarlimab-gxly	Jemperli
durvalumab	Imfinzi
ipilimumab	Yervoy
nivolumab	Opdivo
nivolumab-relatlimab-rmbw	Opdualag
pembrolizumab	Keytruda
retifanlimab-dlwr	Zynyz
tremelimumab-actl	Imjudo
<b>Tyrosine Kinase Inhibitors</b>	
acalabrutinib	Calquence
acalabrutinib maleate	Calquence (acalabrutinib mal)
afatinib dimaleate	Gilotrif
alectinib HCl	Alecensa
asciminib hydrochloride	Scemblix
avapritinib	Ayvakit
axitinib	Inlyta
bosutinib	Bosulif
brigatinib	Alunbrig
capmatinib hydrochloride	Tabrecta
ceritinib	Zykadia
crizotinib	Xalkori
dacomitinib	Vizimpro
dasatinib	Sprycel
deucravacitinib	Sotyktu
entrectinib	Rozlytrek
erdafitinib	Balversa
erlotinib HCl	Tarceva
erlotinib HCl	erlotinib
fedratinib dihydrochloride	Inrebic
fostamatinib disodium	Tavalisse
futibatinib	Lytgobi
gefitinib	Iressa
gefitinib	gefitinib
gilteritinib fumarate	Xospata
ibrutinib	Imbruvica
imatinib mesylate	Gleevec
imatinib mesylate	imatinib

**Appendix L. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Vedolizumab, Natalizumab, Other Inflammatory Bowel Disease (IBD) Therapies, and Cancer Immunotherapies as Censoring Criteria in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
infigratinib phosphate	Truseltiq
lapatinib ditosylate	Tykerb
lapatinib ditosylate	lapatinib
larotrectinib sulfate	Vitrakvi
lenvatinib mesylate	Lenvima
lorlatinib	Lorbrena
midostaurin	Rydapt
mobocertinib succinate	Exkivity
neratinib maleate	Nerlynx
nilotinib HCl	Tasigna
nintedanib esylate	Ofev
osimertinib mesylate	Tagrisso
pacritinib citrate	Vonjo
pazopanib HCl	Votrient
pazopanib HCl	pazopanib
pemigatinib	Pemazyre
pexidartinib hydrochloride	Turalio
pirtobrutinib	Jaypirca
pralsetinib	Gavreto
quizartinib dihydrochloride	Vanflyta
ripretinib	Qinlock
selpercatinib	Retevmo
sunitinib malate	Sutent
sunitinib malate	sunitinib malate
tepotinib HCl	Tepmetko
tivozanib HCl	Fotivda
tucatinib	Tukysa
vandetanib	Caprelsa
vandetanib	vandetanib
zanubrutinib	Brukinsa

**Appendix M. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Vedolizumab, Natalizumab, Other Inflammatory Bowel Disease (IBD) Therapies, and Cancer Immunotherapies as Censoring Criteria in this Request**

Code	Description	Code Category	Code Type
<b>Vedolizumab</b>			
80280	Vedolizumab antibody assay	Procedure	CPT-4
C9026	Injection, vedolizumab, 1 mg	Procedure	HCPCS
J3380	Injection, vedolizumab, 1 mg	Procedure	HCPCS
<b>Natalizumab</b>			
C9126	Injection natalizumab per 5 mg	Procedure	HCPCS
J2323	Injection, natalizumab, 1 mg	Procedure	HCPCS
Q4079	Injection, natalizumab, 1 mg	Procedure	HCPCS
<b>Methotrexate</b>			
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
<b>Amiodarone</b>			
J0282	Injection, amiodarone HCl, 30 mg	Procedure	HCPCS
J0283	Injection, amiodarone HCl (Nexterone), 30 mg	Procedure	HCPCS
<b>Bleomycin</b>			
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
<b>Azathioprine</b>			
C9436	Azathioprine, parenteral, brand name, per 100 mg	Procedure	HCPCS
J7500	Azathioprine, oral, 50 mg	Procedure	HCPCS
J7501	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
<b>Cyclophosphamide</b>			
C9087	Injection, cyclophosphamide, (AuroMedics), 10 mg	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9071	Injection, cyclophosphamide, (AuroMedics), 5 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS

**Appendix M. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Vedolizumab, Natalizumab, Other Inflammatory Bowel Disease (IBD) Therapies, and Cancer Immunotherapies as Censoring Criteria in this Request**

Code	Description	Code Category	Code Type
<b>Checkpoint Inhibitors</b>			
C9027	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
C9082	Injection, dostarlimab-gxly, 100 mg	Procedure	HCPCS
C9147	Injection, tremelimumab-actl, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9453	Injection, nivolumab, 1 mg	Procedure	HCPCS
C9483	Injection, atezolizumab, 10 mg	Procedure	HCPCS
C9491	Injection, avelumab, 10 mg	Procedure	HCPCS
C9492	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9022	Injection, atezolizumab, 10 mg	Procedure	HCPCS
J9023	Injection, avelumab, 10 mg	Procedure	HCPCS
J9119	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9271	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
J9272	Injection, dostarlimab-gxly, 10 mg	Procedure	HCPCS
J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg	Procedure	HCPCS
J9299	Injection, nivolumab, 1 mg	Procedure	HCPCS
J9345	Injection, retifanlimab-dlwr, 1 mg	Procedure	HCPCS
J9347	Injection, tremelimumab-actl, 1 mg	Procedure	HCPCS
XW03336	Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW033D6	Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW04336	Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW043D6	Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
<b>Tyrosine Kinase Inhibitors</b>			
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS

**Appendix N. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request**

Non-Proprietary Name	Proprietary Name
<b>Methotrexate</b>	
methotrexate	Xatmep
methotrexate sodium	Methotrexate (Anti-Rheumatic)
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	Methotrexate LPF
methotrexate sodium/PF	methotrexate sodium (PF)
methotrexate/PF	Otrexup (PF)
methotrexate/PF	Rasuvo (PF)
methotrexate/PF	RediTrex (PF)
<b>Amiodarone</b>	
amiodarone HCl	Cordarone
amiodarone HCl	Cordarone IV
amiodarone HCl	Pacerone
amiodarone HCl	amiodarone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
<b>Bleomycin</b>	
bleomycin sulfate	Blenoxane
bleomycin sulfate	Bleo 15K
bleomycin sulfate	bleomycin
<b>Azathioprine</b>	
azathioprine	Azasan
azathioprine	Imuran
azathioprine	azathioprine
azathioprine sodium	azathioprine sodium
<b>Cyclophosphamide</b>	
cyclophosphamide	Cytosan
cyclophosphamide	Neosar
cyclophosphamide	cyclophosphamide
<b>Sulfasalazine</b>	
sulfasalazine	Azulfidine
sulfasalazine	Azulfidine EN-tabs
sulfasalazine	Sulfazine
sulfasalazine	sulfasalazine
<b>Checkpoint Inhibitors</b>	
atezolizumab	Tecentriq
avelumab	Bavencio
cemiplimab-rwlc	Libtayo
dostarlimab-gxly	Jemperli



**Appendix N. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request**

Non-Proprietary Name	Proprietary Name
durvalumab	Imfinzi
ipilimumab	Yervoy
nivolumab	Opdivo
nivolumab-relatlimab-rmbw	Opdualag
pembrolizumab	Keytruda
retifanlimab-dlwr	Zynyz
tremelimumab-actl	Imjudo
Tyrosine Kinase Inhibitors	
acalabrutinib	Calquence
acalabrutinib maleate	Calquence (acalabrutinib mal)
afatinib dimaleate	Gilotrif
alectinib HCl	Alecensa
asciminib hydrochloride	Scemblix
avapritinib	Ayvakit
axitinib	Inlyta
bosutinib	Bosulif
brigatinib	Alunbrig
capmatinib hydrochloride	Tabrecta
ceritinib	Zykadia
crizotinib	Xalkori
dacomitinib	Vizimpro
dasatinib	Sprycel
deucravacitinib	Sotyktu
entrectinib	Rozlytrek
erdafitinib	Balversa
erlotinib HCl	Tarceva
erlotinib HCl	erlotinib
fedratinib dihydrochloride	Inrebic
fostamatinib disodium	Tavalisse
futibatinib	Lytgobi
gefitinib	Iressa
gefitinib	gefitinib
gilteritinib fumarate	Xospata
ibrutinib	Imbruvica
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
infigratinib phosphate	Truseltiq
lapatinib ditosylate	Tykerb
lapatinib ditosylate	lapatinib
larotrectinib sulfate	Vitrakvi
lenvatinib mesylate	Lenvima

**Appendix N. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request**

Non-Proprietary Name	Proprietary Name
lorlatinib	Lorbrena
midostaurin	Rydapt
mobocertinib succinate	Exkivity
neratinib maleate	Nerlynx
nilotinib HCl	Tasigna
nintedanib esylate	Ofev
osimertinib mesylate	Tagrisso
pacritinib citrate	Vonjo
pazopanib HCl	Votrient
pazopanib HCl	pazopanib
pemigatinib	Pemazyre
pexidartinib hydrochloride	Turalio
pirtobrutinib	Jaypirca
pralsetinib	Gavreto
quizartinib dihydrochloride	Vanflyta
ripretinib	Qinlock
selpercatinib	Retevmo
sunitinib malate	Sutent
sunitinib malate	sunitinib malate
tepotinib HCl	Tepmetko
tivozanib HCl	Fotivda
tucatinib	Tukysa
vandetanib	Caprelsa
vandetanib	vandetanib
zanubrutinib	Brukina
Tobacco Use	
bupropion HCl	Buproban
bupropion HCl	Zyban
bupropion HCl	bupropion HCl (smoking deter)
nicotine	Habitrol
nicotine	NTS Step 1
nicotine	NTS Step 2
nicotine	NTS Step 3
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine polacrilex	Commit
nicotine polacrilex	Nicorelief
nicotine polacrilex	Nicorette
nicotine polacrilex	Nicorette Refill

**Appendix N. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request**

Non-Proprietary Name	Proprietary Name
nicotine polacrilex	Nicorette Starter Kit
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	Thrive Nicotine
nicotine polacrilex	nicotine (polacrilex)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Continuing Month Pak
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Chantix Starting Month Pak
varenicline tartrate	varenicline

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
<b>Systemic Sclerosis</b>			
359.6	Symptomatic inflammatory myopathy in diseases classified elsewhere	Diagnosis	ICD-9-CM
517.2	Lung involvement in systemic sclerosis	Diagnosis	ICD-9-CM
701.0	Circumscribed scleroderma	Diagnosis	ICD-9-CM
710.1	Systemic sclerosis	Diagnosis	ICD-9-CM
L94.0	Localized scleroderma [morphea]	Diagnosis	ICD-10-CM
L94.1	Linear scleroderma	Diagnosis	ICD-10-CM
M34	Systemic sclerosis [scleroderma]	Diagnosis	ICD-10-CM
M34.0	Progressive systemic sclerosis	Diagnosis	ICD-10-CM
M34.1	CR(E)ST syndrome	Diagnosis	ICD-10-CM
M34.2	Systemic sclerosis induced by drug and chemical	Diagnosis	ICD-10-CM
M34.8	Other forms of systemic sclerosis	Diagnosis	ICD-10-CM
M34.81	Systemic sclerosis with lung involvement	Diagnosis	ICD-10-CM
M34.82	Systemic sclerosis with myopathy	Diagnosis	ICD-10-CM
M34.83	Systemic sclerosis with polyneuropathy	Diagnosis	ICD-10-CM
M34.89	Other systemic sclerosis	Diagnosis	ICD-10-CM
M34.9	Systemic sclerosis, unspecified	Diagnosis	ICD-10-CM
<b>Rheumatoid Arthritis</b>			
359.6	Symptomatic inflammatory myopathy in diseases classified elsewhere	Diagnosis	ICD-9-CM
714	Rheumatoid arthritis and other inflammatory polyarthropathies	Diagnosis	ICD-9-CM
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.81	Rheumatoid lung	Diagnosis	ICD-9-CM
M05	Rheumatoid arthritis with rheumatoid factor	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.1	Rheumatoid lung disease with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.11	Rheumatoid lung disease with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.12	Rheumatoid lung disease with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.13	Rheumatoid lung disease with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.14	Rheumatoid lung disease with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.15	Rheumatoid lung disease with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.16	Rheumatoid lung disease with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.17	Rheumatoid lung disease with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.2	Rheumatoid vasculitis with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.21	Rheumatoid vasculitis with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.22	Rheumatoid vasculitis with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.23	Rheumatoid vasculitis with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.24	Rheumatoid vasculitis with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.25	Rheumatoid vasculitis with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.26	Rheumatoid vasculitis with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.27	Rheumatoid vasculitis with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.3	Rheumatoid heart disease with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.31	Rheumatoid heart disease with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.32	Rheumatoid heart disease with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.33	Rheumatoid heart disease with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.34	Rheumatoid heart disease with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.35	Rheumatoid heart disease with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.36	Rheumatoid heart disease with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.37	Rheumatoid heart disease with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.4	Rheumatoid myopathy with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.41	Rheumatoid myopathy with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.42	Rheumatoid myopathy with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.43	Rheumatoid myopathy with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.44	Rheumatoid myopathy with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.45	Rheumatoid myopathy with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.46	Rheumatoid myopathy with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.47	Rheumatoid myopathy with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.5	Rheumatoid polyneuropathy with rheumatoid arthritis	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.51	Rheumatoid polyneuropathy with rheumatoid arthritis of shoulder	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.52	Rheumatoid polyneuropathy with rheumatoid arthritis of elbow	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.53	Rheumatoid polyneuropathy with rheumatoid arthritis of wrist	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.54	Rheumatoid polyneuropathy with rheumatoid arthritis of hand	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.55	Rheumatoid polyneuropathy with rheumatoid arthritis of hip	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.56	Rheumatoid polyneuropathy with rheumatoid arthritis of knee	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.57	Rheumatoid polyneuropathy with rheumatoid arthritis of ankle and foot	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.6	Rheumatoid arthritis with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.61	Rheumatoid arthritis of shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.62	Rheumatoid arthritis of elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.63	Rheumatoid arthritis of wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.64	Rheumatoid arthritis of hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.65	Rheumatoid arthritis of hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.66	Rheumatoid arthritis of knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.67	Rheumatoid arthritis of ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.7	Rheumatoid arthritis with rheumatoid factor without organ or systems involvement	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.71	Rheumatoid arthritis with rheumatoid factor of shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.72	Rheumatoid arthritis with rheumatoid factor of elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.73	Rheumatoid arthritis with rheumatoid factor of wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.74	Rheumatoid arthritis with rheumatoid factor of hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.75	Rheumatoid arthritis with rheumatoid factor of hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.76	Rheumatoid arthritis with rheumatoid factor of knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.77	Rheumatoid arthritis with rheumatoid factor of ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.8	Other rheumatoid arthritis with rheumatoid factor	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.81	Other rheumatoid arthritis with rheumatoid factor of shoulder	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.82	Other rheumatoid arthritis with rheumatoid factor of elbow	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.83	Other rheumatoid arthritis with rheumatoid factor of wrist	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.84	Other rheumatoid arthritis with rheumatoid factor of hand	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.85	Other rheumatoid arthritis with rheumatoid factor of hip	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.86	Other rheumatoid arthritis with rheumatoid factor of knee	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.87	Other rheumatoid arthritis with rheumatoid factor of ankle and foot	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06	Other rheumatoid arthritis	Diagnosis	ICD-10-CM
M06.0	Rheumatoid arthritis without rheumatoid factor	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.01	Rheumatoid arthritis without rheumatoid factor, shoulder	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.02	Rheumatoid arthritis without rheumatoid factor, elbow	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.03	Rheumatoid arthritis without rheumatoid factor, wrist	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.04	Rheumatoid arthritis without rheumatoid factor, hand	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.05	Rheumatoid arthritis without rheumatoid factor, hip	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.06	Rheumatoid arthritis without rheumatoid factor, knee	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.07	Rheumatoid arthritis without rheumatoid factor, ankle and foot	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.2	Rheumatoid bursitis	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.21	Rheumatoid bursitis, shoulder	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.22	Rheumatoid bursitis, elbow	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.23	Rheumatoid bursitis, wrist	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M06.24	Rheumatoid bursitis, hand	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.25	Rheumatoid bursitis, hip	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.26	Rheumatoid bursitis, knee	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.27	Rheumatoid bursitis, ankle and foot	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.3	Rheumatoid nodule	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.31	Rheumatoid nodule, shoulder	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.32	Rheumatoid nodule, elbow	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.33	Rheumatoid nodule, wrist	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.34	Rheumatoid nodule, hand	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M06.35	Rheumatoid nodule, hip	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.36	Rheumatoid nodule, knee	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.37	Rheumatoid nodule, ankle and foot	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.8	Other specified rheumatoid arthritis	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.81	Other specified rheumatoid arthritis, shoulder	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.82	Other specified rheumatoid arthritis, elbow	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.83	Other specified rheumatoid arthritis, wrist	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.84	Other specified rheumatoid arthritis, hand	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.85	Other specified rheumatoid arthritis, hip	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M06.86	Other specified rheumatoid arthritis, knee	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.87	Other specified rheumatoid arthritis, ankle and foot	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
<b>Dermatomyositis/Polymyositis</b>			
359.71	Inclusion body myositis	Diagnosis	ICD-9-CM
710.3	Dermatomyositis	Diagnosis	ICD-9-CM
710.4	Polymyositis	Diagnosis	ICD-9-CM
M33	Dermatopolymyositis	Diagnosis	ICD-10-CM
M33.1	Other dermatomyositis	Diagnosis	ICD-10-CM
M33.10	Other dermatomyositis, organ involvement unspecified	Diagnosis	ICD-10-CM
M33.11	Other dermatomyositis with respiratory involvement	Diagnosis	ICD-10-CM
M33.12	Other dermatomyositis with myopathy	Diagnosis	ICD-10-CM
M33.13	Other dermatomyositis without myopathy	Diagnosis	ICD-10-CM
M33.19	Other dermatomyositis with other organ involvement	Diagnosis	ICD-10-CM
M33.2	Polymyositis	Diagnosis	ICD-10-CM
M33.20	Polymyositis, organ involvement unspecified	Diagnosis	ICD-10-CM
M33.21	Polymyositis with respiratory involvement	Diagnosis	ICD-10-CM
M33.22	Polymyositis with myopathy	Diagnosis	ICD-10-CM
M33.29	Polymyositis with other organ involvement	Diagnosis	ICD-10-CM
M33.9	Dermatopolymyositis, unspecified	Diagnosis	ICD-10-CM
M33.90	Dermatopolymyositis, unspecified, organ involvement unspecified	Diagnosis	ICD-10-CM
M33.91	Dermatopolymyositis, unspecified with respiratory involvement	Diagnosis	ICD-10-CM
M33.92	Dermatopolymyositis, unspecified with myopathy	Diagnosis	ICD-10-CM
M33.93	Dermatopolymyositis, unspecified without myopathy	Diagnosis	ICD-10-CM
M33.99	Dermatopolymyositis, unspecified with other organ involvement	Diagnosis	ICD-10-CM
M36.0	Dermato(poly)myositis in neoplastic disease	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
<b>Anti-Synthetase Syndrome</b>			
359.79	Other inflammatory and immune myopathies, NEC	Diagnosis	ICD-9-CM
G72.4	Inflammatory and immune myopathies, not elsewhere classified	Diagnosis	ICD-10-CM
G72.49	Other inflammatory and immune myopathies, not elsewhere classified	Diagnosis	ICD-10-CM
<b>Methotrexate</b>			
80204	Methotrexate	Procedure	CPT-4
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
<b>Amiodarone</b>			
80151	amiodarone	Procedure	CPT-4
J0282	Injection, amiodarone HCl, 30 mg	Procedure	HCPCS
J0283	Injection, amiodarone HCl (Nexterone), 30 mg	Procedure	HCPCS
<b>Bleomycin</b>			
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
<b>Azathioprine</b>			
C9436	Azathioprine, parenteral, brand name, per 100 mg	Procedure	HCPCS
J7500	Azathioprine, oral, 50 mg	Procedure	HCPCS
J7501	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
<b>Cyclophosphamide</b>			
C9087	Injection, cyclophosphamide, (AuroMedics), 10 mg	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9071	Injection, cyclophosphamide, (AuroMedics), 5 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
<b>Checkpoint Inhibitors</b>			
C9027	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
C9082	Injection, dostarlimab-gxly, 100 mg	Procedure	HCPCS
C9147	Injection, tremelimumab-actl, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9453	Injection, nivolumab, 1 mg	Procedure	HCPCS
C9483	Injection, atezolizumab, 10 mg	Procedure	HCPCS
C9491	Injection, avelumab, 10 mg	Procedure	HCPCS
C9492	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9022	Injection, atezolizumab, 10 mg	Procedure	HCPCS
J9023	Injection, avelumab, 10 mg	Procedure	HCPCS
J9119	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9271	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
J9272	Injection, dostarlimab-gxly, 10 mg	Procedure	HCPCS
J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg	Procedure	HCPCS
J9299	Injection, nivolumab, 1 mg	Procedure	HCPCS
J9345	Injection, retifanlimab-dlwr, 1 mg	Procedure	HCPCS
J9347	Injection, tremelimumab-actl, 1 mg	Procedure	HCPCS
XW03336	Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW033D6	Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW04336	Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW043D6	Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
<b>Tyrosine Kinase Inhibitors</b>			
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS
<b>Tobacco Use</b>			
305.1	Nondependent tobacco use disorder	Diagnosis	ICD-9-CM
649.00	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care or not applicable	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
649.01	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
649.02	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
649.03	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication	Diagnosis	ICD-9-CM
649.04	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
989.84	Toxic effect of tobacco	Diagnosis	ICD-9-CM
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z72.0	Tobacco use	Diagnosis	ICD-10-CM
<b>Acquired Hypothyroidism</b>			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
<b>Acute Myocardial Infarction</b>			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
<b>Alzheimer's Disease</b>			
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
<b>Alzheimer's Disease and Related Disorders or Senile Dementia</b>			

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
<b>Anemia</b>			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
<b>Asthma</b>			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
<b>Atrial Fibrillation</b>			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
<b>Benign Prostatic Hyperplasia</b>			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
<b>Breast Cancer</b>			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
<b>Colorectal Cancer</b>			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
<b>Endometrial Cancer</b>			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
<b>Lung Cancer</b>			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
<b>Prostate Cancer</b>			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
<b>Cataract</b>			
366.01	Anterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.02	Posterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.03	Cortical, lamellar, or zonular cataract, nonsenile	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
366.04	Nuclear cataract, nonsenile	Diagnosis	ICD-9-CM
366.09	Other and combined forms of nonsenile cataract	Diagnosis	ICD-9-CM
366.10	Unspecified senile cataract	Diagnosis	ICD-9-CM
366.12	Incipient cataract	Diagnosis	ICD-9-CM
366.13	Anterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.14	Posterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.15	Cortical senile cataract	Diagnosis	ICD-9-CM
366.16	Nuclear sclerosis	Diagnosis	ICD-9-CM
366.17	Total or mature senile cataract	Diagnosis	ICD-9-CM
366.18	Hypermaturation senile cataract	Diagnosis	ICD-9-CM
366.19	Other and combined forms of senile cataract	Diagnosis	ICD-9-CM
366.20	Unspecified traumatic cataract	Diagnosis	ICD-9-CM
366.21	Localized traumatic opacities of cataract	Diagnosis	ICD-9-CM
366.22	Total traumatic cataract	Diagnosis	ICD-9-CM
366.23	Partially resolved traumatic cataract	Diagnosis	ICD-9-CM
366.30	Unspecified cataracta complicata	Diagnosis	ICD-9-CM
366.45	Toxic cataract	Diagnosis	ICD-9-CM
366.46	Cataract associated with radiation and other physical influences	Diagnosis	ICD-9-CM
366.50	Unspecified after-cataract	Diagnosis	ICD-9-CM
366.51	Soemmering's ring	Diagnosis	ICD-9-CM
366.52	Other after-cataract, not obscuring vision	Diagnosis	ICD-9-CM
366.53	After-cataract, obscuring vision	Diagnosis	ICD-9-CM
366.8	Other cataract	Diagnosis	ICD-9-CM
366.9	Unspecified cataract	Diagnosis	ICD-9-CM
379.26	Vitreous prolapse	Diagnosis	ICD-9-CM
379.31	Aphakia	Diagnosis	ICD-9-CM
379.39	Other disorders of lens	Diagnosis	ICD-9-CM
743.30	Unspecified congenital cataract	Diagnosis	ICD-9-CM
743.31	Congenital capsular and subcapsular cataract	Diagnosis	ICD-9-CM
743.32	Congenital cortical and zonular cataract	Diagnosis	ICD-9-CM
743.33	Congenital nuclear cataract	Diagnosis	ICD-9-CM
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.031	Anterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H25.032	Anterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.033	Anterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.039	Anterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.091	Other age-related incipient cataract, right eye	Diagnosis	ICD-10-CM
H25.092	Other age-related incipient cataract, left eye	Diagnosis	ICD-10-CM
H25.093	Other age-related incipient cataract, bilateral	Diagnosis	ICD-10-CM
H25.099	Other age-related incipient cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.10	Age-related nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.11	Age-related nuclear cataract, right eye	Diagnosis	ICD-10-CM
H25.12	Age-related nuclear cataract, left eye	Diagnosis	ICD-10-CM
H25.13	Age-related nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H25.20	Age-related cataract, morgagnian type, unspecified eye	Diagnosis	ICD-10-CM
H25.21	Age-related cataract, morgagnian type, right eye	Diagnosis	ICD-10-CM
H25.22	Age-related cataract, morgagnian type, left eye	Diagnosis	ICD-10-CM
H25.23	Age-related cataract, morgagnian type, bilateral	Diagnosis	ICD-10-CM
H25.811	Combined forms of age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.812	Combined forms of age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.813	Combined forms of age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.819	Combined forms of age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.89	Other age-related cataract	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye	Diagnosis	ICD-10-CM
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye	Diagnosis	ICD-10-CM
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral	Diagnosis	ICD-10-CM
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.031	Infantile and juvenile nuclear cataract, right eye	Diagnosis	ICD-10-CM
H26.032	Infantile and juvenile nuclear cataract, left eye	Diagnosis	ICD-10-CM
H26.033	Infantile and juvenile nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H26.039	Infantile and juvenile nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.062	Combined forms of infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.063	Combined forms of infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.102	Unspecified traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.103	Unspecified traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.109	Unspecified traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, right eye	Diagnosis	ICD-10-CM
H26.112	Localized traumatic opacities, left eye	Diagnosis	ICD-10-CM
H26.113	Localized traumatic opacities, bilateral	Diagnosis	ICD-10-CM
H26.119	Localized traumatic opacities, unspecified eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.122	Partially resolved traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.123	Partially resolved traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.129	Partially resolved traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.132	Total traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.133	Total traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.139	Total traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, right eye	Diagnosis	ICD-10-CM
H26.212	Cataract with neovascularization, left eye	Diagnosis	ICD-10-CM
H26.213	Cataract with neovascularization, bilateral	Diagnosis	ICD-10-CM
H26.219	Cataract with neovascularization, unspecified eye	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
H26.411	Soemmering's ring, right eye	Diagnosis	ICD-10-CM
H26.412	Soemmering's ring, left eye	Diagnosis	ICD-10-CM
H26.413	Soemmering's ring, bilateral	Diagnosis	ICD-10-CM
H26.419	Soemmering's ring, unspecified eye	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM
H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
Q12.0	Congenital cataract	Diagnosis	ICD-10-CM
V43.1	Lens replaced by other means	Diagnosis	ICD-9-CM
Z96.1	Presence of intraocular lens	Diagnosis	ICD-10-CM
<b>Chronic Kidney Disease</b>			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sjogren syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
<b>Chronic Obstructive Pulmonary Disease and Bronchiectasis</b>			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
<b>Depression</b>			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
<b>Diabetes</b>			
249	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.1	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.2	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.3	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.4	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
249.5	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.6	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.7	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.8	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.9	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.1	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.2	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.3	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
250.4	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.5	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.6	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.7	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.8	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.9	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
<b>Glaucoma</b>			
362.85	Retinal nerve fiber bundle defects	Diagnosis	ICD-9-CM
365	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.1	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.2	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.6	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
<b>Heart Failure</b>			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.2	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.3	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.4	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
<b>Hip/Pelvic Fracture</b>			
733.14	Pathologic fracture of neck of femur	Diagnosis	ICD-9-CM
733.15	Pathologic fracture of other specified part of femur	Diagnosis	ICD-9-CM
733.96	Stress fracture of femoral neck	Diagnosis	ICD-9-CM
733.97	Stress fracture of shaft of femur	Diagnosis	ICD-9-CM
733.98	Stress fracture of pelvis	Diagnosis	ICD-9-CM
808.0	Closed fracture of acetabulum	Diagnosis	ICD-9-CM
808.1	Open fracture of acetabulum	Diagnosis	ICD-9-CM
808.2	Closed fracture of pubis	Diagnosis	ICD-9-CM
808.3	Open fracture of pubis	Diagnosis	ICD-9-CM
808.41	Closed fracture of ilium	Diagnosis	ICD-9-CM
808.42	Closed fracture of ischium	Diagnosis	ICD-9-CM
808.43	Multiple closed pelvic fractures with disruption of pelvic circle	Diagnosis	ICD-9-CM
808.44	Multiple closed pelvic fractures without disruption of pelvic circle	Diagnosis	ICD-9-CM
808.49	Closed fracture of other specified part of pelvis	Diagnosis	ICD-9-CM
808.51	Open fracture of ilium	Diagnosis	ICD-9-CM
808.52	Open fracture of ischium	Diagnosis	ICD-9-CM
808.53	Multiple open pelvic fractures with disruption of pelvic circle	Diagnosis	ICD-9-CM
808.54	Multiple open pelvic fractures without disruption of pelvic circle	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
808.59	Open fracture of other specified part of pelvis	Diagnosis	ICD-9-CM
808.8	Unspecified closed fracture of pelvis	Diagnosis	ICD-9-CM
808.9	Unspecified open fracture of pelvis	Diagnosis	ICD-9-CM
820.00	Closed fracture of unspecified intracapsular section of neck of femur	Diagnosis	ICD-9-CM
820.01	Closed fracture of epiphysis (separation) (upper) of neck of femur	Diagnosis	ICD-9-CM
820.02	Closed fracture of midcervical section of femur	Diagnosis	ICD-9-CM
820.03	Closed fracture of base of neck of femur	Diagnosis	ICD-9-CM
820.09	Other closed transcervical fracture of femur	Diagnosis	ICD-9-CM
820.10	Open fracture of unspecified intracapsular section of neck of femur	Diagnosis	ICD-9-CM
820.11	Open fracture of epiphysis (separation) (upper) of neck of femur	Diagnosis	ICD-9-CM
820.12	Open fracture of midcervical section of femur	Diagnosis	ICD-9-CM
820.13	Open fracture of base of neck of femur	Diagnosis	ICD-9-CM
820.19	Other open transcervical fracture of femur	Diagnosis	ICD-9-CM
820.20	Closed fracture of unspecified trochanteric section of femur	Diagnosis	ICD-9-CM
820.21	Closed fracture of intertrochanteric section of femur	Diagnosis	ICD-9-CM
820.22	Closed fracture of subtrochanteric section of femur	Diagnosis	ICD-9-CM
820.30	Open fracture of unspecified trochanteric section of femur	Diagnosis	ICD-9-CM
820.31	Open fracture of intertrochanteric section of femur	Diagnosis	ICD-9-CM
820.32	Open fracture of subtrochanteric section of femur	Diagnosis	ICD-9-CM
820.8	Closed fracture of unspecified part of neck of femur	Diagnosis	ICD-9-CM
820.9	Open fracture of unspecified part of neck of femur	Diagnosis	ICD-9-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.350A	Stress fracture, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.351A	Stress fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.352A	Stress fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M84.353A	Stress fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.359A	Stress fracture, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.451A	Pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.452A	Pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.453A	Pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.459A	Pathological fracture, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.550A	Pathological fracture in neoplastic disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.551A	Pathological fracture in neoplastic disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.552A	Pathological fracture in neoplastic disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.553A	Pathological fracture in neoplastic disease, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.559A	Pathological fracture in neoplastic disease, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.650A	Pathological fracture in other disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.651A	Pathological fracture in other disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.652A	Pathological fracture in other disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.653A	Pathological fracture in other disease, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.659A	Pathological fracture in other disease, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
S32.301A	Unspecified fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.301B	Unspecified fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.302A	Unspecified fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.302B	Unspecified fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.309A	Unspecified fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.309B	Unspecified fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.311A	Displaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.311B	Displaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.312A	Displaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.312B	Displaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.313A	Displaced avulsion fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.313B	Displaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.314A	Nondisplaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.314B	Nondisplaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.315A	Nondisplaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.315B	Nondisplaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.316A	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.316B	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.391A	Other fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.391B	Other fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.392A	Other fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.392B	Other fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.399A	Other fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.399B	Other fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.401A	Unspecified fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.401B	Unspecified fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.402A	Unspecified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.402B	Unspecified fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.409A	Unspecified fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.409B	Unspecified fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.411A	Displaced fracture of anterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.411B	Displaced fracture of anterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.412A	Displaced fracture of anterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.412B	Displaced fracture of anterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.413A	Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.413B	Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.414A	Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.414B	Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.415A	Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.415B	Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.416A	Nondisplaced fracture of anterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.416B	Nondisplaced fracture of anterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.421A	Displaced fracture of posterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.421B	Displaced fracture of posterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.422A	Displaced fracture of posterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.422B	Displaced fracture of posterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.423A	Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.423B	Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.424A	Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.424B	Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.425A	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.425B	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.426A	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.426B	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.431A	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.431B	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.432A	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.432B	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.433A	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.433B	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.434A	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.434B	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.435A	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.435B	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.436A	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.436B	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.441A	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.441B	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.442A	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.442B	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.443A	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.443B	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.444A	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.444B	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.445A	Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.445B	Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.446A	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.446B	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.451A	Displaced transverse fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.451B	Displaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.452A	Displaced transverse fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.452B	Displaced transverse fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.453A	Displaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.453B	Displaced transverse fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.454A	Nondisplaced transverse fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.454B	Nondisplaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.455A	Nondisplaced transverse fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.455B	Nondisplaced transverse fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.456A	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.456B	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.461A	Displaced associated transverse-posterior fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.461B	Displaced associated transverse-posterior fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.462A	Displaced associated transverse-posterior fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.462B	Displaced associated transverse-posterior fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.463A	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.463B	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.464A	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.464B	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.465A	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.465B	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.466A	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.466B	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.471A	Displaced fracture of medial wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.471B	Displaced fracture of medial wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.472A	Displaced fracture of medial wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.472B	Displaced fracture of medial wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.473A	Displaced fracture of medial wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.473B	Displaced fracture of medial wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.474A	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.474B	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.475A	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.475B	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.476A	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.476B	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.481A	Displaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.481B	Displaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.482A	Displaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.482B	Displaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.483A	Displaced dome fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.483B	Displaced dome fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.484A	Nondisplaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.484B	Nondisplaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.485A	Nondisplaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.485B	Nondisplaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.486A	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.486B	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.491A	Other specified fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.491B	Other specified fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.492A	Other specified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.492B	Other specified fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.499A	Other specified fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.499B	Other specified fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.501A	Unspecified fracture of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.501B	Unspecified fracture of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.502A	Unspecified fracture of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.502B	Unspecified fracture of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.509A	Unspecified fracture of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.509B	Unspecified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.511A	Fracture of superior rim of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.511B	Fracture of superior rim of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.512A	Fracture of superior rim of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.512B	Fracture of superior rim of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.519A	Fracture of superior rim of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.519B	Fracture of superior rim of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.591A	Other specified fracture of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.591B	Other specified fracture of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.592A	Other specified fracture of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.592B	Other specified fracture of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.599A	Other specified fracture of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.599B	Other specified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.601A	Unspecified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.601B	Unspecified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.602A	Unspecified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.602B	Unspecified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.609A	Unspecified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.609B	Unspecified fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.611A	Displaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.611B	Displaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.612A	Displaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.612B	Displaced avulsion fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.613A	Displaced avulsion fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.613B	Displaced avulsion fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.614A	Nondisplaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.614B	Nondisplaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.615A	Nondisplaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.615B	Nondisplaced avulsion fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.616A	Nondisplaced avulsion fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.616B	Nondisplaced avulsion fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.691A	Other specified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.691B	Other specified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.692A	Other specified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.692B	Other specified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.699A	Other specified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.699B	Other specified fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S32.810A	Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.810B	Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.811A	Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.811B	Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.82XA	Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.82XB	Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.89XA	Fracture of other parts of pelvis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.89XB	Fracture of other parts of pelvis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.9XXA	Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.9XXB	Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S72.001A	Fracture of unspecified part of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.001B	Fracture of unspecified part of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.001C	Fracture of unspecified part of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.002A	Fracture of unspecified part of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.002B	Fracture of unspecified part of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.002C	Fracture of unspecified part of neck of left femur, initial encounter for open fracture	Diagnosis	ICD-10-CM
S72.009A	Fracture of unspecified part of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.009B	Fracture of unspecified part of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.009C	Fracture of unspecified part of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.011A	Unspecified intracapsular fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.011B	Unspecified intracapsular fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.011C	Unspecified intracapsular fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.012A	Unspecified intracapsular fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.012B	Unspecified intracapsular fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.012C	Unspecified intracapsular fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.019A	Unspecified intracapsular fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.019B	Unspecified intracapsular fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.019C	Unspecified intracapsular fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.021A	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.021B	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.021C	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.022A	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.022B	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.022C	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.023A	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.023B	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.023C	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.024A	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.024B	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.024C	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.025A	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.025B	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.025C	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.026A	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.026B	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.026C	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.031A	Displaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.031B	Displaced midcervical fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.031C	Displaced midcervical fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.032A	Displaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.032B	Displaced midcervical fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.032C	Displaced midcervical fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.033A	Displaced midcervical fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.033B	Displaced midcervical fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.033C	Displaced midcervical fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.034A	Nondisplaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.034B	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.034C	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.035A	Nondisplaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.035B	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.035C	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.036A	Nondisplaced midcervical fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.036B	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.036C	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.041A	Displaced fracture of base of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.041B	Displaced fracture of base of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.041C	Displaced fracture of base of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.042A	Displaced fracture of base of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.042B	Displaced fracture of base of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.042C	Displaced fracture of base of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.043A	Displaced fracture of base of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.043B	Displaced fracture of base of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.043C	Displaced fracture of base of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.044A	Nondisplaced fracture of base of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.044B	Nondisplaced fracture of base of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.044C	Nondisplaced fracture of base of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.045A	Nondisplaced fracture of base of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.045B	Nondisplaced fracture of base of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.045C	Nondisplaced fracture of base of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.046A	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.046B	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.046C	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.051A	Unspecified fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.051B	Unspecified fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.051C	Unspecified fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.052A	Unspecified fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.052B	Unspecified fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.052C	Unspecified fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.059A	Unspecified fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.059B	Unspecified fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.059C	Unspecified fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.061A	Displaced articular fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.061B	Displaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.061C	Displaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.062A	Displaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.062B	Displaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.062C	Displaced articular fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.063A	Displaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.063B	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.063C	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.064A	Nondisplaced articular fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.064B	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.064C	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.065A	Nondisplaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.065B	Nondisplaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.065C	Nondisplaced articular fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.066A	Nondisplaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.066B	Nondisplaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.066C	Nondisplaced articular fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.091A	Other fracture of head and neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.091B	Other fracture of head and neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.091C	Other fracture of head and neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.092A	Other fracture of head and neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.092B	Other fracture of head and neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.092C	Other fracture of head and neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.099A	Other fracture of head and neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.099B	Other fracture of head and neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.099C	Other fracture of head and neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.101A	Unspecified trochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.101B	Unspecified trochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.101C	Unspecified trochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.102A	Unspecified trochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.102B	Unspecified trochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.102C	Unspecified trochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.109A	Unspecified trochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.109B	Unspecified trochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.109C	Unspecified trochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.111A	Displaced fracture of greater trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.111B	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.111C	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.112A	Displaced fracture of greater trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.112B	Displaced fracture of greater trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.112C	Displaced fracture of greater trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.113A	Displaced fracture of greater trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.113B	Displaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.113C	Displaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.114A	Nondisplaced fracture of greater trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.114B	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.114C	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.115A	Nondisplaced fracture of greater trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.115B	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.115C	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.116A	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.116B	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.116C	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.121A	Displaced fracture of lesser trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.121B	Displaced fracture of lesser trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.121C	Displaced fracture of lesser trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.122A	Displaced fracture of lesser trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.122B	Displaced fracture of lesser trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.122C	Displaced fracture of lesser trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.123A	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.123B	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.123C	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.124A	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.124B	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.124C	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.125A	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.125B	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.125C	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.126A	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.126B	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.126C	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.131A	Displaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.131B	Displaced apophyseal fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.131C	Displaced apophyseal fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.132A	Displaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.132B	Displaced apophyseal fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.132C	Displaced apophyseal fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.133A	Displaced apophyseal fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.133B	Displaced apophyseal fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.133C	Displaced apophyseal fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.134A	Nondisplaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.134B	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.134C	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.135A	Nondisplaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.135B	Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.135C	Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.136A	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.136B	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.136C	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.141A	Displaced intertrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.141B	Displaced intertrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.141C	Displaced intertrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.142A	Displaced intertrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.142B	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.142C	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.143A	Displaced intertrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.143B	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.143C	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.144A	Nondisplaced intertrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.144B	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.144C	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.145A	Nondisplaced intertrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.145B	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.145C	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.146A	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.146B	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.146C	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.21XA	Displaced subtrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.21XB	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.21XC	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.22XA	Displaced subtrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.22XB	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.22XC	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.23XA	Displaced subtrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.23XB	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.23XC	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
S72.24XA	Nondisplaced subtrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.24XB	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.24XC	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.25XA	Nondisplaced subtrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.25XB	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.25XC	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.26XA	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.26XB	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.26XC	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S79.001A	Unspecified physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.002A	Unspecified physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.009A	Unspecified physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.011A	Salter-Harris Type I physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.012A	Salter-Harris Type I physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.019A	Salter-Harris Type I physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.091A	Other physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.092A	Other physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.099A	Other physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

**Hyperlipidemia**

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
<b>Hypertension</b>			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
<b>Ischemic Heart Disease</b>			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
<b>Osteoporosis</b>			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
<b>Rheumatoid Arthritis/Osteoarthritis</b>			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthritis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthritis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthritis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthritis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthritis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthritis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthritis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthritis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthritis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
715.35	Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthritis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthritis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthritis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthritis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthritis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthritis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthritis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthritis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthritis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM
715.95	Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthritis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthritis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
<b>Stroke/Transient Ischemic Attack</b>			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM



**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM

**Appendix O. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code Category	Code Type
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

## Appendix P. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool version 13.0.1 to estimate background rates of interstitial lung disease (ILD) in patients with inflammatory bowel disease (IBD) in the Sentinel Distributed Database (SDD). This updated post-hoc analysis aims to estimate incidence of ILD in IBD patients without evidence of natalizumab or vedolizumab exposure and amongst those receiving an advanced therapy for IBD.

**Query period:** 01/01/2006 - 4/30/2023<sup>1</sup>  
**Coverage requirement:** Medical and prescription drug coverage  
**Pre-index enrollment requirement:** 183 days  
**Post-index requirement:** 0 days  
**Post-episode requirement for Type 2 analyses:** 0 days  
**Enrollment gap:** 45 days  
**Age groups:** 18-24, 25-34, 35-44, 45-54, 55-64, 65+ years  
**Stratifications:** Age group, sex, race, ethnicity, year of diagnosis  
**Censor output categorization:** Range of follow-up time specified  
**Restrictions:** Male and female sex only  
**Envelope macro:** Reclassify encounters during inpatient stay as inpatient  
**Distribution of index-defining codes:** Not requested  
**Never-exposed cohort:** Not requested  
**Freeze data:** No

Scenario	Cohort Description	Index Event	Cohort Definition	Exposure							
				Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration	Minimum Days Supplied	Maximum Exposure Episode Duration
1	Prevalent IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use	IBD	First valid index event during query period	0	--	Yes	--	--	--	--	--
2	Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/ Natalizumab Use	CD	First valid index event during query period	0	--	Yes	--	--	--	--	--
3	Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/ Natalizumab Use	UC	First valid index event during query period	0	--	Yes	--	--	--	--	--

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Index Event	Cohort Definition	Exposure							
				Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration	Minimum Days Supplied	Maximum Exposure Episode Duration
4	Incident IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use	IBD	First valid index event during query period	ever	--	Yes	--	--	--	--	--
5	Incident CD Cohort Excluding Prior Vedolizumab/ Natalizumab Use	CD	First valid index event during query period	ever	--	Yes	--	--	--	--	--
6	Incident UC Cohort Excluding Prior Vedolizumab/ Natalizumab Use	UC	First valid index event during query period	ever	--	Yes	--	--	--	--	--
7	Prevalent IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	IBD	First valid index event during query period	0	--	Yes	--	--	--	--	--
8	Prevalent CD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	CD	First valid index event during query period	0	--	Yes	--	--	--	--	--

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Index Event	Cohort Definition	Exposure							
				Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration	Minimum Days Supplied	Maximum Exposure Episode Duration
9	Prevalent UC Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	UC	First valid index event during query period	0	--	Yes	--	--	--	--	--
10	Incident IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	IBD	First valid index event during query period	ever	--	Yes	--	--	--	--	--
11	Incident CD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	CD	First valid index event during query period	ever	--	Yes	--	--	--	--	--
12	Incident UC Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	UC	First valid index event during query period	ever	--	Yes	--	--	--	--	--



# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Index Event	Cohort Definition	Exposure							
				Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration	Minimum Days Supplied	Maximum Exposure Episode Duration
13	Prevalent IBD Cohort	IBD	First valid index event during query period	0	--	Yes	--	--	--	--	--
14	Prevalent CD Cohort	CD	First valid index event during query period	0	--	Yes	--	--	--	--	--
15	Prevalent UC Cohort	UC	First valid index event during query period	0	--	Yes	--	--	--	--	--
16	Incident IBD Cohort	IBD	First valid index event during query period	ever	--	Yes	--	--	--	--	--
17	Incident CD Cohort	CD	First valid index event during query period	ever	--	Yes	--	--	--	--	--
18	Incident UC Cohort	UC	First valid index event during query period	ever	--	Yes	--	--	--	--	--

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Index Event	Cohort Definition	Exposure							
				Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration	Minimum Days Supplied	Maximum Exposure Episode Duration
19	Advanced Therapy Initiators with IBD	Advanced Therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	First valid index event during query period	183 days	Evaluation period should search for evidence of days supply	Yes	N/A	N/A	N/A	N/A	none
20	Advanced Therapy Initiators with CD	Advanced Therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	First valid index event during query period	183 days	Evaluation period should search for evidence of days supply	Yes	N/A	N/A	N/A	N/A	none
21	Advanced Therapy Initiators with UC	infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib	First valid index event during query period	183 days	Evaluation period should search for evidence of days supply	Yes	N/A	N/A	N/A	N/A	none

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Care Setting	Exposure				Create Baseline Table?	Censor Episode at Evidence of:
			Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Forced Supply to Attach to Procedures			
1	Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use	Any care setting	Any	--	--		Yes	*Data Partner (DP) end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
2	Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
3	Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
4	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Forced Supply to Attach to Procedures	Create Baseline Table?	Exposure	Censor Episode at Evidence of:
5	Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use	Any care setting	Any	--	--	Yes		*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
6	Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use	Any care setting	Any	--	--	Yes		*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
7	Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	Any care setting	Any	--	--	Yes		*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
8	Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	Any care setting	Any	--	--	Yes		*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Care Setting	Exposure				Create Baseline Table?	Censor Episode at Evidence of:
			Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Forced Supply to Attach to Procedures			
9	Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
10	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
11	Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab
12	Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest; *Initiation of vedolizumab <sup>2</sup> or natalizumab

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Care Setting	Exposure				Create Baseline Table?	Censor Episode at Evidence of:
			Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Forced Supply to Attach to Procedures			
13	Prevalent IBD Cohort	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest
14	Prevalent CD Cohort	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest
15	Prevalent UC Cohort	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest
16	Incident IBD Cohort	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest
17	Incident CD Cohort	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest
18	Incident UC Cohort	Any care setting	Any	--	--		Yes	*DP end date; *Query end date; *Death; *Disenrollment; *Development of the outcome of interest

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Forced Supply to Attach to Procedures	Exposure	
						Create Baseline Table?	Censor Episode at Evidence of:
19	Advanced Therapy Initiators with IBD	Any Care Setting	NA	N/A	N/A	Yes	*DP end date; *Query end date; *Receipt of vedolizumab <sup>2</sup> or natalizumab; *Receipt of other IBD treatments including: methotrexate, amiodarone, bleomycin, azathioprine, cyclophosphamide, sulfasalazine, checkpoint inhibitors (Cytotoxic T lymphocyte-associated antigen 4: ipilimumab and tremelimumab; Programmed cell death receptor 1: nivolumab, pembrolizumab, cemiplimab, dostarlimab, and retifanlimab ; and programmed cell death ligand 1: atezolimumab, durvalumab and avelumab) or tyrosine kinase inhibitors; *Death; *Disenrollment; *Development of the outcome of interest
20	Advanced Therapy Initiators with CD	Any Care Setting	NA	N/A	N/A	Yes	*DP end date; *Query end date; *Receipt of vedolizumab <sup>2</sup> or natalizumab; *Receipt of other IBD treatments including: methotrexate, amiodarone, bleomycin, azathioprine, cyclophosphamide, sulfasalazine, checkpoint inhibitors (Cytotoxic T lymphocyte-associated antigen 4: ipilimumab and tremelimumab; Programmed cell death receptor 1: nivolumab, pembrolizumab, cemiplimab, dostarlimab, and retifanlimab ; and programmed cell death ligand 1: atezolimumab, durvalumab and avelumab) or tyrosine kinase inhibitors; *Death; *Disenrollment; *Development of the outcome of interest

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Forced Supply to Attach to Procedures	Exposure	
						Create Baseline Table?	Censor Episode at Evidence of:
21	Advanced Therapy Initiators with UC	Any Care Setting	NA	N/A	N/A	Yes	*DP end date; *Query end date; *Receipt of vedolizumab <sup>2</sup> or natalizumab; *Receipt of other IBD treatments including: methotrexate, amiodarone, bleomycin, azathioprine, cyclophosphamide, sulfasalazine, checkpoint inhibitors (Cytotoxic T lymphocyte-associated antigen 4: ipilimumab and tremelimumab; Programmed cell death receptor 1: nivolumab, pembrolizumab, cemiplimab, dostarlimab, and retifanlimab ; and programmed cell death ligand 1: atezolimumab, durvalumab and avelumab) or tyrosine kinase inhibitors; *Death; *Disenrollment; *Development of the outcome of interest



# Appendix P. Specifications Defining Parameters for this Request

Inclusion/Exclusion Criteria											
Scenario	Cohort Description	Inclusion/Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Forced Supply to Attach to Dispensings and Procedures	Exclude Evidence of Days Supply if Inclusion/Exclusion Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	
1	Prevalent IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use	*prior vedolizumab use <sup>2</sup>	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
2	Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/ Natalizumab Use	*prior vedolizumab use <sup>2</sup>	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*Prior UC or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	
3	Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/ Natalizumab Use	*prior vedolizumab use <sup>2</sup>	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*Prior CD or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	
4	Incident IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use	*prior vedolizumab use <sup>2</sup>	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
5	Incident CD Cohort Excluding Prior Vedolizumab/ Natalizumab Use	*prior vedolizumab use <sup>2</sup>	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*Prior UC or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	

# Appendix P. Specifications Defining Parameters for this Request

Inclusion/Exclusion Criteria										
Scenario	Cohort Description	Inclusion/Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Forced Supply to Attach to Dispensings and Procedures	Exclude Evidence of Days Supply if Inclusion/Exclusion Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period
6	Incident UC Cohort Excluding Prior Vedolizumab/ Natalizumab Use	*prior vedolizumab use <sup>2</sup>	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
		*Prior CD or indeterminite colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1
7	Prevalent IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	*prior vedolizumab use <sup>2</sup>	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
		*prior use of advanced therapy for IBD (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	Inclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
8	Prevalent CD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	*prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
		*prior use of advanced therapy for IBD (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	Inclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1
		*Prior UC or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1

# Appendix P. Specifications Defining Parameters for this Request

Inclusion/Exclusion Criteria											
Scenario	Cohort Description	Inclusion/Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Forced Supply to Attach to Dispensings and Procedures	Exclude Evidence of Days Supply if Inclusion/Exclusion Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	
9	Prevalent UC Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	*prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior use of advanced therapy for IBD (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	Inclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*Prior CD or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	
10	Incident IBD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	*prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior use of advanced therapy for IBD (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	Inclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	

# Appendix P. Specifications Defining Parameters for this Request

Inclusion/Exclusion Criteria											
Scenario	Cohort Description	Inclusion/Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Forced Supply to Attach to Dispensings and Procedures	Exclude Evidence of Days Supply if Inclusion/Exclusion Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	
11	Incident CD Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	*prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior use of advanced therapy for IBD (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	Inclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*Prior UC or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	
12	Incident UC Cohort Excluding Prior Vedolizumab/ Natalizumab Use and Requiring Other Advanced Therapy	*prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior natalizumab use	Exclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*prior use of advanced therapy for IBD (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib)	Inclusion	N/A	N/A	-ever	0		Evaluation period should search for evidence of days supply	1	
		*Prior CD or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Inclusion/Exclusion Criteria									
		Inclusion/Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Forced Supply to Attach to Dispensings and Procedures	Exclude Evidence of Days Supply if Inclusion/Exclusion Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	
13	Prevalent IBD Cohort	--	--		--	--	--	--	--	--	
14	Prevalent CD Cohort	*Prior UC or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	
15	Prevalent UC Cohort	*Prior CD or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	
16	Incident IBD Cohort	--	--	--	--	--	--		--	--	
17	Incident CD Cohort	*Prior UC or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0		N/A	1	
18	Incident UC Cohort	*Prior CD or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0	N/A	N/A	1	

# Appendix P. Specifications Defining Parameters for this Request

Inclusion/Exclusion Criteria										
Scenario	Cohort Description	Inclusion/Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Forced Supply to Attach to Dispensings and Procedures	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period
19	Advanced Therapy Initiators with IBD	*IBD	Inclusion	Any care setting	Any	-ever	0	N/A	N/A	1
		*Prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-183	0	128 days	Evaluation period should search for evidence of days supply	1
		*Prior natalizumab use	Exclusion	N/A	N/A	-183	0	55 days	Evaluation period should search for evidence of days supply	1
		*Prior use of other IBD treatments and cancer immunotherapies	Exclusion	N/A	N/A	Drug dependent (-5x halflife rounded up), see Appendix A	0	N/A	Evaluation period should search for evidence of days supply	1
		*Prior amiodarone use	Exclusion	N/A	N/A	0	0	710 days	Evaluation period should search for evidence of days supply	1
20	Advanced Therapy Initiators with CD	*CD	Inclusion	Any care setting	Any	-ever	0	N/A	N/A	1
		*Prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-183	0	128 days	Evaluation period should search for evidence of days supply	1
		*Prior natalizumab use	Exclusion	N/A	N/A	-183	0	55 days	Evaluation period should search for evidence of days supply	1
		*Prior use of other IBD treatments and cancer immunotherapies	Exclusion	N/A	N/A	Drug dependent (-5x halflife rounded up), see Appendix A	0	N/A	Evaluation period should search for evidence of days supply	1
		*Prior amiodarone use	Exclusion	N/A	N/A	0	0	710 days	Evaluation period should search for evidence of days supply	1
		*Prior UC or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0	N/A	N/A	1

# Appendix P. Specifications Defining Parameters for this Request

Inclusion/Exclusion Criteria										
Scenario	Cohort Description	Inclusion/Exclusion Group	Criteria	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Forced Supply to Attach to Dispensings and Procedures	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period
21	Advanced Therapy Initiators with UC	*UC	Inclusion	Any care setting	Any	-ever	0	N/A	N/A	1
		*Prior vedolizumab <sup>2</sup> use	Exclusion	N/A	N/A	-183	0	128 days	Evaluation period should search for evidence of days supply	1
		*Prior natalizumab use	Exclusion	N/A	N/A	-183	0	55 days	Evaluation period should search for evidence of days supply	1
		*Prior use of other IBD treatments and cancer immunotherapies	Exclusion	N/A	N/A	Drug dependent (-5x half-life rounded up), see Appendix A	0	N/A	Evaluation period should search for evidence of days supply	1
		*Prior amiodarone use	Exclusion	N/A	N/A	0	0	710 days	Evaluation period should search for evidence of days supply	1
		*Prior CD or indeterminate colitis	Exclusion	Any care setting	Any	-ever	0	N/A	N/A	1

# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Event	Event Outcome						
			Incident Event Washout Period	Care Setting	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Blackout Period	Risk Window Interval Start	Forced Supply to Attach to Dispensings
1	Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
2	Prevalent Crohn's Disease (CD) Cohort Excluding Prior Vedolizumab/Natalizumab Use	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
3	Prevalent Ulcerative Colitis (UC) Cohort Excluding Prior Vedolizumab/Natalizumab Use	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
4	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
5	Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
6	Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
7	Prevalent IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
8	Prevalent CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
9	Prevalent UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A



# Appendix P. Specifications Defining Parameters for this Request

Scenario	Cohort Description	Event Outcome							
		Event	Incident Event Washout Period	Care Setting	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Blackout Period	Risk Window Interval Start	Forced Supply to Attach to Dispensings
10	Incident IBD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
11	Incident CD Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
12	Incident UC Cohort Excluding Prior Vedolizumab/Natalizumab Use and Requiring Other Advanced Therapy	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
13	Prevalent IBD Cohort	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
14	Prevalent CD Cohort	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
15	Prevalent UC Cohort	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
16	Incident IBD Cohort	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
17	Incident CD Cohort	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
18	Incident UC Cohort	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A

# Appendix P. Specifications Defining Parameters for this Request

Event Outcome									
Scenario	Cohort Description	Event	Incident Event Washout Period	Care Setting	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Blackout Period	Risk Window Interval Start	Forced Supply to Attach to Dispensings
19	Advanced Therapy Initiators with IBD	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
20	Advanced Therapy Intiators with CD	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A
21	Advanced Therapy Initiators with UC	ILD	ever	Any care setting	Any	--	N/A	Day 1	N/A

N/A: Not applicable

International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.

National Drug Codes (NDCs) are checked against First Data Bank's FDB MedKnowledge®.

<sup>1</sup>Date of data availability as of distribution of previous query

<sup>2</sup>In addition to drug and procedure codes for vedolizumab dispensing or administration, a CPT code for vedolizumab assay is included.

# Appendix Q. Baseline Characteristics Used In This Request

Covariate Number	Covariate	Description	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Covariate Includes Dispensings	Number of Instances the Covariate Should Be Found in Evaluation Period
1	Systemic Sclerosis	--	*Any care setting	*Any	-183	0	N/A	1
2	Rheumatoid Arthritis	--	*Any care setting	*Any	-183	0	N/A	1
3	Dermatomyositis/Polymyositis	--	*Any care setting	*Any	-183	0	N/A	1
4	Anti-Synthetase Syndrome	--	*Any care setting	*Any	-183	0	N/A	1
5	Acquired Hypothyroidism	--	*Any care setting	*Any	-ever	0	N/A	1
6	Acute Myocardial Infarction	--	*Any care setting	*Any	-ever	0	N/A	1
7	Alzheimer's Disease	--	*Any care setting	*Any	-ever	0	N/A	1
8	Alzheimer's Disease and Related Disorders or Senile Dementia	--	*Any care setting	*Any	-ever	0	N/A	1
9	Anemia	--	*Any care setting	*Any	-ever	0	N/A	1
10	Asthma	--	*Any care setting	*Any	-ever	0	N/A	1
11	Atrial Fibrillation	--	*Any care setting	*Any	-ever	0	N/A	1
12	Benign Prostatic Hyperplasia	--	*Any care setting	*Any	-ever	0	N/A	1
13	Cancer, Breast	--	*Any care setting	*Any	-ever	0	N/A	1
14	Cancer, Colorectal	--	*Any care setting	*Any	-ever	0	N/A	1
15	Cancer, Endometrial	--	*Any care setting	*Any	-ever	0	N/A	1
16	Cancer, Lung	--	*Any care setting	*Any	-ever	0	N/A	1
17	Cancer, Prostate	--	*Any care setting	*Any	-ever	0	N/A	1
18	Cataract	--	*Any care setting	*Any	-ever	0	N/A	1
19	Chronic Kidney Disease	--	*Any care setting	*Any	-ever	0	N/A	1
20	Chronic Obstructive Pulmonary Disease and Bronchiectasis	--	*Any care setting	*Any	-ever	0	N/A	1
21	Depression	--	*Any care setting	*Any	-ever	0	N/A	1

# Appendix Q. Baseline Characteristics Used In This Request

Covariate Number	Covariate	Description	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Covariate Includes Dispensings	Number of Instances the Covariate Should Be Found in Evaluation Period
22	Diabetes	--	*Any care setting	*Any	-ever	0	N/A	1
23	Glaucoma	--	*Any care setting	*Any	-ever	0	N/A	1
24	Heart Failure	--	*Any care setting	*Any	-ever	0	N/A	1
25	Hip/Pelvic Fracture	--	*Any care setting	*Any	-ever	0	N/A	1
26	Hyperlipidemia	--	*Any care setting	*Any	-ever	0	N/A	1
27	Hypertension	--	*Any care setting	*Any	-ever	0	N/A	1
28	Ischemic Heart Disease	--	*Any care setting	*Any	-ever	0	N/A	1
29	Osteoporosis	--	*Any care setting	*Any	-ever	0	N/A	1
30	Rheumatoid Arthritis/Osteoarthritis	--	*Any care setting	*Any	-ever	0	N/A	1
31	Stroke/Transient Ischemic Attack	--	*Any care setting	*Any	-ever	0	N/A	1
32	Tobacco Use	--	*Any care setting	*Any	-183	0	N/A	1
33	Methotrexate	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1
34	Amiodarone	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1
35	Bleomycin	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1
36	Azathioprine	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1
37	Cyclophosphamide	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1

# Appendix Q. Baseline Characteristics Used In This Request

Covariate Number	Covariate	Description	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Covariate Includes Dispensings	Number of Instances the Covariate Should Be Found in Evaluation Period
38	Sulfasalazine	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1
39	Checkpoint Inhibitors	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1
40	Tyrosine Kinase Inhibitors	--	N/A	N/A	-183	0	*Evaluation period should search for evidence of days supply	1
41	Inflammatory Bowel Disease (IBD) in -364 to 0 (<1 year of IBD history) [See combo tab]	--	Any	Any	-364 (0 for input file purpose)	0 (0 for input file purpose)	N/A	1
42	IBD in -729 to -365 [See combo tab]	--	Any	Any	-729 (0 for input file purpose)	-365 (0 for input file purpose)	N/A	1
43	≥2 Years of IBD History [See combo tab]	--	Any	Any	-ever (0 for input file purpose)	-730 (0 for input file purpose)	N/A	1
44	<1 Year of IBD History	Covar 41 AND NOT (Covar 42 or Covar 43)	--	--	--	--	--	--
45	1-<2 Years of IBD History	Covar 42 AND NOT Covar 43	--	--	--	--	--	--
46	Combined Comorbidity Score	--	*Any care setting	*Any	-ever	0	N/A	1

# Background Rates Cohorts 1-18

**Cohort Entry Date: Day 0**  
**IBD, CD, or UC**  
**diagnosis code\***

\* Cohort entry date represents first valid diagnosis code during query period

## Enrollment Window

[Medical and Drug Coverage,  $\geq 183$  days]

## Inclusion/Exclusion Assessment Window, varies by cohort

1. All cohorts, Exclude prior ILD: [-ever, -1]
2. Cohorts 1-12, Exclude prior VED and NAT use: [-ever, 0]
3. Cohorts 7-12, Require prior use of other advanced therapy for IBD (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, risankizumab, mirikizumab, ozanimod, etrasimod, tofacitinib, or upadacitinib): [-ever, 0]
4. All UC or CD cohorts, Exclude prior diagnosis of opposite IBD subtype or indeterminate colitis: [-ever, 0]
5. All incident IBD/UC/CD cohorts, Washout for prior IBD/UC/CD, respectively [-ever, -1]

## Characteristics and Assessment Periods

1. Demographics: Age, sex, race, ethnicity [0, 0]
2. Year of index date [0, 0]
3. Immune comorbidities [-183, 0]
4. Healthcare utilization parameters [-183, -1]
5. Drug utilization parameters [-183, -1]
6. IBD medication use prior to baseline [-183, 0]
7. Cancer immunotherapy use prior to baseline [-183, 0]
8. CCW conditions, Combined Comorbidity Score [-ever, 0]
9. Tobacco use [-183, 0]

## Censoring Events

1. DP end date
2. Query end date
3. Death
4. Disenrollment
5. Development of ILD
6. Cohorts 1-12, Initiation of natalizumab or vedolizumab

## Characteristic Assessment Window

[characteristic dependent]

## Follow-Up Window

[1, censor]

Jan. 1, 2006

-All available data-

April 30, 2023

Note: interstitial lung disease (ILD), inflammatory bowel disease (IBD), natalizumab (NAT), vedolizumab (VED), ulcerative colitis (UC), Crohn's disease (CD)



# Advanced Therapy Cohorts 19-21

Cohort Entry Date: Day 0  
Initiation\* of Advanced  
IBD Therapy

## Enrollment window

[Medical and Drug Coverage,  $\geq 183$  days]

## Inclusion/Exclusion Assessment Window

1. Exclude prior ILD: [-ever, -1]
2. Exclude prior advanced therapy: [-183, -1]
3. Cohort 19: Require IBD diagnosis: [-ever, 0]
4. Cohort 20: Require CD diagnosis: [-ever, 0], Exclude UC or indeterminate colitis [-ever, 0]
5. Cohort 21: Require UC diagnosis: [-ever, 0], Exclude CD or indeterminate colitis [-ever, 0]
6. Exclude prior VED and NAT use: [-183, 0]
7. Exclude prior IBD treatments: [-5x half-life of drug\*\*, 0]
8. Exclude prior amiodarone use: [0, 0; forced supply of 710 days]
9. Exclude prior cancer immunotherapy: [-5x half-life of drug\*\*, 0]

## Characteristics and assessment periods

1. Demographics: Age, sex, race, ethnicity [0, 0]
2. Year of index date [0, 0]
3. Immune comorbidities [-183, 0]
4. Healthcare utilization parameters [-183, -1]
5. Drug utilization parameters [-183, -1]
6. IBD medication use prior to baseline [-183, 0]
7. Cancer immunotherapy use prior to baseline [-183, 0]
8. Years of IBD history in the database [-ever, 0]
9. CCW conditions, Combined Comorbidity Score [-ever, 0]
10. Tobacco use [-183, 0]

## Censoring events

1. DP end date
2. Query end date
3. Disenrollment
4. Diagnosis of ILD
5. Initiation of natalizumab or vedolizumab
6. Initiation of other IBD therapies or cancer immunotherapy
7. Death

## Characteristic Assessment Window

[characteristic dependent]

## Follow-Up Window

[1, censor]

Jan. 1, 2006

April 30, 2023

\* Cohort indexed on 1<sup>st</sup> valid exposure episode during the query period after a 183-day washout

\*\* See Appendix K.1 in report for information on drug-specific half-lives

Note: interstitial lung disease (ILD), inflammatory bowel disease (IBD), natalizumab (NAT), vedolizumab (VED), ulcerative colitis (UC), Crohn's disease (CD)